{
  "usdmVersion": "4.0",
  "generatedAt": "2026-01-02T22:09:48.734686",
  "generator": "Protocol2USDM v6.5.0",
  "study": {
    "id": "88b30a51-c346-41d5-8a5a-a1b86a1c835b",
    "instanceType": "Study",
    "versions": [
      {
        "id": "f7b63caf-6ee5-49c8-adc6-c66745d12e02",
        "instanceType": "StudyVersion",
        "versionIdentifier": "1.0",
        "studyDesigns": [
          {
            "id": "8e29806d-d0ec-46c0-a7df-f1f096e7f0c5",
            "name": "Study Design",
            "rationale": "Protocol-defined study design for investigating efficacy and safety",
            "instanceType": "InterventionalStudyDesign",
            "blindingSchema": {
              "id": "f6731959-7bb6-4772-af34-9dfc45902b2b",
              "standardCode": {
                "id": "8a88248e-8d1e-431b-aba5-57e0ffcc226c",
                "code": "Open Label",
                "codeSystem": "http://www.cdisc.org",
                "codeSystemVersion": "2024-09-27",
                "decode": "Open Label",
                "instanceType": "Code"
              },
              "instanceType": "AliasCode"
            },
            "randomizationType": {
              "code": "Non-Randomized"
            },
            "arms": [
              {
                "id": "eb7c2e9b-d602-4eef-805f-d6b6026b384e",
                "name": "ALXN1840 Treatment",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "All participants receive ALXN1840, starting at 15 mg/day for approximately 28 days, followed by titration up to 30 mg/day.",
                "type": {
                  "id": "C174266",
                  "code": "C174266",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Investigational Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "ec32793f-ff18-48bb-9acb-5d7d815aaa8f",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              }
            ],
            "studyCohorts": [
              {
                "id": "07edd262-6aba-4a41-8a6b-e8e6a0790ce2",
                "name": "Cohort 1 (treatment experienced)",
                "instanceType": "StudyCohort",
                "characteristic": "Patients who have received WD therapy for > 28 days"
              },
              {
                "id": "6b46a100-5f80-46ca-9013-ff0836448dfb",
                "name": "Cohort 2 (treatment naïve)",
                "instanceType": "StudyCohort",
                "characteristic": "Patients who have received WD therapy for ≤ 28 days"
              }
            ],
            "studyCells": [
              {
                "id": "1450ea01-c653-4cb6-8353-91d693df3b8a",
                "armId": "eb7c2e9b-d602-4eef-805f-d6b6026b384e",
                "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "8968300e-b9fe-44e0-8f5e-0438d764f364",
                "armId": "eb7c2e9b-d602-4eef-805f-d6b6026b384e",
                "epochId": "60aa5dc9-3d59-4e23-a442-e7e996d38969",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "8f5cef4c-ecea-4500-b1f3-13860acfdfd8",
                "armId": "eb7c2e9b-d602-4eef-805f-d6b6026b384e",
                "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "2541545e-edbb-4010-accd-d2fc9337b98c",
                "armId": "eb7c2e9b-d602-4eef-805f-d6b6026b384e",
                "epochId": "9910e2f6-6088-4468-998c-9dadba3878e1",
                "elementIds": [],
                "instanceType": "StudyCell"
              }
            ],
            "eligibilityCriteria": [
              {
                "id": "59e2e74e-a637-488a-9ca5-6890c380c331",
                "identifier": "1",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "b2f51e24-c5c4-437a-966b-076c6607f1a5",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 1",
                "nextId": "50e92b59-5e85-4d23-9375-000167fb6d15"
              },
              {
                "id": "50e92b59-5e85-4d23-9375-000167fb6d15",
                "identifier": "2",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "f6370240-fc7e-4598-b558-480f6203a869",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 2",
                "previousId": "59e2e74e-a637-488a-9ca5-6890c380c331",
                "nextId": "734d8d91-a26c-421a-824c-bc916f4ccf37"
              },
              {
                "id": "734d8d91-a26c-421a-824c-bc916f4ccf37",
                "identifier": "3",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "cbf829bd-51c0-47c0-9131-0831df348f77",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 3",
                "previousId": "50e92b59-5e85-4d23-9375-000167fb6d15",
                "nextId": "06b8dca7-d290-4eb2-8c0c-84a454188177"
              },
              {
                "id": "06b8dca7-d290-4eb2-8c0c-84a454188177",
                "identifier": "4",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "69e5535c-0bab-4ccd-8e4f-8524d9f14a9c",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 4",
                "previousId": "734d8d91-a26c-421a-824c-bc916f4ccf37",
                "nextId": "2e114c79-6ccd-441f-81de-518bf095fccc"
              },
              {
                "id": "2e114c79-6ccd-441f-81de-518bf095fccc",
                "identifier": "5",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "ded41175-22f6-45e3-ba91-d57febdbc2cb",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 5",
                "previousId": "06b8dca7-d290-4eb2-8c0c-84a454188177",
                "nextId": "5abae019-222a-4d80-91ce-0d05fa3b37e0"
              },
              {
                "id": "5abae019-222a-4d80-91ce-0d05fa3b37e0",
                "identifier": "6",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "440c7567-855a-421b-bdcb-1f3a6bf9538d",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 6",
                "previousId": "2e114c79-6ccd-441f-81de-518bf095fccc",
                "nextId": "6848d8ed-e594-492a-88ad-dad769d9a44a"
              },
              {
                "id": "6848d8ed-e594-492a-88ad-dad769d9a44a",
                "identifier": "7",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "9dbde838-c224-4c8a-814b-126ed2452a42",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 7",
                "previousId": "5abae019-222a-4d80-91ce-0d05fa3b37e0",
                "nextId": "95866012-c266-4bd2-9b1f-f2a017d0aef1"
              },
              {
                "id": "95866012-c266-4bd2-9b1f-f2a017d0aef1",
                "identifier": "8",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "ab378618-3130-499b-a756-55802f968bcb",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 8",
                "previousId": "6848d8ed-e594-492a-88ad-dad769d9a44a",
                "nextId": "08dab467-6e31-403d-afd6-60759f6bc514"
              },
              {
                "id": "08dab467-6e31-403d-afd6-60759f6bc514",
                "identifier": "9",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "0b8b19b8-f144-4c91-b3f8-8f7a68587499",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 9",
                "previousId": "95866012-c266-4bd2-9b1f-f2a017d0aef1",
                "nextId": "ed3c28aa-4ea2-42ec-a8b0-c979fe685fca"
              },
              {
                "id": "ed3c28aa-4ea2-42ec-a8b0-c979fe685fca",
                "identifier": "10",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "774a063a-9612-4123-b3e7-eb9932ecea4a",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 10",
                "previousId": "08dab467-6e31-403d-afd6-60759f6bc514",
                "nextId": "7f6a2dfb-5d82-48a5-89d8-49f960fa30b9"
              },
              {
                "id": "7f6a2dfb-5d82-48a5-89d8-49f960fa30b9",
                "identifier": "11",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "9a8e28af-0bf1-4a50-ab6d-1e4fc9314b89",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 11",
                "previousId": "ed3c28aa-4ea2-42ec-a8b0-c979fe685fca",
                "nextId": "8cec31b3-47cd-4d7b-a303-3012a44f4aec"
              },
              {
                "id": "8cec31b3-47cd-4d7b-a303-3012a44f4aec",
                "identifier": "12",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "4faffc6f-373d-4d6f-9774-5247e53165e5",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 12",
                "previousId": "7f6a2dfb-5d82-48a5-89d8-49f960fa30b9"
              },
              {
                "id": "ff262925-a022-4438-a435-524bb0b70eec",
                "identifier": "1",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "62083091-f811-4e6a-a742-1d61e1b98f25",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 13",
                "nextId": "0521587a-4958-4bfd-9091-ab9fed2b0bca"
              },
              {
                "id": "0521587a-4958-4bfd-9091-ab9fed2b0bca",
                "identifier": "2",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "aa39a194-c243-4c61-b50d-d93c08ddddc7",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 14",
                "previousId": "ff262925-a022-4438-a435-524bb0b70eec",
                "nextId": "ffbb9838-d939-4c2b-a39c-378d862f65e2"
              },
              {
                "id": "ffbb9838-d939-4c2b-a39c-378d862f65e2",
                "identifier": "3",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "23e42a7e-f809-4eda-9147-69b9f1e4e1fc",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 15",
                "previousId": "0521587a-4958-4bfd-9091-ab9fed2b0bca",
                "nextId": "6c82e698-d339-4e09-9372-330b82224634"
              },
              {
                "id": "6c82e698-d339-4e09-9372-330b82224634",
                "identifier": "4",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "945421b7-1a77-4505-9816-53492101b03e",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 16",
                "previousId": "ffbb9838-d939-4c2b-a39c-378d862f65e2",
                "nextId": "9e785417-f82f-432e-ad3e-5f649eca2262"
              },
              {
                "id": "9e785417-f82f-432e-ad3e-5f649eca2262",
                "identifier": "5",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "6fb6b934-18b2-4769-a692-dea40a2afc40",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 17",
                "previousId": "6c82e698-d339-4e09-9372-330b82224634",
                "nextId": "099de5f1-b279-4115-9947-27abac44f186"
              },
              {
                "id": "099de5f1-b279-4115-9947-27abac44f186",
                "identifier": "6",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "41cd35ec-4225-4c61-9915-ff50f51b797d",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 18",
                "previousId": "9e785417-f82f-432e-ad3e-5f649eca2262",
                "nextId": "298296ca-f443-4a76-aec5-6dc8c3c45596"
              },
              {
                "id": "298296ca-f443-4a76-aec5-6dc8c3c45596",
                "identifier": "7",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "c91e82c7-d3d7-42bc-b7c1-cd7f053c9277",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 19",
                "previousId": "099de5f1-b279-4115-9947-27abac44f186",
                "nextId": "c3342cb4-9490-41d9-a907-c39216300622"
              },
              {
                "id": "c3342cb4-9490-41d9-a907-c39216300622",
                "identifier": "8",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "9cf8567c-4122-4c05-a60d-13d88dcbef45",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 20",
                "previousId": "298296ca-f443-4a76-aec5-6dc8c3c45596",
                "nextId": "16c77ccc-94b2-4f6d-8948-922d723f8e26"
              },
              {
                "id": "16c77ccc-94b2-4f6d-8948-922d723f8e26",
                "identifier": "9",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "1cb5fc17-def3-4ef2-ab9e-582aec2955b9",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 21",
                "previousId": "c3342cb4-9490-41d9-a907-c39216300622",
                "nextId": "3557c71d-bf21-483c-a6a2-1ef30311f817"
              },
              {
                "id": "3557c71d-bf21-483c-a6a2-1ef30311f817",
                "identifier": "10",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "256dd8bd-4423-4329-b1c9-3dd38bc1feae",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 22",
                "previousId": "16c77ccc-94b2-4f6d-8948-922d723f8e26",
                "nextId": "65c0d8c9-9105-4df2-b467-a60de9d9b372"
              },
              {
                "id": "65c0d8c9-9105-4df2-b467-a60de9d9b372",
                "identifier": "11",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "b0ca9344-0fd5-480d-95e5-8d2aa3d2479d",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 23",
                "previousId": "3557c71d-bf21-483c-a6a2-1ef30311f817",
                "nextId": "21ed6e24-c7e1-4252-bdc9-034a11692bf6"
              },
              {
                "id": "21ed6e24-c7e1-4252-bdc9-034a11692bf6",
                "identifier": "12",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "618db30e-99f4-4484-855c-39d5ce049952",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 24",
                "previousId": "65c0d8c9-9105-4df2-b467-a60de9d9b372",
                "nextId": "24a22dfa-e6e9-490e-80ad-aaaa40fbfd57"
              },
              {
                "id": "24a22dfa-e6e9-490e-80ad-aaaa40fbfd57",
                "identifier": "13",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "17ba90f4-0565-48f0-8921-90b5ed7acc33",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 25",
                "previousId": "21ed6e24-c7e1-4252-bdc9-034a11692bf6",
                "nextId": "2f614fe9-adf6-44c5-ac25-3faafa99807d"
              },
              {
                "id": "2f614fe9-adf6-44c5-ac25-3faafa99807d",
                "identifier": "14",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "1507e990-0e9f-4ae9-b57e-cffa6bb67c77",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 26",
                "previousId": "24a22dfa-e6e9-490e-80ad-aaaa40fbfd57",
                "nextId": "fb0cafb9-9c78-470d-ae9e-52896f193336"
              },
              {
                "id": "fb0cafb9-9c78-470d-ae9e-52896f193336",
                "identifier": "15",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "ac4cff5a-203d-441a-ba87-11d54423c1bf",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 27",
                "previousId": "2f614fe9-adf6-44c5-ac25-3faafa99807d",
                "nextId": "e8f4fc22-b61b-4e9f-b299-f51038162d16"
              },
              {
                "id": "e8f4fc22-b61b-4e9f-b299-f51038162d16",
                "identifier": "16",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "6b3df426-b921-4f89-bb50-4dd561b22b2a",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 28",
                "previousId": "fb0cafb9-9c78-470d-ae9e-52896f193336",
                "nextId": "e0ec8516-ca13-4ea0-bf9f-5a971baa7b90"
              },
              {
                "id": "e0ec8516-ca13-4ea0-bf9f-5a971baa7b90",
                "identifier": "17",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "924fffb5-b930-4247-93f5-7b034ab673d6",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 29",
                "previousId": "e8f4fc22-b61b-4e9f-b299-f51038162d16",
                "nextId": "622cb02c-4083-46e4-a473-96855c99a51f"
              },
              {
                "id": "622cb02c-4083-46e4-a473-96855c99a51f",
                "identifier": "18",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "5c286157-4859-4896-a5d7-4c14ca25604b",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 30",
                "previousId": "e0ec8516-ca13-4ea0-bf9f-5a971baa7b90",
                "nextId": "dd044d95-5508-4503-933e-eed3054a4e79"
              },
              {
                "id": "dd044d95-5508-4503-933e-eed3054a4e79",
                "identifier": "19",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "67fa510a-f42c-4307-bf82-df8377cc6484",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 31",
                "previousId": "622cb02c-4083-46e4-a473-96855c99a51f"
              }
            ],
            "population": {
              "id": "8503b894-74ee-424c-adcb-bf11afb67cc4",
              "name": "Study Population",
              "includesHealthySubjects": false,
              "criterionIds": [
                "59e2e74e-a637-488a-9ca5-6890c380c331",
                "50e92b59-5e85-4d23-9375-000167fb6d15",
                "734d8d91-a26c-421a-824c-bc916f4ccf37",
                "06b8dca7-d290-4eb2-8c0c-84a454188177",
                "2e114c79-6ccd-441f-81de-518bf095fccc",
                "5abae019-222a-4d80-91ce-0d05fa3b37e0",
                "6848d8ed-e594-492a-88ad-dad769d9a44a",
                "95866012-c266-4bd2-9b1f-f2a017d0aef1",
                "08dab467-6e31-403d-afd6-60759f6bc514",
                "ed3c28aa-4ea2-42ec-a8b0-c979fe685fca",
                "7f6a2dfb-5d82-48a5-89d8-49f960fa30b9",
                "8cec31b3-47cd-4d7b-a303-3012a44f4aec",
                "ff262925-a022-4438-a435-524bb0b70eec",
                "0521587a-4958-4bfd-9091-ab9fed2b0bca",
                "ffbb9838-d939-4c2b-a39c-378d862f65e2",
                "6c82e698-d339-4e09-9372-330b82224634",
                "9e785417-f82f-432e-ad3e-5f649eca2262",
                "099de5f1-b279-4115-9947-27abac44f186",
                "298296ca-f443-4a76-aec5-6dc8c3c45596",
                "c3342cb4-9490-41d9-a907-c39216300622",
                "16c77ccc-94b2-4f6d-8948-922d723f8e26",
                "3557c71d-bf21-483c-a6a2-1ef30311f817",
                "65c0d8c9-9105-4df2-b467-a60de9d9b372",
                "21ed6e24-c7e1-4252-bdc9-034a11692bf6",
                "24a22dfa-e6e9-490e-80ad-aaaa40fbfd57",
                "2f614fe9-adf6-44c5-ac25-3faafa99807d",
                "fb0cafb9-9c78-470d-ae9e-52896f193336",
                "e8f4fc22-b61b-4e9f-b299-f51038162d16",
                "e0ec8516-ca13-4ea0-bf9f-5a971baa7b90",
                "622cb02c-4083-46e4-a473-96855c99a51f",
                "dd044d95-5508-4503-933e-eed3054a4e79"
              ],
              "instanceType": "StudyDesignPopulation",
              "description": "Target population defined by eligibility criteria"
            },
            "objectives": [
              {
                "id": "de2713fe-71ec-4220-8915-621a0b0a3b15",
                "name": "Assess net copper balance with daily repeat-dose ALXN1840 treatment (15 mg and 30 mg) in participant...",
                "text": "Assess net copper balance with daily repeat-dose ALXN1840 treatment (15 mg and 30 mg) in participants with Wilson disease (WD)",
                "level": {
                  "id": "C85826",
                  "code": "C85826",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Primary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "d936ad93-c5ab-419d-ae46-fb98cff24027"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "95671988-5494-4330-93a1-b41324334ddf",
                "name": "Assess change in copper balance in response to ALXN1840 15 mg/day and 30 mg/day during ALXN1840 accu...",
                "text": "Assess change in copper balance in response to ALXN1840 15 mg/day and 30 mg/day during ALXN1840 accumulation and at steady state periods versus the pretreatment baseline in participants with WD",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "57ba9e3c-db29-4e16-b0bc-230d76d94fbd"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "e5604c16-ecf5-4341-a284-37df0a6f6e07",
                "name": "Investigate the effect of ALXN1840 (15 mg/day and 30 mg/day) on the disposition of copper in partici...",
                "text": "Investigate the effect of ALXN1840 (15 mg/day and 30 mg/day) on the disposition of copper in participants with WD",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "fffa32b9-39c9-438b-b095-08d80866ab8a"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "0ab43b12-92d9-4cbc-975e-a06b3d8a45be",
                "name": "Investigate the effect of ALXN1840 on the disposition of molybdenum at steady state at 15 mg/day and...",
                "text": "Investigate the effect of ALXN1840 on the disposition of molybdenum at steady state at 15 mg/day and 30 mg/day in participants with WD",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "819b4ed7-4e2d-47be-a8c8-9265824977b7"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "b12773ee-b4d0-4df3-a60c-8ab2496d07b9",
                "name": "Assess steady-state total molybdenum balance as a measure of ALXN1840 15 mg/day and 30 mg/day in par...",
                "text": "Assess steady-state total molybdenum balance as a measure of ALXN1840 15 mg/day and 30 mg/day in participants with WD",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "dd8890f1-e74f-490c-8345-83cb9cde86f9"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "558bbf13-4962-4b52-8baa-aa51a0de933e",
                "name": "Assess accumulation of molybdenum with ALXN1840 treatment at 15 mg/day and 30 mg/day in participants...",
                "text": "Assess accumulation of molybdenum with ALXN1840 treatment at 15 mg/day and 30 mg/day in participants with WD",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "c45f6a5e-7967-49d7-b434-7c20979ebfe0"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "85b5ebaa-32cd-417b-b3f9-555cf14cdd59",
                "name": "Determine the steady-state plasma pharmacokinetic (PK) of total molybdenum and plasma ultrafiltrate ...",
                "text": "Determine the steady-state plasma pharmacokinetic (PK) of total molybdenum and plasma ultrafiltrate (PUF) molybdenum (as surrogate measures of ALXN1840, 15 mg and 30 mg) in participants with WD",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "4a440623-7339-4cf4-bf2a-1a62df50d4c2"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "f8444066-5a76-4207-a959-cebaab392732",
                "name": "Evaluate the safety and tolerability of repeated-dose administration of ALXN1840 15 mg/day and 30 mg...",
                "text": "Evaluate the safety and tolerability of repeated-dose administration of ALXN1840 15 mg/day and 30 mg/day in participants with WD",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "5a4acf4e-e773-4432-a549-bd5152dbebe7",
                  "b073ed06-5079-4954-9205-3a00f58cb4ca",
                  "5b6e4dc5-a04f-4b5f-9422-8b971bec882c",
                  "54730bd0-07aa-421b-b86c-82e03d627d5b",
                  "9f61d7b4-3076-488a-8546-5054ce72574a"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "ee80a837-42ef-4096-b57d-05720178090f",
                "name": "Determine dose response of ALXN1840 15 mg/day and 30 mg/day for copper balance in participants with ...",
                "text": "Determine dose response of ALXN1840 15 mg/day and 30 mg/day for copper balance in participants with WD",
                "level": {
                  "id": "C163559",
                  "code": "C163559",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Exploratory Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "8b35798e-9c51-4045-b0ec-484e684e6e6e"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "21f4874a-f9b8-486b-9f90-ee7b35385000",
                "name": "Determine the effect of treatment duration on copper balance in participants with WD",
                "text": "Determine the effect of treatment duration on copper balance in participants with WD",
                "level": {
                  "id": "C163559",
                  "code": "C163559",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Exploratory Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "275693fa-0aa7-476e-b360-0284a2eed214"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "470b399f-52b7-4225-ad78-06b35fce3d55",
                "name": "Assess the effects of ALXN1840 on ceruloplasmin, ceruloplasmin-bound copper LBC profiles in plasma i...",
                "text": "Assess the effects of ALXN1840 on ceruloplasmin, ceruloplasmin-bound copper LBC profiles in plasma in participants with WD",
                "level": {
                  "id": "C163559",
                  "code": "C163559",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Exploratory Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "d367dce3-f994-49ab-b0c7-cf7daccf2174"
                ],
                "instanceType": "Objective"
              }
            ],
            "endpoints": [
              {
                "id": "d936ad93-c5ab-419d-ae46-fb98cff24027",
                "name": "",
                "text": "Mean daily copper balance where copper balance is measured by the calculated difference between copper intake (in food and drink) and copper output (in feces and urine) during ALXN1840 accumulation and steady-state periods for each dose",
                "level": {
                  "id": "C98772",
                  "code": "C98772",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Primary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "57ba9e3c-db29-4e16-b0bc-230d76d94fbd",
                "name": "",
                "text": "Change in mean daily copper balance as measured by the calculated difference between copper intake (in food and drink) and copper output (in feces and urine) from pretreatment baseline (Days -4 through -1) and ALXN1840 accumulation and steady-state periods for each dose",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "fffa32b9-39c9-438b-b095-08d80866ab8a",
                "name": "",
                "text": "Copper quantified in food, drink, feces, and urine, including plasma total and labile bound copper (LBC) during ALXN1840 accumulation and steady-state periods for each dose",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "819b4ed7-4e2d-47be-a8c8-9265824977b7",
                "name": "",
                "text": "Molybdenum quantified in food, drink, feces, and urine, plasma total molybdenum at ALXN1840 steady state",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Pharmacokinetic"
              },
              {
                "id": "dd8890f1-e74f-490c-8345-83cb9cde86f9",
                "name": "",
                "text": "Mean daily molybdenum balance as demonstrated through measurement of molybdenum intake (in food, drink and ALXN1840), and molybdenum output (feces and urine) representing ALXN1840 steady state",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Pharmacokinetic"
              },
              {
                "id": "c45f6a5e-7967-49d7-b434-7c20979ebfe0",
                "name": "",
                "text": "Accumulation of molybdenum as determined by molybdenum balance",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Pharmacokinetic"
              },
              {
                "id": "4a440623-7339-4cf4-bf2a-1a62df50d4c2",
                "name": "",
                "text": "PK parameters for plasma total and PUF-molybdenum",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Pharmacokinetic"
              },
              {
                "id": "5a4acf4e-e773-4432-a549-bd5152dbebe7",
                "name": "",
                "text": "Treatment emergent adverse events (TEAEs)/serious adverse events (SAEs)",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "b073ed06-5079-4954-9205-3a00f58cb4ca",
                "name": "",
                "text": "Clinical laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis)",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "5b6e4dc5-a04f-4b5f-9422-8b971bec882c",
                "name": "",
                "text": "Physical examinations",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "54730bd0-07aa-421b-b86c-82e03d627d5b",
                "name": "",
                "text": "Heart rate, intervals (PR, QRS, QT and QTc), and clinically significant electrocardiogram (ECG) findings as determined by triplicate 12-lead ECG",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "9f61d7b4-3076-488a-8546-5054ce72574a",
                "name": "",
                "text": "Vital sign assessments (blood pressure and heart rate)",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "8b35798e-9c51-4045-b0ec-484e684e6e6e",
                "name": "",
                "text": "Assess dose response of ALXN1840 on copper balance focusing on copper balance",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "275693fa-0aa7-476e-b360-0284a2eed214",
                "name": "",
                "text": "Determine the effect of time following initiation of ALXN1840 treatment on copper balance",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "d367dce3-f994-49ab-b0c7-cf7daccf2174",
                "name": "",
                "text": "Ceruloplasmin, ceruloplasmin-bound copper, and LBC: Change in ceruloplasmin at Days 1, 8, 25, 29, 36, and Day 39 compared with predose",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Biomarker"
              }
            ],
            "scheduleTimelines": [
              {
                "id": "d0335fa2-abb8-417d-ba97-d4c674d5b221",
                "name": "Main Schedule Timeline",
                "mainTimeline": true,
                "instanceType": "ScheduleTimeline",
                "entryCondition": "Subject enrolled in study",
                "entryId": "b29306da-536a-4795-beec-ff63567ba79e",
                "instances": [
                  {
                    "id": "b29306da-536a-4795-beec-ff63567ba79e",
                    "activityIds": [
                      "2685bbcf-8d05-4df0-9a3e-084c54f655b3"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Informed consent @ Screening (-42 to -9)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "7b5788e5-7c88-4e27-9817-602e4fd08e42"
                  },
                  {
                    "id": "87abf57d-e49f-4c0a-ad9f-51ffb37fc3af",
                    "activityIds": [
                      "2fd8a19d-0e62-47fa-8453-683d56ad82c7"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Admit to unit @ Screening (-8)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "0e439567-df59-4e5c-bb7b-587d42e8d6e5"
                  },
                  {
                    "id": "56259851-3f13-45fc-afeb-8e04982a4c06",
                    "activityIds": [
                      "2fd8a19d-0e62-47fa-8453-683d56ad82c7"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Admit to unit @ Inpatient Period 2 (Day 23)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "aa57efe0-a9cc-4427-855a-140fb1aee54a",
                    "timingId": "c25aa467-3ccc-4b17-90b3-da2087b3d190"
                  },
                  {
                    "id": "625dae54-1508-4442-97fd-52c243076997",
                    "activityIds": [
                      "2c4c5521-bb8c-4190-bd37-1a1c8d63f6a4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Discharge from unit @ Inpatient Period 1 (Day 9)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "810b7563-321e-474a-a8e3-116349030a6f"
                  },
                  {
                    "id": "645782e8-964b-4b4a-8b21-3dc2687be1a0",
                    "activityIds": [
                      "2c4c5521-bb8c-4190-bd37-1a1c8d63f6a4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Discharge from unit @ Inpatient Period 2 (Day 40)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "337a47c6-f667-43ff-bd15-7f8bdf884351"
                  },
                  {
                    "id": "f93eafa0-1c50-4d59-8215-37b077fb3e68",
                    "activityIds": [
                      "f3094b41-79e2-458c-ac16-7f8a1f469330"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Outpatient visit or phone call @ OP (Day 10-22)",
                    "epochId": "9910e2f6-6088-4468-998c-9dadba3878e1",
                    "encounterId": "7d28a964-6964-443c-861d-3fb24dac0c73"
                  },
                  {
                    "id": "0850a17d-b467-4889-b6c6-474fedbd821a",
                    "activityIds": [
                      "d67d9994-08e3-49a8-9048-5ab7688fa7dd"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Inclusion/exclusion @ Screening (-42 to -9)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "7b5788e5-7c88-4e27-9817-602e4fd08e42"
                  },
                  {
                    "id": "c11f3da2-17cc-4579-905f-1553a0e5a685",
                    "activityIds": [
                      "d67d9994-08e3-49a8-9048-5ab7688fa7dd"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Inclusion/exclusion @ Screening (-8)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "0e439567-df59-4e5c-bb7b-587d42e8d6e5"
                  },
                  {
                    "id": "e8d4bc43-2680-4645-944c-47d1accef694",
                    "activityIds": [
                      "d67d9994-08e3-49a8-9048-5ab7688fa7dd"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Inclusion/exclusion @ Inpatient Period 1 (Day 1)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "639aca4b-f8c1-4726-a940-720a97b4e096",
                    "timingId": "0eed086c-55f3-4d2a-ae2d-dc7fed68ccf7"
                  },
                  {
                    "id": "2f7c945a-91f6-420a-8700-9d1719d880ba",
                    "activityIds": [
                      "2aa2422a-c51b-4cb9-8ed0-26c77643e137"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Discuss/document contraception @ Screening (-42 to -9)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "7b5788e5-7c88-4e27-9817-602e4fd08e42"
                  },
                  {
                    "id": "5bf92485-80bb-401f-89a7-0a5338c2319c",
                    "activityIds": [
                      "2aa2422a-c51b-4cb9-8ed0-26c77643e137"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Discuss/document contraception @ Screening (-8)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "0e439567-df59-4e5c-bb7b-587d42e8d6e5"
                  },
                  {
                    "id": "aedba898-b7f0-48bc-90f8-f06abc19b3dc",
                    "activityIds": [
                      "2aa2422a-c51b-4cb9-8ed0-26c77643e137"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Discuss/document contraception @ Inpatient Period 1 (Day 9)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "810b7563-321e-474a-a8e3-116349030a6f"
                  },
                  {
                    "id": "b93e0f47-93e4-4afc-bb1e-ba8ba91d0203",
                    "activityIds": [
                      "2aa2422a-c51b-4cb9-8ed0-26c77643e137"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Discuss/document contraception @ EOS Day 54+/-2",
                    "epochId": "9a99dd8f-b4d4-4d8c-b419-9db33003f93f",
                    "encounterId": "efed4e68-51b4-4eaf-984d-1eb3d833217b",
                    "timingId": "da91e438-b182-49a3-9239-81cd7c35d854"
                  },
                  {
                    "id": "19f6e38c-1f51-4beb-a50b-ba7dd3249f45",
                    "activityIds": [
                      "481c7f4d-f155-45ec-8ff8-c655bf6fd4cf"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Follicle-stimulating hormone (post-menopausal f... @ Screening (-42 to -9)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "7b5788e5-7c88-4e27-9817-602e4fd08e42"
                  },
                  {
                    "id": "8f55e955-881a-4551-9028-2ac7aa92af27",
                    "activityIds": [
                      "7c5f656d-e9b8-4249-94e7-0a06cfe4c24a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Alcohol test @ Screening (-42 to -9)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "7b5788e5-7c88-4e27-9817-602e4fd08e42"
                  },
                  {
                    "id": "4c0953d8-5cbf-40ba-947b-4c0dcf809324",
                    "activityIds": [
                      "7c5f656d-e9b8-4249-94e7-0a06cfe4c24a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Alcohol test @ Screening (-8)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "0e439567-df59-4e5c-bb7b-587d42e8d6e5"
                  },
                  {
                    "id": "1bb2265e-d07c-4a82-8936-e57f9d2738b3",
                    "activityIds": [
                      "80d45301-f45d-444f-b98c-60276964c28d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urine drug screen @ Screening (-42 to -9)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "7b5788e5-7c88-4e27-9817-602e4fd08e42"
                  },
                  {
                    "id": "24933fb6-1029-436e-9038-0b1bff4f9c1d",
                    "activityIds": [
                      "80d45301-f45d-444f-b98c-60276964c28d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urine drug screen @ Screening (-8)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "0e439567-df59-4e5c-bb7b-587d42e8d6e5"
                  },
                  {
                    "id": "2fb9d591-a323-46c0-8c06-ffb8cb33bb66",
                    "activityIds": [
                      "1caced06-467d-43c6-a39f-ca2f78a5529a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "HIV, hepatitis B and C screen @ Screening (-42 to -9)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "7b5788e5-7c88-4e27-9817-602e4fd08e42"
                  },
                  {
                    "id": "0f8dcabe-cc2e-4865-8b11-0ab495fcb00d",
                    "activityIds": [
                      "02fe9dc7-b7f3-4063-a8f3-24219f33238a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Medical history/demographics @ Screening (-42 to -9)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "7b5788e5-7c88-4e27-9817-602e4fd08e42"
                  },
                  {
                    "id": "520eaf32-ce09-42c9-9ffa-197b52c49734",
                    "activityIds": [
                      "6ed1568b-7eae-4cbf-a3ef-d979624e3306"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "WD history @ Screening (-42 to -9)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "7b5788e5-7c88-4e27-9817-602e4fd08e42"
                  },
                  {
                    "id": "8e91c522-e0cb-4f56-aa72-15ffba0d1bde",
                    "activityIds": [
                      "7d7fac7f-4d71-4154-adb4-73d0ea0496ae"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Prior WD treatment @ Screening (-42 to -9)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "7b5788e5-7c88-4e27-9817-602e4fd08e42"
                  },
                  {
                    "id": "e2848055-f7bf-4e0a-b804-661962631e7b",
                    "activityIds": [
                      "7d7fac7f-4d71-4154-adb4-73d0ea0496ae"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Prior WD treatment @ C-I (-1)",
                    "epochId": "60aa5dc9-3d59-4e23-a442-e7e996d38969",
                    "encounterId": "0ceeab15-73a7-4e34-8878-c26ff7a2d13a"
                  },
                  {
                    "id": "50332f29-d2e1-45cf-8c4a-5d74d1411199",
                    "activityIds": [
                      "6dd82ade-fe18-45fc-8e98-df4c651ae864"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Physical examination @ Screening (-42 to -9)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "7b5788e5-7c88-4e27-9817-602e4fd08e42"
                  },
                  {
                    "id": "991e96f2-f371-4478-9eae-4601a36145a6",
                    "activityIds": [
                      "6dd82ade-fe18-45fc-8e98-df4c651ae864"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Physical examination @ Screening (-8)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "0e439567-df59-4e5c-bb7b-587d42e8d6e5"
                  },
                  {
                    "id": "9a248457-39cc-477a-9f0a-5de190f9b2f7",
                    "activityIds": [
                      "6dd82ade-fe18-45fc-8e98-df4c651ae864"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Physical examination @ Inpatient Period 2 (Day 23)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "aa57efe0-a9cc-4427-855a-140fb1aee54a",
                    "timingId": "c25aa467-3ccc-4b17-90b3-da2087b3d190"
                  },
                  {
                    "id": "44c535b8-6316-4cc5-a49e-144cd2b20883",
                    "activityIds": [
                      "6dd82ade-fe18-45fc-8e98-df4c651ae864"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Physical examination @ EOS Day 54+/-2",
                    "epochId": "9a99dd8f-b4d4-4d8c-b419-9db33003f93f",
                    "encounterId": "efed4e68-51b4-4eaf-984d-1eb3d833217b",
                    "timingId": "da91e438-b182-49a3-9239-81cd7c35d854"
                  },
                  {
                    "id": "8c394dc8-990b-462b-9eec-4dcdf1be8b6e",
                    "activityIds": [
                      "e977a927-cd09-46f7-8134-1294c97dea27"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Height, weight, and BMI @ Screening (-42 to -9)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "7b5788e5-7c88-4e27-9817-602e4fd08e42"
                  },
                  {
                    "id": "88b81e48-830a-457f-b524-57c4e7e96bcd",
                    "activityIds": [
                      "e977a927-cd09-46f7-8134-1294c97dea27"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Height, weight, and BMI @ Screening (-8)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "0e439567-df59-4e5c-bb7b-587d42e8d6e5"
                  },
                  {
                    "id": "30ca59fe-08e8-482c-8e06-57d0f7aa4695",
                    "activityIds": [
                      "e977a927-cd09-46f7-8134-1294c97dea27"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Height, weight, and BMI @ Inpatient Period 2 (Day 23)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "aa57efe0-a9cc-4427-855a-140fb1aee54a",
                    "timingId": "c25aa467-3ccc-4b17-90b3-da2087b3d190"
                  },
                  {
                    "id": "621bb858-e12a-47dc-a3c7-ed6a05a12caa",
                    "activityIds": [
                      "e977a927-cd09-46f7-8134-1294c97dea27"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Height, weight, and BMI @ EOS Day 54+/-2",
                    "epochId": "9a99dd8f-b4d4-4d8c-b419-9db33003f93f",
                    "encounterId": "efed4e68-51b4-4eaf-984d-1eb3d833217b",
                    "timingId": "da91e438-b182-49a3-9239-81cd7c35d854"
                  },
                  {
                    "id": "a5900180-058c-437d-97a7-439971adc003",
                    "activityIds": [
                      "095516a4-2655-4f1e-8cd5-81dbe6a45969"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Enrollment/inclusion @ Screening (-7)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "6b799dc8-6ffb-4d23-84e0-fdd68e3f981c"
                  },
                  {
                    "id": "e331ed3d-7c75-49a7-88a3-8d8ee8055e05",
                    "activityIds": [
                      "9e6d729d-392b-4f08-95a7-ad2dd90032de"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Discontinue chelation therapy @ C-I (-6 through -4)",
                    "epochId": "60aa5dc9-3d59-4e23-a442-e7e996d38969",
                    "encounterId": "594db433-91aa-47e5-84df-08250900a397"
                  },
                  {
                    "id": "9d5b5673-039f-400e-8aa7-5c7eb0ff6ed6",
                    "activityIds": [
                      "05e22e79-ce61-4789-ab0b-ddfb0587ef40"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Discontinue zinc therapy @ Screening (-21)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "4741a38a-ac42-4ef4-ad4f-2c0e571ceed2"
                  },
                  {
                    "id": "17c6b97b-70ea-4cba-84e7-aae738ded536",
                    "activityIds": [
                      "1dd9e020-e442-4831-a718-c1e4bda4ee47"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "ALXN1840 15 mg/day @ Inpatient Period 1 (Day 1)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "639aca4b-f8c1-4726-a940-720a97b4e096",
                    "timingId": "0eed086c-55f3-4d2a-ae2d-dc7fed68ccf7"
                  },
                  {
                    "id": "c44a111e-acb5-4585-b9e4-229d48329959",
                    "activityIds": [
                      "1dd9e020-e442-4831-a718-c1e4bda4ee47"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "ALXN1840 15 mg/day @ Inpatient Period 1 (Day 2-3)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "5cff5914-49e0-4d25-add3-b817a9b42c44"
                  },
                  {
                    "id": "490d719a-c9e0-4529-8dc2-7e8b611abb11",
                    "activityIds": [
                      "1dd9e020-e442-4831-a718-c1e4bda4ee47"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "ALXN1840 15 mg/day @ Inpatient Period 1 (Day 4-7)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "f5ee1059-deac-4caf-a9db-97cb9fc3e849",
                    "timingId": "b36ece54-11a3-4776-ba9d-53657d600963"
                  },
                  {
                    "id": "fd3b3eb1-10f9-40a7-93ec-de8c44ac9840",
                    "activityIds": [
                      "1dd9e020-e442-4831-a718-c1e4bda4ee47"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "ALXN1840 15 mg/day @ Inpatient Period 1 (Day 8)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "2d0168c6-9f46-48ff-b3d4-a01f0dddbce3"
                  },
                  {
                    "id": "89d32fb4-6620-427c-b288-dd535cea9dd0",
                    "activityIds": [
                      "1dd9e020-e442-4831-a718-c1e4bda4ee47"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "ALXN1840 15 mg/day @ Inpatient Period 1 (Day 9)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "810b7563-321e-474a-a8e3-116349030a6f"
                  },
                  {
                    "id": "d0678de6-78f6-41e8-9b0d-57d6b9aec8d7",
                    "activityIds": [
                      "1dd9e020-e442-4831-a718-c1e4bda4ee47"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "ALXN1840 15 mg/day @ OP (Day 10-22)",
                    "epochId": "9910e2f6-6088-4468-998c-9dadba3878e1",
                    "encounterId": "7d28a964-6964-443c-861d-3fb24dac0c73"
                  },
                  {
                    "id": "5d64b0db-26e2-4466-a615-6b7435efea69",
                    "activityIds": [
                      "1dd9e020-e442-4831-a718-c1e4bda4ee47"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "ALXN1840 15 mg/day @ Inpatient Period 2 (Day 23)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "aa57efe0-a9cc-4427-855a-140fb1aee54a",
                    "timingId": "c25aa467-3ccc-4b17-90b3-da2087b3d190"
                  },
                  {
                    "id": "00aa361b-60db-4002-b6c7-674f848d9f6f",
                    "activityIds": [
                      "1dd9e020-e442-4831-a718-c1e4bda4ee47"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "ALXN1840 15 mg/day @ Inpatient Period 2 (Day 24)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "52c2db34-fc24-4f51-855d-a5995b69da8e"
                  },
                  {
                    "id": "6620b6c7-4ed1-423d-ab11-53a3c420631a",
                    "activityIds": [
                      "1dd9e020-e442-4831-a718-c1e4bda4ee47"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "ALXN1840 15 mg/day @ Inpatient Period 2 (Day 25)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "e88d07ab-f998-47c7-8e8b-c2949d1b2b9c"
                  },
                  {
                    "id": "85dadae7-7e54-4424-9247-8baa0defb2f3",
                    "activityIds": [
                      "1dd9e020-e442-4831-a718-c1e4bda4ee47"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "ALXN1840 15 mg/day @ Inpatient Period 2 (Day 26-28)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "fcb42287-c2cb-4d0d-9b55-ecd4c62a406b"
                  },
                  {
                    "id": "61893320-4a84-4500-b4a0-0e6da5b6f579",
                    "activityIds": [
                      "c6b3a06f-da18-4715-b845-f41f3e254c13"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "ALXN1840 30 mg/day @ Inpatient Period 2 (Day 29)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "551f8be3-847f-4b04-a2f6-0df5257e72b7",
                    "timingId": "5417665e-780d-4818-b65e-68ba6784706b"
                  },
                  {
                    "id": "4b3f1d5f-e393-4c94-ac91-c48d19960368",
                    "activityIds": [
                      "c6b3a06f-da18-4715-b845-f41f3e254c13"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "ALXN1840 30 mg/day @ Inpatient Period 2 (Day 30-35)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "2a28a085-2487-44bc-8a20-7e8f783adb7b"
                  },
                  {
                    "id": "f0834bfc-699b-4188-9b1e-744f52e5f920",
                    "activityIds": [
                      "c6b3a06f-da18-4715-b845-f41f3e254c13"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "ALXN1840 30 mg/day @ Inpatient Period 2 (Day 36)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "5a75526e-73c8-4e2b-bed6-46324bb62098"
                  },
                  {
                    "id": "cd598190-a0f7-4c8f-b77b-b0947dec6280",
                    "activityIds": [
                      "c6b3a06f-da18-4715-b845-f41f3e254c13"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "ALXN1840 30 mg/day @ Inpatient Period 2 (Day 37-38)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "6c0c9841-f92b-4e90-88d9-82a75e98c8f8"
                  },
                  {
                    "id": "655e0abe-8fdb-4bbe-b490-f771a6fb3d2d",
                    "activityIds": [
                      "c6b3a06f-da18-4715-b845-f41f3e254c13"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "ALXN1840 30 mg/day @ Inpatient Period 2 (Day 39)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "6a447147-87eb-42c7-b2a6-598b03af3afc"
                  },
                  {
                    "id": "bc48ffd4-df2c-46b4-8eba-666beba2a9be",
                    "activityIds": [
                      "2b06c94f-fc28-4e2e-bc25-f13aae8a4ce0"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Study intervention compliance @ OP (Day 10-22)",
                    "epochId": "9910e2f6-6088-4468-998c-9dadba3878e1",
                    "encounterId": "7d28a964-6964-443c-861d-3fb24dac0c73"
                  },
                  {
                    "id": "69c16452-9414-4467-9191-974933bf4077",
                    "activityIds": [
                      "2b06c94f-fc28-4e2e-bc25-f13aae8a4ce0"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Study intervention compliance @ Inpatient Period 2 (Day 23)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "aa57efe0-a9cc-4427-855a-140fb1aee54a",
                    "timingId": "c25aa467-3ccc-4b17-90b3-da2087b3d190"
                  },
                  {
                    "id": "1bca1865-479c-4d4f-a15d-a2bc70e66f86",
                    "activityIds": [
                      "0603453c-99da-4ddf-b8f3-f2e9496d2145"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Blood sampling for PK: Plasma total Mo and PUF-Mo @ C-I (-1)",
                    "epochId": "60aa5dc9-3d59-4e23-a442-e7e996d38969",
                    "encounterId": "0ceeab15-73a7-4e34-8878-c26ff7a2d13a"
                  },
                  {
                    "id": "b52f7703-5487-42b1-bf03-7f31ca886da3",
                    "activityIds": [
                      "0603453c-99da-4ddf-b8f3-f2e9496d2145"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Blood sampling for PK: Plasma total Mo and PUF-Mo @ Inpatient Period 1 (Day 1)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "639aca4b-f8c1-4726-a940-720a97b4e096",
                    "timingId": "0eed086c-55f3-4d2a-ae2d-dc7fed68ccf7"
                  },
                  {
                    "id": "e88ae652-6557-4aa8-a973-4006db23d52e",
                    "activityIds": [
                      "0603453c-99da-4ddf-b8f3-f2e9496d2145"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Blood sampling for PK: Plasma total Mo and PUF-Mo @ Inpatient Period 1 (Day 4-7)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "f5ee1059-deac-4caf-a9db-97cb9fc3e849",
                    "timingId": "b36ece54-11a3-4776-ba9d-53657d600963"
                  },
                  {
                    "id": "f6d1d55a-615e-45e0-84b5-2930f6be1ac2",
                    "activityIds": [
                      "0603453c-99da-4ddf-b8f3-f2e9496d2145"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Blood sampling for PK: Plasma total Mo and PUF-Mo @ Inpatient Period 2 (Day 23)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "aa57efe0-a9cc-4427-855a-140fb1aee54a",
                    "timingId": "c25aa467-3ccc-4b17-90b3-da2087b3d190"
                  },
                  {
                    "id": "41fb185d-0030-4d08-979c-e78c5a0f5c9d",
                    "activityIds": [
                      "0603453c-99da-4ddf-b8f3-f2e9496d2145"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Blood sampling for PK: Plasma total Mo and PUF-Mo @ Inpatient Period 2 (Day 25)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "e88d07ab-f998-47c7-8e8b-c2949d1b2b9c"
                  },
                  {
                    "id": "edea5889-080f-4e1f-870a-d2b95bbb5f87",
                    "activityIds": [
                      "0603453c-99da-4ddf-b8f3-f2e9496d2145"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Blood sampling for PK: Plasma total Mo and PUF-Mo @ Inpatient Period 2 (Day 26-28)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "fcb42287-c2cb-4d0d-9b55-ecd4c62a406b"
                  },
                  {
                    "id": "0745808c-4d4e-4afa-884c-9198a8477291",
                    "activityIds": [
                      "0603453c-99da-4ddf-b8f3-f2e9496d2145"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Blood sampling for PK: Plasma total Mo and PUF-Mo @ Inpatient Period 2 (Day 29)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "551f8be3-847f-4b04-a2f6-0df5257e72b7",
                    "timingId": "5417665e-780d-4818-b65e-68ba6784706b"
                  },
                  {
                    "id": "68abc801-e9cf-457a-b2cf-b945b8942ea2",
                    "activityIds": [
                      "0603453c-99da-4ddf-b8f3-f2e9496d2145"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Blood sampling for PK: Plasma total Mo and PUF-Mo @ Inpatient Period 2 (Day 30-35)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "2a28a085-2487-44bc-8a20-7e8f783adb7b"
                  },
                  {
                    "id": "c36726cd-8e63-4db4-85d3-86a96f7c7813",
                    "activityIds": [
                      "0603453c-99da-4ddf-b8f3-f2e9496d2145"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Blood sampling for PK: Plasma total Mo and PUF-Mo @ Inpatient Period 2 (Day 36)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "5a75526e-73c8-4e2b-bed6-46324bb62098"
                  },
                  {
                    "id": "324cdb31-1722-4368-b95a-d32b8791feed",
                    "activityIds": [
                      "0603453c-99da-4ddf-b8f3-f2e9496d2145"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Blood sampling for PK: Plasma total Mo and PUF-Mo @ Inpatient Period 2 (Day 39)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "6a447147-87eb-42c7-b2a6-598b03af3afc"
                  },
                  {
                    "id": "ff13bc7c-4b0f-4392-9bb2-122428de9a25",
                    "activityIds": [
                      "0603453c-99da-4ddf-b8f3-f2e9496d2145"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Blood sampling for PK: Plasma total Mo and PUF-Mo @ EOS Day 54+/-2",
                    "epochId": "9a99dd8f-b4d4-4d8c-b419-9db33003f93f",
                    "encounterId": "efed4e68-51b4-4eaf-984d-1eb3d833217b",
                    "timingId": "da91e438-b182-49a3-9239-81cd7c35d854"
                  },
                  {
                    "id": "c272dc51-fcb9-47ab-a755-c47060e16141",
                    "activityIds": [
                      "13dacf21-6052-4139-8397-16846d827a06"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Chemistry, hematology, Coagulation @ Screening (-42 to -9)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "7b5788e5-7c88-4e27-9817-602e4fd08e42"
                  },
                  {
                    "id": "139b51c6-aa9c-4751-964a-47d6c54f3911",
                    "activityIds": [
                      "13dacf21-6052-4139-8397-16846d827a06"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Chemistry, hematology, Coagulation @ Screening (-8)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "0e439567-df59-4e5c-bb7b-587d42e8d6e5"
                  },
                  {
                    "id": "0a7b8ca2-7c3e-4e84-8af4-2faa26946ad5",
                    "activityIds": [
                      "13dacf21-6052-4139-8397-16846d827a06"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Chemistry, hematology, Coagulation @ C-I (-1)",
                    "epochId": "60aa5dc9-3d59-4e23-a442-e7e996d38969",
                    "encounterId": "0ceeab15-73a7-4e34-8878-c26ff7a2d13a"
                  },
                  {
                    "id": "14dc14c5-bd46-47cf-9ec7-471ba5d85d35",
                    "activityIds": [
                      "13dacf21-6052-4139-8397-16846d827a06"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Chemistry, hematology, Coagulation @ Inpatient Period 1 (Day 8)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "2d0168c6-9f46-48ff-b3d4-a01f0dddbce3"
                  },
                  {
                    "id": "875435e8-74bf-4ca2-87b6-55c939365fc6",
                    "activityIds": [
                      "13dacf21-6052-4139-8397-16846d827a06"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Chemistry, hematology, Coagulation @ OP (Day 10-22)",
                    "epochId": "9910e2f6-6088-4468-998c-9dadba3878e1",
                    "encounterId": "7d28a964-6964-443c-861d-3fb24dac0c73"
                  },
                  {
                    "id": "26d8ecbe-1649-4be4-b1fc-0dd01efebbb6",
                    "activityIds": [
                      "13dacf21-6052-4139-8397-16846d827a06"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Chemistry, hematology, Coagulation @ Inpatient Period 2 (Day 23)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "aa57efe0-a9cc-4427-855a-140fb1aee54a",
                    "timingId": "c25aa467-3ccc-4b17-90b3-da2087b3d190"
                  },
                  {
                    "id": "ab5a69cd-152d-4b57-8f6a-a2e96f445866",
                    "activityIds": [
                      "13dacf21-6052-4139-8397-16846d827a06"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Chemistry, hematology, Coagulation @ Inpatient Period 2 (Day 26-28)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "fcb42287-c2cb-4d0d-9b55-ecd4c62a406b"
                  },
                  {
                    "id": "9f8f9f16-ad2d-49e5-b083-f044515a9769",
                    "activityIds": [
                      "13dacf21-6052-4139-8397-16846d827a06"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Chemistry, hematology, Coagulation @ Inpatient Period 2 (Day 30-35)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "2a28a085-2487-44bc-8a20-7e8f783adb7b"
                  },
                  {
                    "id": "2ec8dfca-85e3-4926-9787-1a36def7a959",
                    "activityIds": [
                      "13dacf21-6052-4139-8397-16846d827a06"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Chemistry, hematology, Coagulation @ Inpatient Period 2 (Day 40)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "337a47c6-f667-43ff-bd15-7f8bdf884351"
                  },
                  {
                    "id": "fadf7173-2ccb-4744-a1b7-04892cde5a82",
                    "activityIds": [
                      "13dacf21-6052-4139-8397-16846d827a06"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Chemistry, hematology, Coagulation @ EOS Day 54+/-2",
                    "epochId": "9a99dd8f-b4d4-4d8c-b419-9db33003f93f",
                    "encounterId": "efed4e68-51b4-4eaf-984d-1eb3d833217b",
                    "timingId": "da91e438-b182-49a3-9239-81cd7c35d854"
                  },
                  {
                    "id": "d07c63ac-ec62-4e59-8105-65b4635289bd",
                    "activityIds": [
                      "09d48280-a545-4f5f-a213-6bfa0d3a36b2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urinalysis @ Screening (-42 to -9)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "7b5788e5-7c88-4e27-9817-602e4fd08e42"
                  },
                  {
                    "id": "a6375136-024d-470e-9b18-222bb10f86e6",
                    "activityIds": [
                      "09d48280-a545-4f5f-a213-6bfa0d3a36b2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urinalysis @ Screening (-8)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "0e439567-df59-4e5c-bb7b-587d42e8d6e5"
                  },
                  {
                    "id": "852ec794-b2e9-411c-9a61-1d50f1b5ee38",
                    "activityIds": [
                      "09d48280-a545-4f5f-a213-6bfa0d3a36b2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urinalysis @ Inpatient Period 1 (Day 8)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "2d0168c6-9f46-48ff-b3d4-a01f0dddbce3"
                  },
                  {
                    "id": "b1a41689-8154-4c5a-847b-c484bc981655",
                    "activityIds": [
                      "09d48280-a545-4f5f-a213-6bfa0d3a36b2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urinalysis @ OP (Day 10-22)",
                    "epochId": "9910e2f6-6088-4468-998c-9dadba3878e1",
                    "encounterId": "7d28a964-6964-443c-861d-3fb24dac0c73"
                  },
                  {
                    "id": "4b4d082d-e124-4b83-9b9d-6648706df105",
                    "activityIds": [
                      "09d48280-a545-4f5f-a213-6bfa0d3a36b2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urinalysis @ Inpatient Period 2 (Day 23)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "aa57efe0-a9cc-4427-855a-140fb1aee54a",
                    "timingId": "c25aa467-3ccc-4b17-90b3-da2087b3d190"
                  },
                  {
                    "id": "405f4218-32e3-4e6a-b27f-3dae60b7ff70",
                    "activityIds": [
                      "09d48280-a545-4f5f-a213-6bfa0d3a36b2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urinalysis @ Inpatient Period 2 (Day 26-28)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "fcb42287-c2cb-4d0d-9b55-ecd4c62a406b"
                  },
                  {
                    "id": "ecbc0cfd-286d-4d9f-94c9-b8a015cfcd43",
                    "activityIds": [
                      "09d48280-a545-4f5f-a213-6bfa0d3a36b2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urinalysis @ Inpatient Period 2 (Day 40)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "337a47c6-f667-43ff-bd15-7f8bdf884351"
                  },
                  {
                    "id": "e32c6d51-59c5-47e0-a8a9-e6de2b9d24d9",
                    "activityIds": [
                      "09d48280-a545-4f5f-a213-6bfa0d3a36b2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urinalysis @ EOS Day 54+/-2",
                    "epochId": "9a99dd8f-b4d4-4d8c-b419-9db33003f93f",
                    "encounterId": "efed4e68-51b4-4eaf-984d-1eb3d833217b",
                    "timingId": "da91e438-b182-49a3-9239-81cd7c35d854"
                  },
                  {
                    "id": "68a1ac5a-1918-40a6-b3d2-13880ab3c7ac",
                    "activityIds": [
                      "15901dd8-31c5-4006-80ce-b1e27c23a388"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urine/serum pregnancy test @ Screening (-42 to -9)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "7b5788e5-7c88-4e27-9817-602e4fd08e42"
                  },
                  {
                    "id": "ef541a4a-890a-4a02-a658-b61523e1c6cb",
                    "activityIds": [
                      "15901dd8-31c5-4006-80ce-b1e27c23a388"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urine/serum pregnancy test @ Screening (-8)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "0e439567-df59-4e5c-bb7b-587d42e8d6e5"
                  },
                  {
                    "id": "382ed294-cdad-4137-8f05-3cc23f33bc85",
                    "activityIds": [
                      "15901dd8-31c5-4006-80ce-b1e27c23a388"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urine/serum pregnancy test @ Inpatient Period 2 (Day 23)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "aa57efe0-a9cc-4427-855a-140fb1aee54a",
                    "timingId": "c25aa467-3ccc-4b17-90b3-da2087b3d190"
                  },
                  {
                    "id": "274fca14-cccc-46de-86c9-f2b786e264ba",
                    "activityIds": [
                      "15901dd8-31c5-4006-80ce-b1e27c23a388"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urine/serum pregnancy test @ EOS Day 54+/-2",
                    "epochId": "9a99dd8f-b4d4-4d8c-b419-9db33003f93f",
                    "encounterId": "efed4e68-51b4-4eaf-984d-1eb3d833217b",
                    "timingId": "da91e438-b182-49a3-9239-81cd7c35d854"
                  },
                  {
                    "id": "c8dc308a-7ba7-4ff5-83cc-dd3e457a7fab",
                    "activityIds": [
                      "b5d5d409-b4e9-4971-8d35-460700a09e7f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Retained serum sample (safety) @ Screening (-7)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "6b799dc8-6ffb-4d23-84e0-fdd68e3f981c"
                  },
                  {
                    "id": "8413c250-dc34-4c67-89ca-7b5116a10a8d",
                    "activityIds": [
                      "b0e71e41-6828-4061-b8f6-0cbc384c9388"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Vitals sign measurements @ Screening (-42 to -9)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "7b5788e5-7c88-4e27-9817-602e4fd08e42"
                  },
                  {
                    "id": "00be848e-c7b0-41c2-aa0b-7f5f4177d18b",
                    "activityIds": [
                      "b0e71e41-6828-4061-b8f6-0cbc384c9388"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Vitals sign measurements @ Screening (-7)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "6b799dc8-6ffb-4d23-84e0-fdd68e3f981c"
                  },
                  {
                    "id": "606df6fb-80e8-4276-b4ed-c6b150193f6f",
                    "activityIds": [
                      "b0e71e41-6828-4061-b8f6-0cbc384c9388"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Vitals sign measurements @ Inpatient Period 1 (Day 1)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "639aca4b-f8c1-4726-a940-720a97b4e096",
                    "timingId": "0eed086c-55f3-4d2a-ae2d-dc7fed68ccf7"
                  },
                  {
                    "id": "785bf68d-a6a4-4e36-aa88-8cfa449ff58f",
                    "activityIds": [
                      "b0e71e41-6828-4061-b8f6-0cbc384c9388"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Vitals sign measurements @ Inpatient Period 1 (Day 9)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "810b7563-321e-474a-a8e3-116349030a6f"
                  },
                  {
                    "id": "56b61ba1-8c3d-49ac-8054-ad09c6be4bdc",
                    "activityIds": [
                      "b0e71e41-6828-4061-b8f6-0cbc384c9388"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Vitals sign measurements @ Inpatient Period 2 (Day 23)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "aa57efe0-a9cc-4427-855a-140fb1aee54a",
                    "timingId": "c25aa467-3ccc-4b17-90b3-da2087b3d190"
                  },
                  {
                    "id": "24e5eb5d-c82f-460f-b2bd-9229f58d1ed0",
                    "activityIds": [
                      "b0e71e41-6828-4061-b8f6-0cbc384c9388"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Vitals sign measurements @ Inpatient Period 2 (Day 39)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "6a447147-87eb-42c7-b2a6-598b03af3afc"
                  },
                  {
                    "id": "67b309e8-5384-4858-a79c-7ffd2154cf0d",
                    "activityIds": [
                      "b0e71e41-6828-4061-b8f6-0cbc384c9388"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Vitals sign measurements @ EOS Day 54+/-2",
                    "epochId": "9a99dd8f-b4d4-4d8c-b419-9db33003f93f",
                    "encounterId": "efed4e68-51b4-4eaf-984d-1eb3d833217b",
                    "timingId": "da91e438-b182-49a3-9239-81cd7c35d854"
                  },
                  {
                    "id": "7f2d3356-8671-4728-aea2-bb41e4e9d616",
                    "activityIds": [
                      "587124ff-d858-4f2a-8b5c-78c06fe8db7a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "12-lead ECG (triplicate) @ Screening (-42 to -9)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "7b5788e5-7c88-4e27-9817-602e4fd08e42"
                  },
                  {
                    "id": "83904601-e118-4c4b-b5c0-0509510c52cb",
                    "activityIds": [
                      "587124ff-d858-4f2a-8b5c-78c06fe8db7a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "12-lead ECG (triplicate) @ Screening (-7)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "6b799dc8-6ffb-4d23-84e0-fdd68e3f981c"
                  },
                  {
                    "id": "f5d9c630-c9c9-4448-877e-5d25d9c60e9c",
                    "activityIds": [
                      "587124ff-d858-4f2a-8b5c-78c06fe8db7a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "12-lead ECG (triplicate) @ Inpatient Period 1 (Day 1)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "639aca4b-f8c1-4726-a940-720a97b4e096",
                    "timingId": "0eed086c-55f3-4d2a-ae2d-dc7fed68ccf7"
                  },
                  {
                    "id": "8d723d10-ca72-442d-bae6-c7ccac0f7d34",
                    "activityIds": [
                      "587124ff-d858-4f2a-8b5c-78c06fe8db7a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "12-lead ECG (triplicate) @ Inpatient Period 1 (Day 9)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "810b7563-321e-474a-a8e3-116349030a6f"
                  },
                  {
                    "id": "723d73fe-d96f-4f19-b7df-cfbea78c2fa0",
                    "activityIds": [
                      "587124ff-d858-4f2a-8b5c-78c06fe8db7a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "12-lead ECG (triplicate) @ Inpatient Period 2 (Day 23)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "aa57efe0-a9cc-4427-855a-140fb1aee54a",
                    "timingId": "c25aa467-3ccc-4b17-90b3-da2087b3d190"
                  },
                  {
                    "id": "da9ab004-1290-4549-910f-126bac4ec8b5",
                    "activityIds": [
                      "587124ff-d858-4f2a-8b5c-78c06fe8db7a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "12-lead ECG (triplicate) @ Inpatient Period 2 (Day 39)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "6a447147-87eb-42c7-b2a6-598b03af3afc"
                  },
                  {
                    "id": "2e56ff01-d4c6-431d-b8c7-90c4e2eef570",
                    "activityIds": [
                      "587124ff-d858-4f2a-8b5c-78c06fe8db7a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "12-lead ECG (triplicate) @ EOS Day 54+/-2",
                    "epochId": "9a99dd8f-b4d4-4d8c-b419-9db33003f93f",
                    "encounterId": "efed4e68-51b4-4eaf-984d-1eb3d833217b",
                    "timingId": "da91e438-b182-49a3-9239-81cd7c35d854"
                  },
                  {
                    "id": "fc625aa4-2580-48c9-8024-30b4b35acb76",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ Screening (-42 to -9)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "7b5788e5-7c88-4e27-9817-602e4fd08e42"
                  },
                  {
                    "id": "915fdf1d-5eea-426d-976c-58234cce12b2",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ Screening (-8)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "0e439567-df59-4e5c-bb7b-587d42e8d6e5"
                  },
                  {
                    "id": "80ee49c8-8e3f-4eaf-941d-a3acff727fcc",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ Screening (-7)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "6b799dc8-6ffb-4d23-84e0-fdd68e3f981c"
                  },
                  {
                    "id": "3ea03840-fd61-426b-853b-a51bf1b0499a",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ C-I (-6 through -4)",
                    "epochId": "60aa5dc9-3d59-4e23-a442-e7e996d38969",
                    "encounterId": "594db433-91aa-47e5-84df-08250900a397"
                  },
                  {
                    "id": "16154c8a-8759-42ba-8727-d4b2c9d615d4",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ C-I (-1)",
                    "epochId": "60aa5dc9-3d59-4e23-a442-e7e996d38969",
                    "encounterId": "0ceeab15-73a7-4e34-8878-c26ff7a2d13a"
                  },
                  {
                    "id": "feadee1a-662a-4ffa-be78-a86902289ae5",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ Inpatient Period 1 (Day 1)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "639aca4b-f8c1-4726-a940-720a97b4e096",
                    "timingId": "0eed086c-55f3-4d2a-ae2d-dc7fed68ccf7"
                  },
                  {
                    "id": "3a2e8851-21d5-46d8-a028-8ce0825eb5c8",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ Inpatient Period 1 (Day 2-3)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "5cff5914-49e0-4d25-add3-b817a9b42c44"
                  },
                  {
                    "id": "615575ba-bf52-4173-b2f9-fa5f27efc158",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ Inpatient Period 1 (Day 4-7)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "f5ee1059-deac-4caf-a9db-97cb9fc3e849",
                    "timingId": "b36ece54-11a3-4776-ba9d-53657d600963"
                  },
                  {
                    "id": "3844dc32-6781-4b6d-a645-845acb4c5ada",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ Inpatient Period 1 (Day 8)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "2d0168c6-9f46-48ff-b3d4-a01f0dddbce3"
                  },
                  {
                    "id": "204705e6-834a-45e4-aae4-d88e0957fc50",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ Inpatient Period 1 (Day 9)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "810b7563-321e-474a-a8e3-116349030a6f"
                  },
                  {
                    "id": "4d26e881-5bbd-4742-8841-7d4bcf9f1fd2",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ OP (Day 10-22)",
                    "epochId": "9910e2f6-6088-4468-998c-9dadba3878e1",
                    "encounterId": "7d28a964-6964-443c-861d-3fb24dac0c73"
                  },
                  {
                    "id": "9b7f28bf-f071-4977-8c87-585da4cb05c1",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ Inpatient Period 2 (Day 23)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "aa57efe0-a9cc-4427-855a-140fb1aee54a",
                    "timingId": "c25aa467-3ccc-4b17-90b3-da2087b3d190"
                  },
                  {
                    "id": "81b99a21-f6ae-4713-9310-3b968dc52208",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ Inpatient Period 2 (Day 24)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "52c2db34-fc24-4f51-855d-a5995b69da8e"
                  },
                  {
                    "id": "b0c26ed8-7ea7-41b5-b4fa-e7f0e561133e",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ Inpatient Period 2 (Day 25)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "e88d07ab-f998-47c7-8e8b-c2949d1b2b9c"
                  },
                  {
                    "id": "32ca230f-1b69-45d7-a298-a47f6d60312d",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ Inpatient Period 2 (Day 26-28)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "fcb42287-c2cb-4d0d-9b55-ecd4c62a406b"
                  },
                  {
                    "id": "db2442f8-ab6c-4c48-954e-9b667be5ba0c",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ Inpatient Period 2 (Day 29)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "551f8be3-847f-4b04-a2f6-0df5257e72b7",
                    "timingId": "5417665e-780d-4818-b65e-68ba6784706b"
                  },
                  {
                    "id": "acf2a7d4-21bb-42e4-950d-73b6cc5a4e60",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ Inpatient Period 2 (Day 30-35)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "2a28a085-2487-44bc-8a20-7e8f783adb7b"
                  },
                  {
                    "id": "8c12cedd-97be-4084-bec9-977e16cb5ef0",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ Inpatient Period 2 (Day 36)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "5a75526e-73c8-4e2b-bed6-46324bb62098"
                  },
                  {
                    "id": "5be769ac-a81b-49fb-a3c5-cf83db8bdcf5",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ Inpatient Period 2 (Day 37-38)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "6c0c9841-f92b-4e90-88d9-82a75e98c8f8"
                  },
                  {
                    "id": "41f42084-4bae-4cda-b4cb-8905c8a8d872",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ Inpatient Period 2 (Day 39)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "6a447147-87eb-42c7-b2a6-598b03af3afc"
                  },
                  {
                    "id": "d81349a2-fef0-4c91-8acb-2c7a6735ae2e",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ Inpatient Period 2 (Day 40)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "337a47c6-f667-43ff-bd15-7f8bdf884351"
                  },
                  {
                    "id": "3dee5a0d-5e74-4120-b5e1-707858db0c42",
                    "activityIds": [
                      "c25a9d0e-98d7-411b-916d-c07298b040d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Adverse events @ EOS Day 54+/-2",
                    "epochId": "9a99dd8f-b4d4-4d8c-b419-9db33003f93f",
                    "encounterId": "efed4e68-51b4-4eaf-984d-1eb3d833217b",
                    "timingId": "da91e438-b182-49a3-9239-81cd7c35d854"
                  },
                  {
                    "id": "75d4d65c-76e1-4958-8466-215e898548e6",
                    "activityIds": [
                      "9a58c970-fa45-487b-afe9-094a3819d719"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Cu/Mo-controlled meals @ Screening (-7)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "6b799dc8-6ffb-4d23-84e0-fdd68e3f981c"
                  },
                  {
                    "id": "21fdd94b-1c5d-415c-b6d6-a2849f2acfba",
                    "activityIds": [
                      "9a58c970-fa45-487b-afe9-094a3819d719"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Cu/Mo-controlled meals @ C-I (-6 through -4)",
                    "epochId": "60aa5dc9-3d59-4e23-a442-e7e996d38969",
                    "encounterId": "594db433-91aa-47e5-84df-08250900a397"
                  },
                  {
                    "id": "d65c48ca-ba3a-4183-8d3d-a3b2c4fc265a",
                    "activityIds": [
                      "9a58c970-fa45-487b-afe9-094a3819d719"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Cu/Mo-controlled meals @ C-I (-1)",
                    "epochId": "60aa5dc9-3d59-4e23-a442-e7e996d38969",
                    "encounterId": "0ceeab15-73a7-4e34-8878-c26ff7a2d13a"
                  },
                  {
                    "id": "69786be8-fe8c-4667-9209-caf69cea5960",
                    "activityIds": [
                      "9a58c970-fa45-487b-afe9-094a3819d719"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Cu/Mo-controlled meals @ Inpatient Period 1 (Day 1)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "639aca4b-f8c1-4726-a940-720a97b4e096",
                    "timingId": "0eed086c-55f3-4d2a-ae2d-dc7fed68ccf7"
                  },
                  {
                    "id": "3183da86-fc45-453f-88d9-880ee774eb02",
                    "activityIds": [
                      "9a58c970-fa45-487b-afe9-094a3819d719"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Cu/Mo-controlled meals @ Inpatient Period 1 (Day 2-3)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "5cff5914-49e0-4d25-add3-b817a9b42c44"
                  },
                  {
                    "id": "69069824-ed16-4b34-8e76-6ca2234b0ee9",
                    "activityIds": [
                      "9a58c970-fa45-487b-afe9-094a3819d719"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Cu/Mo-controlled meals @ Inpatient Period 1 (Day 4-7)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "f5ee1059-deac-4caf-a9db-97cb9fc3e849",
                    "timingId": "b36ece54-11a3-4776-ba9d-53657d600963"
                  },
                  {
                    "id": "c46bb37d-7a3f-4df4-81fd-e6055d01e95b",
                    "activityIds": [
                      "9a58c970-fa45-487b-afe9-094a3819d719"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Cu/Mo-controlled meals @ Inpatient Period 1 (Day 8)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "2d0168c6-9f46-48ff-b3d4-a01f0dddbce3"
                  },
                  {
                    "id": "87abd295-3789-439b-b3ed-9db83180f949",
                    "activityIds": [
                      "9a58c970-fa45-487b-afe9-094a3819d719"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Cu/Mo-controlled meals @ Inpatient Period 1 (Day 9)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "810b7563-321e-474a-a8e3-116349030a6f"
                  },
                  {
                    "id": "39e2a172-71ee-4c19-a56a-26e202840c10",
                    "activityIds": [
                      "9a58c970-fa45-487b-afe9-094a3819d719"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Cu/Mo-controlled meals @ Inpatient Period 2 (Day 23)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "aa57efe0-a9cc-4427-855a-140fb1aee54a",
                    "timingId": "c25aa467-3ccc-4b17-90b3-da2087b3d190"
                  },
                  {
                    "id": "dd8838b1-7601-498c-a220-b189821b0e23",
                    "activityIds": [
                      "9a58c970-fa45-487b-afe9-094a3819d719"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Cu/Mo-controlled meals @ Inpatient Period 2 (Day 24)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "52c2db34-fc24-4f51-855d-a5995b69da8e"
                  },
                  {
                    "id": "02a54395-7fc0-464e-80bb-ab20115800ec",
                    "activityIds": [
                      "9a58c970-fa45-487b-afe9-094a3819d719"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Cu/Mo-controlled meals @ Inpatient Period 2 (Day 25)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "e88d07ab-f998-47c7-8e8b-c2949d1b2b9c"
                  },
                  {
                    "id": "78ab0c10-6d28-436d-8848-274e66a77eae",
                    "activityIds": [
                      "9a58c970-fa45-487b-afe9-094a3819d719"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Cu/Mo-controlled meals @ Inpatient Period 2 (Day 26-28)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "fcb42287-c2cb-4d0d-9b55-ecd4c62a406b"
                  },
                  {
                    "id": "5dba3bf0-7164-405c-b972-b5b7a4a3877d",
                    "activityIds": [
                      "9a58c970-fa45-487b-afe9-094a3819d719"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Cu/Mo-controlled meals @ Inpatient Period 2 (Day 29)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "551f8be3-847f-4b04-a2f6-0df5257e72b7",
                    "timingId": "5417665e-780d-4818-b65e-68ba6784706b"
                  },
                  {
                    "id": "96ef00e5-14e4-482c-8652-d9634f62d161",
                    "activityIds": [
                      "9a58c970-fa45-487b-afe9-094a3819d719"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Cu/Mo-controlled meals @ Inpatient Period 2 (Day 30-35)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "2a28a085-2487-44bc-8a20-7e8f783adb7b"
                  },
                  {
                    "id": "1da27318-5892-4672-9180-99511457baa4",
                    "activityIds": [
                      "9a58c970-fa45-487b-afe9-094a3819d719"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Cu/Mo-controlled meals @ Inpatient Period 2 (Day 36)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "5a75526e-73c8-4e2b-bed6-46324bb62098"
                  },
                  {
                    "id": "24fe6627-0139-4879-acbe-c9332fa4df67",
                    "activityIds": [
                      "9a58c970-fa45-487b-afe9-094a3819d719"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Cu/Mo-controlled meals @ Inpatient Period 2 (Day 37-38)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "6c0c9841-f92b-4e90-88d9-82a75e98c8f8"
                  },
                  {
                    "id": "2631a841-7a9d-4ab5-82fa-2fa334084a83",
                    "activityIds": [
                      "9a58c970-fa45-487b-afe9-094a3819d719"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Cu/Mo-controlled meals @ Inpatient Period 2 (Day 39)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "6a447147-87eb-42c7-b2a6-598b03af3afc"
                  },
                  {
                    "id": "e93c5166-3b8c-474b-bf1b-86b8e0074ca9",
                    "activityIds": [
                      "9a58c970-fa45-487b-afe9-094a3819d719"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Cu/Mo-controlled meals @ Inpatient Period 2 (Day 40)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "337a47c6-f667-43ff-bd15-7f8bdf884351"
                  },
                  {
                    "id": "cc440992-c0b9-4301-9fe8-f9691111de3b",
                    "activityIds": [
                      "778d69f6-5d53-4ac8-a835-c35a3c6569a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Light exercise regimen @ Screening (-7)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "6b799dc8-6ffb-4d23-84e0-fdd68e3f981c"
                  },
                  {
                    "id": "db591ea4-c803-477a-a553-42415776d526",
                    "activityIds": [
                      "778d69f6-5d53-4ac8-a835-c35a3c6569a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Light exercise regimen @ C-I (-6 through -4)",
                    "epochId": "60aa5dc9-3d59-4e23-a442-e7e996d38969",
                    "encounterId": "594db433-91aa-47e5-84df-08250900a397"
                  },
                  {
                    "id": "eb0b7942-b2a0-48d3-b65b-a1a1076146a6",
                    "activityIds": [
                      "778d69f6-5d53-4ac8-a835-c35a3c6569a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Light exercise regimen @ C-I (-1)",
                    "epochId": "60aa5dc9-3d59-4e23-a442-e7e996d38969",
                    "encounterId": "0ceeab15-73a7-4e34-8878-c26ff7a2d13a"
                  },
                  {
                    "id": "6183ec4c-5ea8-40b0-9b36-930662b8c999",
                    "activityIds": [
                      "778d69f6-5d53-4ac8-a835-c35a3c6569a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Light exercise regimen @ Inpatient Period 1 (Day 1)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "639aca4b-f8c1-4726-a940-720a97b4e096",
                    "timingId": "0eed086c-55f3-4d2a-ae2d-dc7fed68ccf7"
                  },
                  {
                    "id": "a328d631-2558-4ba1-bf4a-ab951529f9b7",
                    "activityIds": [
                      "778d69f6-5d53-4ac8-a835-c35a3c6569a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Light exercise regimen @ Inpatient Period 1 (Day 2-3)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "5cff5914-49e0-4d25-add3-b817a9b42c44"
                  },
                  {
                    "id": "cd77e59a-5061-49ce-bf37-56beeef762ea",
                    "activityIds": [
                      "778d69f6-5d53-4ac8-a835-c35a3c6569a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Light exercise regimen @ Inpatient Period 1 (Day 4-7)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "f5ee1059-deac-4caf-a9db-97cb9fc3e849",
                    "timingId": "b36ece54-11a3-4776-ba9d-53657d600963"
                  },
                  {
                    "id": "f5948c1d-7318-4a97-b916-4c4f9c14b47e",
                    "activityIds": [
                      "778d69f6-5d53-4ac8-a835-c35a3c6569a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Light exercise regimen @ Inpatient Period 1 (Day 8)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "2d0168c6-9f46-48ff-b3d4-a01f0dddbce3"
                  },
                  {
                    "id": "68c64aad-543a-4951-9792-1c77eeaf5efb",
                    "activityIds": [
                      "778d69f6-5d53-4ac8-a835-c35a3c6569a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Light exercise regimen @ Inpatient Period 1 (Day 9)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "810b7563-321e-474a-a8e3-116349030a6f"
                  },
                  {
                    "id": "d4539420-e0ec-4171-b8cb-dab73f56f67d",
                    "activityIds": [
                      "778d69f6-5d53-4ac8-a835-c35a3c6569a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Light exercise regimen @ OP (Day 10-22)",
                    "epochId": "9910e2f6-6088-4468-998c-9dadba3878e1",
                    "encounterId": "7d28a964-6964-443c-861d-3fb24dac0c73"
                  },
                  {
                    "id": "2a8be623-0f70-4471-8882-7b23f553d6f2",
                    "activityIds": [
                      "778d69f6-5d53-4ac8-a835-c35a3c6569a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Light exercise regimen @ Inpatient Period 2 (Day 23)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "aa57efe0-a9cc-4427-855a-140fb1aee54a",
                    "timingId": "c25aa467-3ccc-4b17-90b3-da2087b3d190"
                  },
                  {
                    "id": "a48cbca3-4145-44be-84d4-642a3ba0e497",
                    "activityIds": [
                      "778d69f6-5d53-4ac8-a835-c35a3c6569a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Light exercise regimen @ Inpatient Period 2 (Day 24)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "52c2db34-fc24-4f51-855d-a5995b69da8e"
                  },
                  {
                    "id": "f4c6035c-c41d-4018-b638-6a56164d290e",
                    "activityIds": [
                      "778d69f6-5d53-4ac8-a835-c35a3c6569a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Light exercise regimen @ Inpatient Period 2 (Day 25)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "e88d07ab-f998-47c7-8e8b-c2949d1b2b9c"
                  },
                  {
                    "id": "68d5d575-dd8c-433b-96c1-5084d195d6a6",
                    "activityIds": [
                      "778d69f6-5d53-4ac8-a835-c35a3c6569a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Light exercise regimen @ Inpatient Period 2 (Day 26-28)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "fcb42287-c2cb-4d0d-9b55-ecd4c62a406b"
                  },
                  {
                    "id": "460a06b8-0b08-4a37-ae0c-e015ac152c2d",
                    "activityIds": [
                      "778d69f6-5d53-4ac8-a835-c35a3c6569a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Light exercise regimen @ Inpatient Period 2 (Day 29)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "551f8be3-847f-4b04-a2f6-0df5257e72b7",
                    "timingId": "5417665e-780d-4818-b65e-68ba6784706b"
                  },
                  {
                    "id": "dbdddac2-574f-4fa3-b129-6c3b499b4a46",
                    "activityIds": [
                      "778d69f6-5d53-4ac8-a835-c35a3c6569a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Light exercise regimen @ Inpatient Period 2 (Day 30-35)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "2a28a085-2487-44bc-8a20-7e8f783adb7b"
                  },
                  {
                    "id": "aa8e4e9b-4100-4d44-bdd7-7b7a09d50536",
                    "activityIds": [
                      "778d69f6-5d53-4ac8-a835-c35a3c6569a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Light exercise regimen @ Inpatient Period 2 (Day 36)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "5a75526e-73c8-4e2b-bed6-46324bb62098"
                  },
                  {
                    "id": "a72ebbc2-d059-4f48-a0bc-8adf0d9d3bd4",
                    "activityIds": [
                      "778d69f6-5d53-4ac8-a835-c35a3c6569a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Light exercise regimen @ Inpatient Period 2 (Day 37-38)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "6c0c9841-f92b-4e90-88d9-82a75e98c8f8"
                  },
                  {
                    "id": "b861c9de-56ab-492a-bbb9-9fdf2d9fcd44",
                    "activityIds": [
                      "778d69f6-5d53-4ac8-a835-c35a3c6569a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Light exercise regimen @ Inpatient Period 2 (Day 39)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "6a447147-87eb-42c7-b2a6-598b03af3afc"
                  },
                  {
                    "id": "5fb12104-6c2c-41c9-9231-a5b4445cae47",
                    "activityIds": [
                      "778d69f6-5d53-4ac8-a835-c35a3c6569a5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Light exercise regimen @ Inpatient Period 2 (Day 40)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "337a47c6-f667-43ff-bd15-7f8bdf884351"
                  },
                  {
                    "id": "a040556a-01a3-4f57-a59e-92e658d7d17e",
                    "activityIds": [
                      "cd0e371f-3d5f-4c31-a9f2-672a5d878a99"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urination and bowel movement monitoring, menstr... @ C-I (-1)",
                    "epochId": "60aa5dc9-3d59-4e23-a442-e7e996d38969",
                    "encounterId": "0ceeab15-73a7-4e34-8878-c26ff7a2d13a"
                  },
                  {
                    "id": "1358879c-a075-4860-91f4-de540bd43070",
                    "activityIds": [
                      "cd0e371f-3d5f-4c31-a9f2-672a5d878a99"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urination and bowel movement monitoring, menstr... @ Inpatient Period 1 (Day 1)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "639aca4b-f8c1-4726-a940-720a97b4e096",
                    "timingId": "0eed086c-55f3-4d2a-ae2d-dc7fed68ccf7"
                  },
                  {
                    "id": "ced0b6ab-a42a-4c16-9914-193a5544e58a",
                    "activityIds": [
                      "cd0e371f-3d5f-4c31-a9f2-672a5d878a99"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urination and bowel movement monitoring, menstr... @ Inpatient Period 1 (Day 2-3)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "5cff5914-49e0-4d25-add3-b817a9b42c44"
                  },
                  {
                    "id": "9f94567d-ca73-4237-bb42-52c0dd9d1b86",
                    "activityIds": [
                      "cd0e371f-3d5f-4c31-a9f2-672a5d878a99"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urination and bowel movement monitoring, menstr... @ Inpatient Period 1 (Day 4-7)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "f5ee1059-deac-4caf-a9db-97cb9fc3e849",
                    "timingId": "b36ece54-11a3-4776-ba9d-53657d600963"
                  },
                  {
                    "id": "f0fef8a0-8594-49c0-90fe-eca90748fdb2",
                    "activityIds": [
                      "cd0e371f-3d5f-4c31-a9f2-672a5d878a99"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urination and bowel movement monitoring, menstr... @ Inpatient Period 1 (Day 8)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "2d0168c6-9f46-48ff-b3d4-a01f0dddbce3"
                  },
                  {
                    "id": "91a69369-500e-4ffa-9b91-5b876bf2d59f",
                    "activityIds": [
                      "cd0e371f-3d5f-4c31-a9f2-672a5d878a99"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urination and bowel movement monitoring, menstr... @ Inpatient Period 1 (Day 9)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "810b7563-321e-474a-a8e3-116349030a6f"
                  },
                  {
                    "id": "c353a83e-3777-47b5-b744-cf4b56249413",
                    "activityIds": [
                      "cd0e371f-3d5f-4c31-a9f2-672a5d878a99"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urination and bowel movement monitoring, menstr... @ Inpatient Period 2 (Day 25)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "e88d07ab-f998-47c7-8e8b-c2949d1b2b9c"
                  },
                  {
                    "id": "86452196-bba2-4c14-9360-588e622aae9e",
                    "activityIds": [
                      "cd0e371f-3d5f-4c31-a9f2-672a5d878a99"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urination and bowel movement monitoring, menstr... @ Inpatient Period 2 (Day 26-28)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "fcb42287-c2cb-4d0d-9b55-ecd4c62a406b"
                  },
                  {
                    "id": "a622adbb-0f6d-4215-8312-c74b75ef6ffd",
                    "activityIds": [
                      "cd0e371f-3d5f-4c31-a9f2-672a5d878a99"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urination and bowel movement monitoring, menstr... @ Inpatient Period 2 (Day 29)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "551f8be3-847f-4b04-a2f6-0df5257e72b7",
                    "timingId": "5417665e-780d-4818-b65e-68ba6784706b"
                  },
                  {
                    "id": "098860b2-e615-430f-bf2f-e370b93ddda9",
                    "activityIds": [
                      "cd0e371f-3d5f-4c31-a9f2-672a5d878a99"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urination and bowel movement monitoring, menstr... @ Inpatient Period 2 (Day 30-35)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "2a28a085-2487-44bc-8a20-7e8f783adb7b"
                  },
                  {
                    "id": "499bb2a3-e52a-4a10-8c81-c878bce1d2e0",
                    "activityIds": [
                      "cd0e371f-3d5f-4c31-a9f2-672a5d878a99"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urination and bowel movement monitoring, menstr... @ Inpatient Period 2 (Day 36)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "5a75526e-73c8-4e2b-bed6-46324bb62098"
                  },
                  {
                    "id": "7ac3b1d9-094a-40b1-84f8-2a7600dd50de",
                    "activityIds": [
                      "cd0e371f-3d5f-4c31-a9f2-672a5d878a99"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urination and bowel movement monitoring, menstr... @ Inpatient Period 2 (Day 37-38)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "6c0c9841-f92b-4e90-88d9-82a75e98c8f8"
                  },
                  {
                    "id": "43e9c357-83a0-445c-8734-8047ae62a7d3",
                    "activityIds": [
                      "cd0e371f-3d5f-4c31-a9f2-672a5d878a99"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urination and bowel movement monitoring, menstr... @ Inpatient Period 2 (Day 39)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "6a447147-87eb-42c7-b2a6-598b03af3afc"
                  },
                  {
                    "id": "d20c8844-1500-4675-bbd3-2da14e6be3fb",
                    "activityIds": [
                      "cd0e371f-3d5f-4c31-a9f2-672a5d878a99"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urination and bowel movement monitoring, menstr... @ Inpatient Period 2 (Day 40)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "337a47c6-f667-43ff-bd15-7f8bdf884351"
                  },
                  {
                    "id": "cf4fefb3-93f8-4ea1-a717-43daf483f8e4",
                    "activityIds": [
                      "6a029e30-f6a0-4ce7-944e-12df47c05d85"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "24-hour urine for Cu and Mo @ C-I (-1)",
                    "epochId": "60aa5dc9-3d59-4e23-a442-e7e996d38969",
                    "encounterId": "0ceeab15-73a7-4e34-8878-c26ff7a2d13a"
                  },
                  {
                    "id": "a4936aa7-29ba-4acc-891c-2f9e8ed3ce29",
                    "activityIds": [
                      "6a029e30-f6a0-4ce7-944e-12df47c05d85"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "24-hour urine for Cu and Mo @ Inpatient Period 1 (Day 1)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "639aca4b-f8c1-4726-a940-720a97b4e096",
                    "timingId": "0eed086c-55f3-4d2a-ae2d-dc7fed68ccf7"
                  },
                  {
                    "id": "25f553f5-e7f0-4a77-9e63-6799946b1c1d",
                    "activityIds": [
                      "6a029e30-f6a0-4ce7-944e-12df47c05d85"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "24-hour urine for Cu and Mo @ Inpatient Period 1 (Day 2-3)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "5cff5914-49e0-4d25-add3-b817a9b42c44"
                  },
                  {
                    "id": "fa8fd485-1a26-4c53-97dc-ab35ed47a0be",
                    "activityIds": [
                      "6a029e30-f6a0-4ce7-944e-12df47c05d85"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "24-hour urine for Cu and Mo @ Inpatient Period 1 (Day 4-7)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "f5ee1059-deac-4caf-a9db-97cb9fc3e849",
                    "timingId": "b36ece54-11a3-4776-ba9d-53657d600963"
                  },
                  {
                    "id": "571d612b-3077-49a4-97b9-a5adb118e527",
                    "activityIds": [
                      "6a029e30-f6a0-4ce7-944e-12df47c05d85"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "24-hour urine for Cu and Mo @ Inpatient Period 1 (Day 8)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "2d0168c6-9f46-48ff-b3d4-a01f0dddbce3"
                  },
                  {
                    "id": "c8fced2c-99fb-485d-90d4-88dc54e510a6",
                    "activityIds": [
                      "6a029e30-f6a0-4ce7-944e-12df47c05d85"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "24-hour urine for Cu and Mo @ Inpatient Period 2 (Day 25)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "e88d07ab-f998-47c7-8e8b-c2949d1b2b9c"
                  },
                  {
                    "id": "ba5ace54-9632-4fd3-856d-5f25eec4dc7f",
                    "activityIds": [
                      "6a029e30-f6a0-4ce7-944e-12df47c05d85"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "24-hour urine for Cu and Mo @ Inpatient Period 2 (Day 26-28)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "fcb42287-c2cb-4d0d-9b55-ecd4c62a406b"
                  },
                  {
                    "id": "eb1607c9-86d4-4cf3-84ce-8ad0532d15d4",
                    "activityIds": [
                      "6a029e30-f6a0-4ce7-944e-12df47c05d85"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "24-hour urine for Cu and Mo @ Inpatient Period 2 (Day 29)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "551f8be3-847f-4b04-a2f6-0df5257e72b7",
                    "timingId": "5417665e-780d-4818-b65e-68ba6784706b"
                  },
                  {
                    "id": "0b18d668-696a-427e-b46d-27aade75eb41",
                    "activityIds": [
                      "6a029e30-f6a0-4ce7-944e-12df47c05d85"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "24-hour urine for Cu and Mo @ Inpatient Period 2 (Day 30-35)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "2a28a085-2487-44bc-8a20-7e8f783adb7b"
                  },
                  {
                    "id": "9566757f-4eac-4d16-9fa2-16310d060a04",
                    "activityIds": [
                      "6a029e30-f6a0-4ce7-944e-12df47c05d85"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "24-hour urine for Cu and Mo @ Inpatient Period 2 (Day 36)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "5a75526e-73c8-4e2b-bed6-46324bb62098"
                  },
                  {
                    "id": "05dfd37d-7f4a-4068-bde5-09d4e5111b3e",
                    "activityIds": [
                      "6a029e30-f6a0-4ce7-944e-12df47c05d85"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "24-hour urine for Cu and Mo @ Inpatient Period 2 (Day 37-38)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "6c0c9841-f92b-4e90-88d9-82a75e98c8f8"
                  },
                  {
                    "id": "cb70391f-e05a-4d3f-8e6d-ab8e7660b6ac",
                    "activityIds": [
                      "6a029e30-f6a0-4ce7-944e-12df47c05d85"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "24-hour urine for Cu and Mo @ Inpatient Period 2 (Day 39)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "6a447147-87eb-42c7-b2a6-598b03af3afc"
                  },
                  {
                    "id": "989d5b90-805e-4a7f-90dc-64dc539e99c3",
                    "activityIds": [
                      "921876c4-2fe5-48c0-baa5-b5994a3df1ce"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Feces for Cu and Mo @ C-I (-1)",
                    "epochId": "60aa5dc9-3d59-4e23-a442-e7e996d38969",
                    "encounterId": "0ceeab15-73a7-4e34-8878-c26ff7a2d13a"
                  },
                  {
                    "id": "63a84500-8afa-4cbb-82f0-e08e9f405a4f",
                    "activityIds": [
                      "921876c4-2fe5-48c0-baa5-b5994a3df1ce"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Feces for Cu and Mo @ Inpatient Period 1 (Day 1)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "639aca4b-f8c1-4726-a940-720a97b4e096",
                    "timingId": "0eed086c-55f3-4d2a-ae2d-dc7fed68ccf7"
                  },
                  {
                    "id": "f15fd53d-5450-4b17-b1ea-566cd31e6bdf",
                    "activityIds": [
                      "921876c4-2fe5-48c0-baa5-b5994a3df1ce"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Feces for Cu and Mo @ Inpatient Period 1 (Day 2-3)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "5cff5914-49e0-4d25-add3-b817a9b42c44"
                  },
                  {
                    "id": "294b6335-a537-40f4-a768-f5962711ca51",
                    "activityIds": [
                      "921876c4-2fe5-48c0-baa5-b5994a3df1ce"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Feces for Cu and Mo @ Inpatient Period 1 (Day 4-7)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "f5ee1059-deac-4caf-a9db-97cb9fc3e849",
                    "timingId": "b36ece54-11a3-4776-ba9d-53657d600963"
                  },
                  {
                    "id": "70b9a0a7-f2e7-4e9d-be92-1851787acd9e",
                    "activityIds": [
                      "921876c4-2fe5-48c0-baa5-b5994a3df1ce"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Feces for Cu and Mo @ Inpatient Period 1 (Day 8)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "2d0168c6-9f46-48ff-b3d4-a01f0dddbce3"
                  },
                  {
                    "id": "21dda7c7-7986-40d8-823a-b269f6b2cb8a",
                    "activityIds": [
                      "921876c4-2fe5-48c0-baa5-b5994a3df1ce"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Feces for Cu and Mo @ Inpatient Period 2 (Day 25)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "e88d07ab-f998-47c7-8e8b-c2949d1b2b9c"
                  },
                  {
                    "id": "fd946027-245b-4c1e-8331-cc5ead8f28ec",
                    "activityIds": [
                      "921876c4-2fe5-48c0-baa5-b5994a3df1ce"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Feces for Cu and Mo @ Inpatient Period 2 (Day 26-28)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "fcb42287-c2cb-4d0d-9b55-ecd4c62a406b"
                  },
                  {
                    "id": "c22b2be7-297d-4459-a693-746110acd0d3",
                    "activityIds": [
                      "921876c4-2fe5-48c0-baa5-b5994a3df1ce"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Feces for Cu and Mo @ Inpatient Period 2 (Day 29)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "551f8be3-847f-4b04-a2f6-0df5257e72b7",
                    "timingId": "5417665e-780d-4818-b65e-68ba6784706b"
                  },
                  {
                    "id": "3ae6bb0a-e3d5-4f36-b008-df227cbac815",
                    "activityIds": [
                      "921876c4-2fe5-48c0-baa5-b5994a3df1ce"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Feces for Cu and Mo @ Inpatient Period 2 (Day 30-35)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "2a28a085-2487-44bc-8a20-7e8f783adb7b"
                  },
                  {
                    "id": "0c6c0f1d-6cc1-452c-b74a-7e5060a4273e",
                    "activityIds": [
                      "921876c4-2fe5-48c0-baa5-b5994a3df1ce"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Feces for Cu and Mo @ Inpatient Period 2 (Day 36)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "5a75526e-73c8-4e2b-bed6-46324bb62098"
                  },
                  {
                    "id": "a9ef5a63-1a1d-48f9-9dee-1985cabaa766",
                    "activityIds": [
                      "921876c4-2fe5-48c0-baa5-b5994a3df1ce"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Feces for Cu and Mo @ Inpatient Period 2 (Day 37-38)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "6c0c9841-f92b-4e90-88d9-82a75e98c8f8"
                  },
                  {
                    "id": "76f6fabf-175b-4bed-b402-0eac462edab6",
                    "activityIds": [
                      "921876c4-2fe5-48c0-baa5-b5994a3df1ce"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Feces for Cu and Mo @ Inpatient Period 2 (Day 39)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "6a447147-87eb-42c7-b2a6-598b03af3afc"
                  },
                  {
                    "id": "a695609d-8f5d-43f6-ac6f-1169b2bbd950",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ Screening (-42 to -9)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "7b5788e5-7c88-4e27-9817-602e4fd08e42"
                  },
                  {
                    "id": "141ee76c-9724-4a75-bc3b-6ef6da890f18",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ Screening (-8)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "0e439567-df59-4e5c-bb7b-587d42e8d6e5"
                  },
                  {
                    "id": "727d7142-9784-4733-9ed4-890b889d3034",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ Screening (-7)",
                    "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                    "encounterId": "6b799dc8-6ffb-4d23-84e0-fdd68e3f981c"
                  },
                  {
                    "id": "ff5b0a05-ac69-4410-aaee-36bb7b1baeb5",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ C-I (-6 through -4)",
                    "epochId": "60aa5dc9-3d59-4e23-a442-e7e996d38969",
                    "encounterId": "594db433-91aa-47e5-84df-08250900a397"
                  },
                  {
                    "id": "77a302d6-f4a5-4897-a9cd-c871dd3db786",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ C-I (-1)",
                    "epochId": "60aa5dc9-3d59-4e23-a442-e7e996d38969",
                    "encounterId": "0ceeab15-73a7-4e34-8878-c26ff7a2d13a"
                  },
                  {
                    "id": "9aeefa64-48ed-45fb-aab1-b73d2c78d171",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ Inpatient Period 1 (Day 1)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "639aca4b-f8c1-4726-a940-720a97b4e096",
                    "timingId": "0eed086c-55f3-4d2a-ae2d-dc7fed68ccf7"
                  },
                  {
                    "id": "aa39ddcc-b8ae-4768-a36c-3249bbf2b50b",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ Inpatient Period 1 (Day 2-3)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "5cff5914-49e0-4d25-add3-b817a9b42c44"
                  },
                  {
                    "id": "552d5e03-be25-4d8d-bc37-40e59b5b5bf8",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ Inpatient Period 1 (Day 4-7)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "f5ee1059-deac-4caf-a9db-97cb9fc3e849",
                    "timingId": "b36ece54-11a3-4776-ba9d-53657d600963"
                  },
                  {
                    "id": "f8fbd927-d1e2-4402-8d3f-61cdf25e5ae0",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ Inpatient Period 1 (Day 8)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "2d0168c6-9f46-48ff-b3d4-a01f0dddbce3"
                  },
                  {
                    "id": "8a21f969-d2e7-4ad4-8320-ca3ee6cc0ed8",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ Inpatient Period 1 (Day 9)",
                    "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                    "encounterId": "810b7563-321e-474a-a8e3-116349030a6f"
                  },
                  {
                    "id": "c96b1505-aff7-48bb-8fd8-1491378e596e",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ OP (Day 10-22)",
                    "epochId": "9910e2f6-6088-4468-998c-9dadba3878e1",
                    "encounterId": "7d28a964-6964-443c-861d-3fb24dac0c73"
                  },
                  {
                    "id": "daaf5e9a-797f-4ebe-969f-605b2d6c1f58",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ Inpatient Period 2 (Day 23)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "aa57efe0-a9cc-4427-855a-140fb1aee54a",
                    "timingId": "c25aa467-3ccc-4b17-90b3-da2087b3d190"
                  },
                  {
                    "id": "ce1886ca-7e21-4b92-a29f-40d25a279908",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ Inpatient Period 2 (Day 24)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "52c2db34-fc24-4f51-855d-a5995b69da8e"
                  },
                  {
                    "id": "db17f069-649b-4c49-a902-ef7b4acfdad9",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ Inpatient Period 2 (Day 25)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "e88d07ab-f998-47c7-8e8b-c2949d1b2b9c"
                  },
                  {
                    "id": "48787ec2-eb6d-4f0d-9ed4-3c951a2d1df0",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ Inpatient Period 2 (Day 26-28)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "fcb42287-c2cb-4d0d-9b55-ecd4c62a406b"
                  },
                  {
                    "id": "dcd1dbc5-d75e-4dba-a867-ae2d7197d310",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ Inpatient Period 2 (Day 29)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "551f8be3-847f-4b04-a2f6-0df5257e72b7",
                    "timingId": "5417665e-780d-4818-b65e-68ba6784706b"
                  },
                  {
                    "id": "039c99ec-fc48-40e3-97ed-e8a06ef5d71a",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ Inpatient Period 2 (Day 30-35)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "2a28a085-2487-44bc-8a20-7e8f783adb7b"
                  },
                  {
                    "id": "e9da73e7-e02d-44cb-88b8-3b417c94c8bf",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ Inpatient Period 2 (Day 36)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "5a75526e-73c8-4e2b-bed6-46324bb62098"
                  },
                  {
                    "id": "dddf50e2-c924-4b68-9da8-c09672f4b7f7",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ Inpatient Period 2 (Day 37-38)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "6c0c9841-f92b-4e90-88d9-82a75e98c8f8"
                  },
                  {
                    "id": "2e095d7b-dd75-4602-899c-de4dd59421df",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ Inpatient Period 2 (Day 39)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "6a447147-87eb-42c7-b2a6-598b03af3afc"
                  },
                  {
                    "id": "0ff7eb74-8d8a-43f3-a8ec-75cebbfd8628",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ Inpatient Period 2 (Day 40)",
                    "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b",
                    "encounterId": "337a47c6-f667-43ff-bd15-7f8bdf884351"
                  },
                  {
                    "id": "12b17b2b-8123-4ca5-ab23-c92db2aa46bc",
                    "activityIds": [
                      "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Concomitant medication and non-pharmacologic th... @ EOS Day 54+/-2",
                    "epochId": "9a99dd8f-b4d4-4d8c-b419-9db33003f93f",
                    "encounterId": "efed4e68-51b4-4eaf-984d-1eb3d833217b",
                    "timingId": "da91e438-b182-49a3-9239-81cd7c35d854"
                  }
                ],
                "timings": [
                  {
                    "id": "a2d16bcd-923f-46ce-87f1-f05352230f76",
                    "name": "Zinc Washout Period",
                    "type": {
                      "id": "187ebc30-f066-4876-8b85-084908c01c9c",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P21D",
                    "valueLabel": "Day 21",
                    "relativeToFrom": {
                      "id": "1bff9b46-2d61-4d3d-9404-0d77becfffd4",
                      "code": "C71155",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "First Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "ae6267a2-c115-4c2a-8a0d-2d9a36744ae5",
                    "instanceType": "Timing",
                    "windowLower": "-P21D",
                    "windowUpper": "-P1D"
                  },
                  {
                    "id": "a4329b8f-35ee-4592-9abb-61408d5d495c",
                    "name": "Experimental Therapy Washout",
                    "type": {
                      "id": "cac6d93f-c455-4bc9-b91a-beed62c52ae3",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P90D",
                    "valueLabel": "Day 90",
                    "relativeToFrom": {
                      "id": "8ca422ea-ef63-43a9-97a0-44b2ef952206",
                      "code": "C71158",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Screening",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "6c0b8376-b4a3-48b7-ac6a-45b5342ed5d8",
                    "instanceType": "Timing",
                    "windowLower": "-P90D",
                    "windowUpper": "-P1D"
                  },
                  {
                    "id": "acdee5d2-23f0-46d9-abbd-9f26121a61d8",
                    "name": "Prescription Medication Washout",
                    "type": {
                      "id": "1fcf1492-29cc-495c-9109-b71f89281161",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P14D",
                    "valueLabel": "Day 14",
                    "relativeToFrom": {
                      "id": "f00434c2-a5a9-41cd-a4c8-172edbe9b22d",
                      "code": "C71153",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Study Start",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "003d4f14-72a8-44e1-bae4-16a0f50f7391",
                    "instanceType": "Timing",
                    "windowLower": "-P14D",
                    "windowUpper": "-P1D"
                  },
                  {
                    "id": "4ecf1968-4d53-457a-aae0-630e91b7c646",
                    "name": "Non-Prescription Medication Washout",
                    "type": {
                      "id": "c6b522bc-2708-465c-bfd2-439a41ed639b",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P7D",
                    "valueLabel": "Day 7",
                    "relativeToFrom": {
                      "id": "71433d64-9557-43fb-aeb6-39d990090d8d",
                      "code": "C71153",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Study Start",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "a5c51515-5685-4c3f-8eb7-2682e4ce2387",
                    "instanceType": "Timing",
                    "windowLower": "-P7D",
                    "windowUpper": "-P1D"
                  },
                  {
                    "id": "51923801-7aac-418e-80ce-d498c33dbaf7",
                    "name": "Alcohol Consumption Washout",
                    "type": {
                      "id": "931dd9fa-899f-4e1d-8094-56a3fc85c6f1",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "PT48H",
                    "valueLabel": "48 hours",
                    "relativeToFrom": {
                      "id": "45632014-334f-4d27-b151-36f62e6254d5",
                      "code": "C71155",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "First Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "09896b64-a6bd-483c-9e78-8c6d71dc6601",
                    "instanceType": "Timing",
                    "windowLower": "-PT48H",
                    "windowUpper": "-PT1H"
                  },
                  {
                    "id": "b36ece54-11a3-4776-ba9d-53657d600963",
                    "name": "Chelator Discontinuation for Baseline",
                    "type": {
                      "id": "b7db5060-03e6-4bde-b1a4-631d15f23cb7",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P4D",
                    "valueLabel": "Day 4",
                    "relativeToFrom": {
                      "id": "5018bd0e-ec38-4ea3-b3b8-69cafba11312",
                      "code": "C71155",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "First Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "d7f8c143-d79d-4efe-a19e-91641690fd9d",
                    "instanceType": "Timing",
                    "windowLower": "-P4D",
                    "windowUpper": "-P1D"
                  },
                  {
                    "id": "da91e438-b182-49a3-9239-81cd7c35d854",
                    "name": "End of Study Visit Window",
                    "type": {
                      "id": "6f28cc17-234b-4aa1-9b5a-74e18d4c85fe",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P54D",
                    "valueLabel": "Day 54",
                    "relativeToFrom": {
                      "id": "c0ce8e91-ae87-4a4b-bf98-1cf2d7322e93",
                      "code": "C71155",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "First Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "da62630a-ebc7-41e9-b710-bcfab9523ef5",
                    "instanceType": "Timing",
                    "windowLower": "-P2D",
                    "windowUpper": "P2D"
                  },
                  {
                    "id": "5417665e-780d-4818-b65e-68ba6784706b",
                    "name": "Dose Titration to 30mg/day",
                    "type": {
                      "id": "b753bc0a-7ea7-444e-9ecc-7b8a74c6e841",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P29D",
                    "valueLabel": "Day 29",
                    "relativeToFrom": {
                      "id": "cfef8f35-bec8-4153-a878-979973916588",
                      "code": "C71155",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "First Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "89bd48f4-b44c-474a-9763-c656a9e8c0ee",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "c25aa467-3ccc-4b17-90b3-da2087b3d190",
                    "name": "Safety Review for Dose Titration",
                    "type": {
                      "id": "29ac11a2-9a29-46eb-a2b1-b4a609cf65c1",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P23D",
                    "valueLabel": "Day 23",
                    "relativeToFrom": {
                      "id": "7a876dbd-a7c6-43e9-b3f6-7ea7b36dfe40",
                      "code": "C71155",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "First Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "d5406fba-2d68-4c7a-bfb1-02f964e31021",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "960875b2-b9e9-4700-a20d-aced1694280e",
                    "name": "Pregnancy Test Frequency",
                    "type": {
                      "id": "80dd4c3e-c3be-4e99-97e4-bebc52c8cebb",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P4W",
                    "valueLabel": "4 weeks",
                    "relativeToFrom": {
                      "id": "bab71b2d-163b-4d77-9166-0c5d9bec7d4e",
                      "code": "C71153",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Study Start",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "ff3c7610-0ae3-43f8-b27e-7280811c0f78",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "0eed086c-55f3-4d2a-ae2d-dc7fed68ccf7",
                    "name": "Tetrathiomolybdate Washout",
                    "type": {
                      "id": "24867942-8fc7-4359-a8ba-44151e0aa032",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P1D",
                    "valueLabel": "1 year",
                    "relativeToFrom": {
                      "id": "bab4c10c-2b06-457c-8f8c-9d00295d6106",
                      "code": "C71155",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "First Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "ceb742e9-fe9f-4d23-bb11-a302e464845f",
                    "instanceType": "Timing",
                    "windowLower": "-P365D",
                    "windowUpper": "-P1D"
                  },
                  {
                    "id": "5b639434-560a-43bd-9e78-5029d2c265d4",
                    "name": "Outpatient Period Extension",
                    "type": {
                      "id": "0fcb3a05-83e1-499b-ae46-181befef25f4",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P14D",
                    "valueLabel": "Day 14",
                    "relativeToFrom": {
                      "id": "2acd66ef-aba6-4390-a940-8ee273ad43e6",
                      "code": "C71153",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Study Start",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "c69d7861-5277-4c08-b797-eecd96505604",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P0D"
                  }
                ],
                "exits": [
                  {
                    "id": "44470920-07f3-4988-89b6-8187694be616",
                    "name": "Study Completion",
                    "exitType": "Completion",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities (SoA)."
                  },
                  {
                    "id": "144014a8-29dd-414d-9f91-d056091bf06d",
                    "name": "Participant Withdrawal by Request",
                    "exitType": "Early Termination",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "A participant may withdraw from the study at any time at his/her own request."
                  },
                  {
                    "id": "27bf8801-e10e-4e14-968c-e623ac8f73f8",
                    "name": "Investigator Discretionary Withdrawal",
                    "exitType": "Early Termination",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons."
                  },
                  {
                    "id": "cead7714-d4c7-407b-929e-fcde7bc2c660",
                    "name": "Lost to Follow-up",
                    "exitType": "Early Termination",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site."
                  },
                  {
                    "id": "8154b6e4-30e8-4bd2-aabe-c1a11993ea85",
                    "name": "Early Study Termination",
                    "exitType": "Early Termination",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "Alexion reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of Alexion."
                  }
                ]
              }
            ],
            "encounters": [
              {
                "id": "7b5788e5-7c88-4e27-9817-602e4fd08e42",
                "name": "Screening (-42 to -9)",
                "instanceType": "Encounter",
                "type": {
                  "id": "32d9a76c-ddfc-467c-ab22-727ccc565103",
                  "code": "C48262",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening",
                  "instanceType": "Code"
                },
                "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb"
              },
              {
                "id": "4741a38a-ac42-4ef4-ad4f-2c0e571ceed2",
                "name": "Screening (-21)",
                "instanceType": "Encounter",
                "type": {
                  "id": "a9e7de59-074c-4615-a966-35dbf4b4ef56",
                  "code": "C48262",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening",
                  "instanceType": "Code"
                },
                "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb"
              },
              {
                "id": "0e439567-df59-4e5c-bb7b-587d42e8d6e5",
                "name": "Screening (-8)",
                "instanceType": "Encounter",
                "type": {
                  "id": "aa77166d-a1aa-459b-ad8e-71470c6600e3",
                  "code": "C48262",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening",
                  "instanceType": "Code"
                },
                "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb"
              },
              {
                "id": "6b799dc8-6ffb-4d23-84e0-fdd68e3f981c",
                "name": "Screening (-7)",
                "instanceType": "Encounter",
                "type": {
                  "id": "0d68487b-f626-486b-acd8-23ba28a42700",
                  "code": "C48262",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening",
                  "instanceType": "Code"
                },
                "epochId": "f323d182-da8e-426d-9f9b-e1cba7973dbb"
              },
              {
                "id": "594db433-91aa-47e5-84df-08250900a397",
                "name": "C-I (-6 through -4)",
                "instanceType": "Encounter",
                "type": {
                  "id": "96dcce44-ef8d-4a2a-b37f-1d6f8208b0b8",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "60aa5dc9-3d59-4e23-a442-e7e996d38969"
              },
              {
                "id": "0ceeab15-73a7-4e34-8878-c26ff7a2d13a",
                "name": "C-I (-1)",
                "instanceType": "Encounter",
                "type": {
                  "id": "aacfa7ac-9f98-4d57-b0f2-ed709ff5f06d",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "60aa5dc9-3d59-4e23-a442-e7e996d38969"
              },
              {
                "id": "639aca4b-f8c1-4726-a940-720a97b4e096",
                "name": "Inpatient Period 1 (Day 1)",
                "instanceType": "Encounter",
                "type": {
                  "id": "f554722b-b0b9-4d69-89a8-92e91268f98e",
                  "code": "C82517",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Baseline",
                  "instanceType": "Code"
                },
                "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615"
              },
              {
                "id": "5cff5914-49e0-4d25-add3-b817a9b42c44",
                "name": "Inpatient Period 1 (Day 2-3)",
                "instanceType": "Encounter",
                "type": {
                  "id": "a16ca4a7-c31c-4660-8699-22f251d1b925",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615"
              },
              {
                "id": "f5ee1059-deac-4caf-a9db-97cb9fc3e849",
                "name": "Inpatient Period 1 (Day 4-7)",
                "instanceType": "Encounter",
                "type": {
                  "id": "2487bff2-8273-47a8-9597-91a0876ebf1c",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615"
              },
              {
                "id": "2d0168c6-9f46-48ff-b3d4-a01f0dddbce3",
                "name": "Inpatient Period 1 (Day 8)",
                "instanceType": "Encounter",
                "type": {
                  "id": "029204f2-b739-488d-bffb-1fa71ceb6e11",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615"
              },
              {
                "id": "810b7563-321e-474a-a8e3-116349030a6f",
                "name": "Inpatient Period 1 (Day 9)",
                "instanceType": "Encounter",
                "type": {
                  "id": "09265d69-25eb-48d0-9eb0-071ee67a1a84",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "ce2375ef-dba2-42e6-a4ff-1da679de1615"
              },
              {
                "id": "7d28a964-6964-443c-861d-3fb24dac0c73",
                "name": "OP (Day 10-22)",
                "instanceType": "Encounter",
                "type": {
                  "id": "16926e9e-5c36-432e-9ac9-725330146601",
                  "code": "C82517",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Baseline",
                  "instanceType": "Code"
                },
                "epochId": "9910e2f6-6088-4468-998c-9dadba3878e1"
              },
              {
                "id": "aa57efe0-a9cc-4427-855a-140fb1aee54a",
                "name": "Inpatient Period 2 (Day 23)",
                "instanceType": "Encounter",
                "type": {
                  "id": "d0e8062c-2a74-4ce4-b44c-f57250c13021",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b"
              },
              {
                "id": "52c2db34-fc24-4f51-855d-a5995b69da8e",
                "name": "Inpatient Period 2 (Day 24)",
                "instanceType": "Encounter",
                "type": {
                  "id": "7e46b0c0-1c64-4d55-abbf-ae42d8d27484",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b"
              },
              {
                "id": "e88d07ab-f998-47c7-8e8b-c2949d1b2b9c",
                "name": "Inpatient Period 2 (Day 25)",
                "instanceType": "Encounter",
                "type": {
                  "id": "c6005eb5-b835-4da0-8d89-5c0fd32f332f",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b"
              },
              {
                "id": "fcb42287-c2cb-4d0d-9b55-ecd4c62a406b",
                "name": "Inpatient Period 2 (Day 26-28)",
                "instanceType": "Encounter",
                "type": {
                  "id": "557f63ec-297a-47c9-a19d-a5165e45c443",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b"
              },
              {
                "id": "551f8be3-847f-4b04-a2f6-0df5257e72b7",
                "name": "Inpatient Period 2 (Day 29)",
                "instanceType": "Encounter",
                "type": {
                  "id": "162ecb2c-ec87-4ffa-9cfd-777d6a685b3f",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b"
              },
              {
                "id": "2a28a085-2487-44bc-8a20-7e8f783adb7b",
                "name": "Inpatient Period 2 (Day 30-35)",
                "instanceType": "Encounter",
                "type": {
                  "id": "69d70dfe-4ce5-4f04-8cfd-80850c697f62",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b"
              },
              {
                "id": "5a75526e-73c8-4e2b-bed6-46324bb62098",
                "name": "Inpatient Period 2 (Day 36)",
                "instanceType": "Encounter",
                "type": {
                  "id": "60dc764c-1926-4ba8-b1ef-9af754a93521",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b"
              },
              {
                "id": "6c0c9841-f92b-4e90-88d9-82a75e98c8f8",
                "name": "Inpatient Period 2 (Day 37-38)",
                "instanceType": "Encounter",
                "type": {
                  "id": "727d6e2b-401e-4470-8c9e-898677408ef4",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b"
              },
              {
                "id": "6a447147-87eb-42c7-b2a6-598b03af3afc",
                "name": "Inpatient Period 2 (Day 39)",
                "instanceType": "Encounter",
                "type": {
                  "id": "6130f42c-443c-4d83-b646-05d727a6cc52",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b"
              },
              {
                "id": "337a47c6-f667-43ff-bd15-7f8bdf884351",
                "name": "Inpatient Period 2 (Day 40)",
                "instanceType": "Encounter",
                "type": {
                  "id": "0decf748-a41e-4933-8283-26ef6eb5c803",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "e13cdf18-257f-406f-ab12-93802e148b6b"
              },
              {
                "id": "efed4e68-51b4-4eaf-984d-1eb3d833217b",
                "name": "EOS Day 54+/-2",
                "instanceType": "Encounter",
                "type": {
                  "id": "3159a731-69f1-4067-8dd4-e388f7f00a3d",
                  "code": "C126070",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "End of Study",
                  "instanceType": "Code"
                },
                "epochId": "9a99dd8f-b4d4-4d8c-b419-9db33003f93f"
              }
            ],
            "activities": [
              {
                "id": "8c36619e-4455-4e15-8801-75403677a763",
                "name": "Eligibility",
                "instanceType": "Activity",
                "childIds": [
                  "2685bbcf-8d05-4df0-9a3e-084c54f655b3",
                  "2fd8a19d-0e62-47fa-8453-683d56ad82c7",
                  "2c4c5521-bb8c-4190-bd37-1a1c8d63f6a4",
                  "f3094b41-79e2-458c-ac16-7f8a1f469330",
                  "2aa2422a-c51b-4cb9-8ed0-26c77643e137",
                  "481c7f4d-f155-45ec-8ff8-c655bf6fd4cf",
                  "7c5f656d-e9b8-4249-94e7-0a06cfe4c24a",
                  "80d45301-f45d-444f-b98c-60276964c28d",
                  "1caced06-467d-43c6-a39f-ca2f78a5529a"
                ],
                "notes": [
                  {
                    "id": "f070c2ab-66bd-4a55-a1ba-ff0b0777baca",
                    "text": "• All screening evaluations must be completed and reviewed to confirm that potential \nparticipants meet all eligibility criteria",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "89bbeefc-c9e7-415f-9663-5a0029ef84a8",
                "name": "Study Administration",
                "instanceType": "Activity",
                "childIds": [
                  "02fe9dc7-b7f3-4063-a8f3-24219f33238a",
                  "6ed1568b-7eae-4cbf-a3ef-d979624e3306",
                  "7d7fac7f-4d71-4154-adb4-73d0ea0496ae",
                  "6dd82ade-fe18-45fc-8e98-df4c651ae864",
                  "e977a927-cd09-46f7-8134-1294c97dea27"
                ],
                "notes": [
                  {
                    "id": "ad4c3956-c43e-4662-b4f1-e94920e6b2f2",
                    "text": "Overall Rationale for the Amendment \nThe main reason for preparation of this amendment was to clarify study procedures occurring \nacross different sites in the US, so as to facilitate participant recruitment across different regions \nof the US, and to lessen inconvenience for participants without compromising the quality of the \nstudy",
                    "instanceType": "Note"
                  },
                  {
                    "id": "33a75686-ffb2-41b6-aed0-2e481c44f836",
                    "text": "Overall Design \nThis is a single-arm, open-label, repeat-dose study to evaluate the effects of ALXN",
                    "instanceType": "Note"
                  },
                  {
                    "id": "bbab2dbd-adcd-41ee-8103-f3f5f97f8173",
                    "text": "k A full physical examination will be performed at Screening, at check-in for the study, and at the End of the study/Early Termination Visit",
                    "instanceType": "Note"
                  },
                  {
                    "id": "e45bd601-d848-4a6a-823b-3ad261fd47eb",
                    "text": "m While in the CRU, study intervention will be administered after an overnight fast",
                    "instanceType": "Note"
                  },
                  {
                    "id": "13dacf5d-7563-464c-ad2a-ef5bc4b0c23b",
                    "text": "n During the outpatient period, participants will use SMS text messaging to confirm study intervention administration",
                    "instanceType": "Note"
                  },
                  {
                    "id": "8216d524-2234-49eb-b353-02a47f6f181f",
                    "text": "The current study will explore copper balance in response to \ntreatment with ALXN",
                    "instanceType": "Note"
                  },
                  {
                    "id": "5ab68e4a-d70c-4616-8534-5eafc8548525",
                    "text": "Over-the-counter medications may be given if they \nare not expected to impact the outcome of the study",
                    "instanceType": "Note"
                  },
                  {
                    "id": "ae3d97c2-8804-4dfd-808a-1d7121ff37a1",
                    "text": "Individuals who do not meet the criteria for participation in this study",
                    "instanceType": "Note"
                  },
                  {
                    "id": "08e353fa-d269-4fc0-a6d4-1a58e578e67b",
                    "text": "If the study intervention is definitively discontinued, the \nparticipant should remain in the study to be evaluated for safety follow-up",
                    "instanceType": "Note"
                  },
                  {
                    "id": "a4f41143-6021-4eac-9d2d-420d6d356327",
                    "text": "Discontinuation of study intervention for abnormal liver function should be considered by the \nInvestigator when a participant meets one of the conditions outlined in the Dose Modification \ncriteria",
                    "instanceType": "Note"
                  },
                  {
                    "id": "733e3b26-d511-4ef8-8ad3-6c24a41ad212",
                    "text": "Participants must be considered for discontinuation from study intervention if any of the \nfollowing occur during the study: \n• Serious hypersensitivity reaction; \n• Severe uncontrolled infection; \n• Use of disallowed medication; \n• Pregnancy or planned pregnancy",
                    "instanceType": "Note"
                  },
                  {
                    "id": "fcebcb3a-a354-4e8b-9dad-43afe3c5b0dc",
                    "text": "The study staff should \nnotify Alexion and their site monitor of all study withdrawals as soon as possible",
                    "instanceType": "Note"
                  },
                  {
                    "id": "10a24942-6e45-44fb-91b5-591a8b5e925d",
                    "text": "• A participant may withdraw from the study at any time at his/her own request, or may \nbe withdrawn at any time at the discretion of the Investigator for safety, behavioral, \ncompliance, or administrative reasons",
                    "instanceType": "Note"
                  },
                  {
                    "id": "bf37af73-3652-4eab-bcc1-d0f549e9c801",
                    "text": "• Immediate safety concerns should be discussed with Alexion immediately upon \noccurrence or awareness to determine if the participant should continue or \ndiscontinue study intervention",
                    "instanceType": "Note"
                  },
                  {
                    "id": "f75edec4-c2af-454e-813b-e3c65418a27d",
                    "text": "Some sites may perform screening procedures only and \nnot any of the remaining study procedures",
                    "instanceType": "Note"
                  },
                  {
                    "id": "b02e0ff1-88b5-44a5-9238-40b04b6f7f1c",
                    "text": "• The Investigator must review the laboratory report, document this review, and record any \nclinically relevant changes occurring during the study in the AE section of the CRF",
                    "instanceType": "Note"
                  },
                  {
                    "id": "08cb7891-5477-49d3-a423-ef27a4c913c2",
                    "text": "Scientific Rationale for Study Design",
                    "instanceType": "Note"
                  },
                  {
                    "id": "f390f024-c9fd-4c51-9030-806fd0ee31b3",
                    "text": "End of Study Definition \nA participant is considered to have completed the study if he/she has completed all phases of the \nstudy including the last scheduled procedure shown in the Schedule of Activities",
                    "instanceType": "Note"
                  },
                  {
                    "id": "dc23d680-09bb-47b1-a9af-74f2b8123246",
                    "text": "Abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule of \nActivities",
                    "instanceType": "Note"
                  },
                  {
                    "id": "21252a3a-f0c8-4e80-a8f0-646441bb045e",
                    "text": "Screen Failures  \nScreen failures are defined as participants who consent to participate in the clinical study but are \nnot subsequently assigned to study intervention",
                    "instanceType": "Note"
                  },
                  {
                    "id": "cf795652-1248-493d-a095-505bf809d840",
                    "text": "Discontinuation of Study Intervention \nIn rare instances, it may be necessary for a participant to permanently discontinue",
                    "instanceType": "Note"
                  },
                  {
                    "id": "77b8adc8-7e4e-4333-83cc-60081d0ae9c0",
                    "text": "Participant Discontinuation/Withdrawal From the Study \n• All efforts should be made to ensure participants are willing to comply with study \nparticipation prior to conducting the screening procedures",
                    "instanceType": "Note"
                  },
                  {
                    "id": "b6f41ff7-ecaa-41a5-ac6a-5b7482b9ddde",
                    "text": "STUDY ASSESSMENTS AND PROCEDURES \n• Study procedures and their timing are summarized in the SoA",
                    "instanceType": "Note"
                  },
                  {
                    "id": "5d827909-08df-4eac-8c9d-2928490ba2e4",
                    "text": "Samples collected for \nanalyses of plasma concentrations may also be used to evaluate safety aspects related \nto concerns arising during or after the study",
                    "instanceType": "Note"
                  },
                  {
                    "id": "907c24d5-9de8-4a45-9d74-581629a0d2c2",
                    "text": "Pharmacodynamics \nPlasma total and PUF-copper, ceruloplasmin, ceruloplasmin-bound copper, and LBC will be \nassessed during the study",
                    "instanceType": "Note"
                  },
                  {
                    "id": "a02f1b33-dab3-463c-8187-cd2656a70d86",
                    "text": "Genetics \nGenetics will not be evaluated in this study",
                    "instanceType": "Note"
                  },
                  {
                    "id": "9630a98b-537b-4ae0-8298-95a6eda6f76c",
                    "text": "Health Economics Data and/or Medical Resource Utilization \nHealth economic and medical resource utilization parameters are not evaluated in this study",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "93466314-8e4b-4700-973a-86b80488394f",
                "name": "Enrollment",
                "instanceType": "Activity",
                "childIds": [
                  "095516a4-2655-4f1e-8cd5-81dbe6a45969",
                  "9e6d729d-392b-4f08-95a7-ad2dd90032de",
                  "05e22e79-ce61-4789-ab0b-ddfb0587ef40"
                ],
                "notes": [
                  {
                    "id": "a5efde45-e7f0-4780-bd67-2c6c111b736e",
                    "text": "Following screening and enrollment, \nparticipants will have a Run-in Period to support diet equilibration",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "19ba2918-5484-4707-8887-8eac33f12328",
                "name": "Administration of Study Intervention",
                "instanceType": "Activity",
                "childIds": [
                  "1dd9e020-e442-4831-a718-c1e4bda4ee47",
                  "c6b3a06f-da18-4715-b845-f41f3e254c13",
                  "2b06c94f-fc28-4e2e-bc25-f13aae8a4ce0"
                ],
                "notes": [
                  {
                    "id": "f88a0055-0abf-4f1f-ad0f-552828709044",
                    "text": "Intervention Groups and Duration: \nTreatment-experienced",
                    "instanceType": "Note"
                  },
                  {
                    "id": "7e145a5d-6d17-471b-9960-5cfa14b7249f",
                    "text": "m While in the CRU, study intervention will be administered after an overnight fast",
                    "instanceType": "Note"
                  },
                  {
                    "id": "b80e64d0-d7e4-4002-9297-2020bd14c944",
                    "text": "n During the outpatient period, participants will use SMS text messaging to confirm study intervention administration",
                    "instanceType": "Note"
                  },
                  {
                    "id": "f31e78d8-9d34-4532-a500-57b68e917f4f",
                    "text": "If the study intervention is definitively discontinued, the \nparticipant should remain in the study to be evaluated for safety follow-up",
                    "instanceType": "Note"
                  },
                  {
                    "id": "01d15326-2f53-4ce1-bd57-e153c1882677",
                    "text": "Discontinuation of study intervention for abnormal liver function should be considered by the \nInvestigator when a participant meets one of the conditions outlined in the Dose Modification \ncriteria",
                    "instanceType": "Note"
                  },
                  {
                    "id": "a8850aac-4f71-49d1-8737-a9627e26e084",
                    "text": "Participants must be considered for discontinuation from study intervention if any of the \nfollowing occur during the study: \n• Serious hypersensitivity reaction; \n• Severe uncontrolled infection; \n• Use of disallowed medication; \n• Pregnancy or planned pregnancy",
                    "instanceType": "Note"
                  },
                  {
                    "id": "4d251576-86ba-4ce6-aade-158c91554b7e",
                    "text": "• Immediate safety concerns should be discussed with Alexion immediately upon \noccurrence or awareness to determine if the participant should continue or \ndiscontinue study intervention",
                    "instanceType": "Note"
                  },
                  {
                    "id": "387503e5-d1d2-4f46-9004-06c0c7b06eac",
                    "text": "Screen Failures  \nScreen failures are defined as participants who consent to participate in the clinical study but are \nnot subsequently assigned to study intervention",
                    "instanceType": "Note"
                  },
                  {
                    "id": "19179f91-5572-4cdd-981d-dfc55fbc9fec",
                    "text": "Discontinuation of Study Intervention \nIn rare instances, it may be necessary for a participant to permanently discontinue",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "7376c114-d666-4459-be54-661280b8c786",
                "name": "PK/PD Analyses",
                "instanceType": "Activity",
                "childIds": [
                  "0603453c-99da-4ddf-b8f3-f2e9496d2145",
                  "a543cd5c-7133-4d2f-8a90-ed3ad6cc872d"
                ],
                "notes": [
                  {
                    "id": "cb72af4c-ddc6-4c41-8cd8-ced877c7f7b4",
                    "text": "p PK/PD collection will include timepoints described in the schedule of PK/PD assessment for Days",
                    "instanceType": "Note"
                  },
                  {
                    "id": "3185f97a-8730-42de-904b-d31cb556228e",
                    "text": "Samples collected for \nanalyses of plasma concentrations may also be used to evaluate safety aspects related \nto concerns arising during or after the study",
                    "instanceType": "Note"
                  },
                  {
                    "id": "01076372-a463-4b2e-8664-7e65d44ce677",
                    "text": "These samples will not be \nused for genetic analyses",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "138497f7-8415-40c8-9bff-2d2954a7c08a",
                "name": "Safety Assessments / Laboratory Analyses",
                "instanceType": "Activity",
                "childIds": [
                  "13dacf21-6052-4139-8397-16846d827a06",
                  "09d48280-a545-4f5f-a213-6bfa0d3a36b2",
                  "15901dd8-31c5-4006-80ce-b1e27c23a388",
                  "b5d5d409-b4e9-4971-8d35-460700a09e7f"
                ],
                "notes": [
                  {
                    "id": "f96aa9a1-ef9e-49db-815c-912acb93e97f",
                    "text": "r Laboratory assessment including chemistry, hematology, and coagulation parameters should be performed on Days -",
                    "instanceType": "Note"
                  },
                  {
                    "id": "971e308d-0bfc-4e1a-b53e-2e767ef394ce",
                    "text": "If the study intervention is definitively discontinued, the \nparticipant should remain in the study to be evaluated for safety follow-up",
                    "instanceType": "Note"
                  },
                  {
                    "id": "eb1e5c01-ed42-4aef-b7d6-d31a20ff1d02",
                    "text": "• A participant may withdraw from the study at any time at his/her own request, or may \nbe withdrawn at any time at the discretion of the Investigator for safety, behavioral, \ncompliance, or administrative reasons",
                    "instanceType": "Note"
                  },
                  {
                    "id": "8a8e461d-1b67-46f9-b97d-80caffcc268a",
                    "text": "• Immediate safety concerns should be discussed with Alexion immediately upon \noccurrence or awareness to determine if the participant should continue or \ndiscontinue study intervention",
                    "instanceType": "Note"
                  },
                  {
                    "id": "9e108a7f-79f3-43f1-8f81-6afa079fcf5d",
                    "text": "Samples will be collected, stored and shipped as detailed in the Laboratory Manual",
                    "instanceType": "Note"
                  },
                  {
                    "id": "68de2caa-2add-4c7e-8f41-16d0f799deda",
                    "text": "All sample handling procedures will be documented in detail as \ndescribed in the Laboratory Manual",
                    "instanceType": "Note"
                  },
                  {
                    "id": "fc36ee47-7abc-43ed-b8d4-a60ed5269ecc",
                    "text": "• The Investigator must review the laboratory report, document this review, and record any \nclinically relevant changes occurring during the study in the AE section of the CRF",
                    "instanceType": "Note"
                  },
                  {
                    "id": "f692c85d-e534-4d25-94a5-f14b159ab701",
                    "text": "Clinically significant \nlaboratory values are those deemed by the Investigator to be clinically significant \nresulting in further evaluation or treatment or those associated with an AE or clinical \nsigns or symptoms",
                    "instanceType": "Note"
                  },
                  {
                    "id": "c4b3878b-9c0d-4593-a142-e982dedad195",
                    "text": "− All laboratory values from non-protocol-specified laboratory assessments must \nalso be recorded in the CRF",
                    "instanceType": "Note"
                  },
                  {
                    "id": "2db6bca2-e2df-4824-bf9c-03b749d53f25",
                    "text": "STUDY ASSESSMENTS AND PROCEDURES \n• Study procedures and their timing are summarized in the SoA",
                    "instanceType": "Note"
                  },
                  {
                    "id": "e4f4f6e9-8f3b-4caf-9508-97293aa3e4ff",
                    "text": "Efficacy Assessments",
                    "instanceType": "Note"
                  },
                  {
                    "id": "859bc721-3cd6-4921-ad51-1b3ac71a9349",
                    "text": "Safety Assessments \nPlanned time points for all safety assessments are provided in the SoA",
                    "instanceType": "Note"
                  },
                  {
                    "id": "43a5fb5e-5f04-4fab-8dc4-cb217720f024",
                    "text": "Physical Examinations \n• A complete physical examination will include, at a minimum, assessments of the \ncardiovascular, respiratory, gastrointestinal, and neurological systems",
                    "instanceType": "Note"
                  },
                  {
                    "id": "311673f4-9e1c-4e80-b064-1a8151d57947",
                    "text": "Clinical Safety Laboratory Assessments \n• See Section",
                    "instanceType": "Note"
                  },
                  {
                    "id": "0eebea5c-c3b5-46c5-92c1-40b45508c9b9",
                    "text": "Samples collected for \nanalyses of plasma concentrations may also be used to evaluate safety aspects related \nto concerns arising during or after the study",
                    "instanceType": "Note"
                  },
                  {
                    "id": "41cbbe60-cf30-4164-9a7a-0c7e36bcc0f2",
                    "text": "Immunogenicity Assessments \nNot applicable",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "77781445-109a-49af-aa88-bd2600ab5c2a",
                "name": "Safety Assessments",
                "instanceType": "Activity",
                "childIds": [
                  "b0e71e41-6828-4061-b8f6-0cbc384c9388",
                  "587124ff-d858-4f2a-8b5c-78c06fe8db7a",
                  "c25a9d0e-98d7-411b-916d-c07298b040d5"
                ],
                "notes": [
                  {
                    "id": "57f26726-d397-4a62-823d-298fbca54de2",
                    "text": "Safety Assessments \nPlanned time points for all safety assessments are provided in the SoA",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "b1ccea3b-35c6-43be-b091-669e286be0f3",
                "name": "Intake assessments",
                "instanceType": "Activity",
                "childIds": [
                  "9a58c970-fa45-487b-afe9-094a3819d719",
                  "778d69f6-5d53-4ac8-a835-c35a3c6569a5",
                  "6a029e30-f6a0-4ce7-944e-12df47c05d85",
                  "921876c4-2fe5-48c0-baa5-b5994a3df1ce"
                ],
                "notes": [
                  {
                    "id": "b5200c27-3ae1-4f13-a363-face294095b8",
                    "text": "Participants will have intake and output collection periods from Day -",
                    "instanceType": "Note"
                  },
                  {
                    "id": "4862d0e2-fced-4310-8b3f-c6edc0bb7343",
                    "text": "Copper and Molybdenum Balance Measurements \nCopper and molybdenum balance measurements will be made on all intake",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "3de30575-25ff-4c55-ba5a-97233184299d",
                "name": "Other",
                "instanceType": "Activity",
                "childIds": [
                  "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f"
                ],
                "notes": [
                  {
                    "id": "68396a62-4a9b-4adc-928c-413f2df65a59",
                    "text": "Otherwise, a symptom-driven physical \nexamination may be performed at other times, at the Principal Investigator’s discretion",
                    "instanceType": "Note"
                  },
                  {
                    "id": "e194c2c4-5e65-4aab-a134-e4900e0aa769",
                    "text": "u Vital signs measurements and ECGs should be performed predose, unless otherwise specified",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "2685bbcf-8d05-4df0-9a3e-084c54f655b3",
                "name": "Informed consent",
                "instanceType": "Activity",
                "description": "Informed consent",
                "notes": [
                  {
                    "id": "48fe6f17-8720-48d2-acd0-52a087d7eb35",
                    "text": "Rescreened participants are not \nrequired to reconsent as long as they have signed the latest version of the ICF",
                    "instanceType": "Note"
                  },
                  {
                    "id": "dec0b35e-6c69-4e24-a5d0-a919539c6af3",
                    "text": "Note: “Enrolled” means all participants who sign the informed consent form",
                    "instanceType": "Note"
                  },
                  {
                    "id": "7af2b738-2758-435b-9cca-d81782661683",
                    "text": "Screen Failures  \nScreen failures are defined as participants who consent to participate in the clinical study but are \nnot subsequently assigned to study intervention",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "2fd8a19d-0e62-47fa-8453-683d56ad82c7",
                "name": "Admit to unit",
                "instanceType": "Activity",
                "description": "Admit to unit",
                "notes": [
                  {
                    "id": "00cca52c-f929-4caa-98d4-a34c8a744481",
                    "text": "Participants may be discharged from the clinical research unit",
                    "instanceType": "Note"
                  },
                  {
                    "id": "422f804c-6c14-4efb-86a4-a5bf7ad75783",
                    "text": "Abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule of \nActivities",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "2c4c5521-bb8c-4190-bd37-1a1c8d63f6a4",
                "name": "Discharge from unit",
                "instanceType": "Activity",
                "description": "Discharge from unit",
                "notes": [
                  {
                    "id": "1653beb3-b3ce-4719-a1df-c33e8d1f94c2",
                    "text": "Participants will have intake and output collection periods from Day -",
                    "instanceType": "Note"
                  },
                  {
                    "id": "e30c60c4-9399-415c-91cb-de8d275701d7",
                    "text": "Participants may be discharged from the clinical research unit",
                    "instanceType": "Note"
                  },
                  {
                    "id": "103cb9c7-042c-4b7b-b869-c7cde8b32e9b",
                    "text": "Deviation from the dose modification guidelines must be agreed with the Alexion Medical \nMonitor",
                    "instanceType": "Note"
                  },
                  {
                    "id": "0b51105e-bf94-4cb0-9406-207aabfdae3b",
                    "text": "Participants must be considered for discontinuation from study intervention if any of the \nfollowing occur during the study: \n• Serious hypersensitivity reaction; \n• Severe uncontrolled infection; \n• Use of disallowed medication; \n• Pregnancy or planned pregnancy",
                    "instanceType": "Note"
                  },
                  {
                    "id": "b715700d-2b13-43d1-89e0-6021aad3e6a4",
                    "text": "• A participant may withdraw from the study at any time at his/her own request, or may \nbe withdrawn at any time at the discretion of the Investigator for safety, behavioral, \ncompliance, or administrative reasons",
                    "instanceType": "Note"
                  },
                  {
                    "id": "4281510c-df72-423c-9252-64f145272a47",
                    "text": "All participants will drink water from the same large water bottle \ndispenser",
                    "instanceType": "Note"
                  },
                  {
                    "id": "6f3e6ed8-368a-483f-9804-e8fcf79eaca7",
                    "text": "− All laboratory values from non-protocol-specified laboratory assessments must \nalso be recorded in the CRF",
                    "instanceType": "Note"
                  },
                  {
                    "id": "5c9a62db-4944-4e92-a26d-9af62e192c5b",
                    "text": "Participant Discontinuation/Withdrawal From the Study \n• All efforts should be made to ensure participants are willing to comply with study \nparticipation prior to conducting the screening procedures",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "f3094b41-79e2-458c-ac16-7f8a1f469330",
                "name": "Outpatient visit or phone call",
                "instanceType": "Activity",
                "description": "Outpatient visit or phone call",
                "notes": [
                  {
                    "id": "6f4ba015-1be2-4cb0-aa3b-5e70b77aa034",
                    "text": "In this situation, participants will be given additional investigational product to support \ndaily dosing throughout the Outpatient Period",
                    "instanceType": "Note"
                  },
                  {
                    "id": "9ac09d1e-6295-463b-a4ba-736d6ba08e25",
                    "text": "k A full physical examination will be performed at Screening, at check-in for the study, and at the End of the study/Early Termination Visit",
                    "instanceType": "Note"
                  },
                  {
                    "id": "c4ccf451-4ba6-4118-a541-8c7e3aff1a96",
                    "text": "As an outpatient, participants are expected to take \nALXN",
                    "instanceType": "Note"
                  },
                  {
                    "id": "0aa2bb5c-0871-4366-b39c-f336cbec7d82",
                    "text": "n During the outpatient period, participants will use SMS text messaging to confirm study intervention administration",
                    "instanceType": "Note"
                  },
                  {
                    "id": "a607869d-af59-4d79-84cb-a578c6853e9c",
                    "text": "After EOS Visit",
                    "instanceType": "Note"
                  },
                  {
                    "id": "c2e7d88b-ae46-42d1-92f5-793f554d4d37",
                    "text": "If a clinically significant finding is identified",
                    "instanceType": "Note"
                  },
                  {
                    "id": "a0cec774-e241-4a4d-a636-98148b9c4a55",
                    "text": "• The Investigator must review the laboratory report, document this review, and record any \nclinically relevant changes occurring during the study in the AE section of the CRF",
                    "instanceType": "Note"
                  },
                  {
                    "id": "c0e7e819-1390-498b-a296-c9a195a3eb13",
                    "text": "Clinically significant \nlaboratory values are those deemed by the Investigator to be clinically significant \nresulting in further evaluation or treatment or those associated with an AE or clinical \nsigns or symptoms",
                    "instanceType": "Note"
                  },
                  {
                    "id": "d25d28df-3d84-40cc-b84d-c582c8598b80",
                    "text": "To ensure flexibility, the Outpatient \nPeriod during Treatment Period",
                    "instanceType": "Note"
                  },
                  {
                    "id": "b1f3d952-546a-4a48-b120-2b373cdfd7e1",
                    "text": "Urine Collection for Measurement of Copper and Molybdenum content \nUrine samples to measure copper and molybdenum content will be collected periodically as \ndescribed in the SoA",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "d67d9994-08e3-49a8-9048-5ab7688fa7dd",
                "name": "Inclusion/exclusion",
                "instanceType": "Activity",
                "description": "Inclusion/exclusion"
              },
              {
                "id": "2aa2422a-c51b-4cb9-8ed0-26c77643e137",
                "name": "Discuss/document contraception",
                "instanceType": "Activity",
                "description": "Discuss/document contraception",
                "notes": [
                  {
                    "id": "800e33d3-1257-44dc-83bd-245775894139",
                    "text": "Contraception \nParticipants must consistently and correctly use one or \nmore of the appropriate contraceptive methods \ndescribed in Section",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "481c7f4d-f155-45ec-8ff8-c655bf6fd4cf",
                "name": "Follicle-stimulating hormone (post-menopausal females only)",
                "instanceType": "Activity",
                "description": "Follicle-stimulating hormone (post-menopausal females only)"
              },
              {
                "id": "7c5f656d-e9b8-4249-94e7-0a06cfe4c24a",
                "name": "Alcohol test",
                "instanceType": "Activity",
                "description": "Alcohol test",
                "notes": [
                  {
                    "id": "faf4a744-b85b-4a14-86b4-f48157696268",
                    "text": "s Menstruation check is for women only; women of childbearing potential should only be enrolled after a negative serum pregnancy test result at Screening",
                    "instanceType": "Note"
                  },
                  {
                    "id": "49b923bf-9b4a-4675-bb62-5b0b9be2da18",
                    "text": "Rescreened participants are not \nrequired to reconsent as long as they have signed the latest version of the ICF",
                    "instanceType": "Note"
                  },
                  {
                    "id": "647268bb-68cd-4b5f-92e6-f063bc73a1b6",
                    "text": "Physical Examinations \n• A complete physical examination will include, at a minimum, assessments of the \ncardiovascular, respiratory, gastrointestinal, and neurological systems",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "80d45301-f45d-444f-b98c-60276964c28d",
                "name": "Urine drug screen",
                "instanceType": "Activity",
                "description": "Urine drug screen",
                "definedProcedures": [
                  {
                    "id": "cebc35f5-7ce9-47ad-b036-4b0d53d522d5",
                    "name": "Urine Drug Screen",
                    "procedureType": "Diagnostic Procedure",
                    "code": {
                      "id": "b5725659-0993-4336-ae9f-7bd9f0364c7d",
                      "code": "C25218",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Urine Drug Screen",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Urine Drug Screen",
                    "description": "Screening for drugs of abuse via urine sample."
                  },
                  {
                    "id": "a6289e82-d009-41f4-bdd1-595e2dd586ec",
                    "name": "Urine Collection",
                    "procedureType": "Biospecimen Collection",
                    "code": {
                      "id": "b4165844-b4ca-4223-9532-485f5a5670eb",
                      "code": "C25218",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Urine Collection",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Urine Sample Collection",
                    "description": "Collection of urine for urinalysis, drug screening, pregnancy testing, and 24-hour measurement of copper and molybdenum content."
                  }
                ],
                "notes": [
                  {
                    "id": "a0eaa97f-67b7-433a-b007-3ef1b4c85001",
                    "text": "Following screening and enrollment, \nparticipants will have a Run-in Period to support diet equilibration",
                    "instanceType": "Note"
                  },
                  {
                    "id": "c05e4554-a70f-42e5-bded-282c3572e693",
                    "text": "k A full physical examination will be performed at Screening, at check-in for the study, and at the End of the study/Early Termination Visit",
                    "instanceType": "Note"
                  },
                  {
                    "id": "45619656-68b7-4731-a366-94ec4b759f1c",
                    "text": "s Menstruation check is for women only; women of childbearing potential should only be enrolled after a negative serum pregnancy test result at Screening",
                    "instanceType": "Note"
                  },
                  {
                    "id": "13bd7fdd-d7c7-4244-81dc-2c860e422072",
                    "text": "A minimal set of screen failure information is \nrequired to ensure transparent reporting of screen failure participants to meet the Consolidated \nStandards of Reporting Trials",
                    "instanceType": "Note"
                  },
                  {
                    "id": "009200a3-c5ef-4289-b81c-5d22d7d5a6c0",
                    "text": "Minimal information includes demography, screen failure details",
                    "instanceType": "Note"
                  },
                  {
                    "id": "2f588aab-2d69-49c3-83e8-2b2ae0383a0b",
                    "text": "Rescreened participants are not \nrequired to reconsent as long as they have signed the latest version of the ICF",
                    "instanceType": "Note"
                  },
                  {
                    "id": "54095a50-50bc-47de-a6a6-55256f7cbc5d",
                    "text": "• All screening evaluations must be completed and reviewed to confirm that potential \nparticipants meet all eligibility criteria",
                    "instanceType": "Note"
                  },
                  {
                    "id": "6f3c690f-20fc-46fd-b299-7c963dc5d0c5",
                    "text": "Some sites may perform screening procedures only and \nnot any of the remaining study procedures",
                    "instanceType": "Note"
                  },
                  {
                    "id": "fe9d5e2d-5c82-4895-becd-2428f68fbb16",
                    "text": "Screen Failures  \nScreen failures are defined as participants who consent to participate in the clinical study but are \nnot subsequently assigned to study intervention",
                    "instanceType": "Note"
                  },
                  {
                    "id": "6502322d-7dd5-4412-8447-f3fb9ecbe91c",
                    "text": "Participant Discontinuation/Withdrawal From the Study \n• All efforts should be made to ensure participants are willing to comply with study \nparticipation prior to conducting the screening procedures",
                    "instanceType": "Note"
                  },
                  {
                    "id": "9317dcfb-e37a-41d2-9257-bbd7f8523480",
                    "text": "Urine Collection for Measurement of Copper and Molybdenum content \nUrine samples to measure copper and molybdenum content will be collected periodically as \ndescribed in the SoA",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "1caced06-467d-43c6-a39f-ca2f78a5529a",
                "name": "HIV, hepatitis B and C screen",
                "instanceType": "Activity",
                "description": "HIV, hepatitis B and C screen"
              },
              {
                "id": "02fe9dc7-b7f3-4063-a8f3-24219f33238a",
                "name": "Medical history/demographics",
                "instanceType": "Activity",
                "description": "Medical history/demographics",
                "notes": [
                  {
                    "id": "c52bf3c2-4407-4487-9c8e-99ea8e31b8bc",
                    "text": "Deviation from the dose modification guidelines must be agreed with the Alexion Medical \nMonitor",
                    "instanceType": "Note"
                  },
                  {
                    "id": "fb8810b5-5588-4232-97e3-d1a8cdfd3237",
                    "text": "Health Economics Data and/or Medical Resource Utilization \nHealth economic and medical resource utilization parameters are not evaluated in this study",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "6ed1568b-7eae-4cbf-a3ef-d979624e3306",
                "name": "WD history",
                "instanceType": "Activity",
                "description": "WD history"
              },
              {
                "id": "7d7fac7f-4d71-4154-adb4-73d0ea0496ae",
                "name": "Prior WD treatment",
                "instanceType": "Activity",
                "description": "Prior WD treatment",
                "notes": [
                  {
                    "id": "68b3e513-7b3d-4709-9409-b4244eb1e700",
                    "text": "Intervention Groups and Duration: \nTreatment-experienced",
                    "instanceType": "Note"
                  },
                  {
                    "id": "da044cb8-3b69-4a2a-be63-22ca6c57444b",
                    "text": "The current study will explore copper balance in response to \ntreatment with ALXN",
                    "instanceType": "Note"
                  },
                  {
                    "id": "2354c1f3-cdd1-400e-8ab9-05fe81de276c",
                    "text": "Clinically significant \nlaboratory values are those deemed by the Investigator to be clinically significant \nresulting in further evaluation or treatment or those associated with an AE or clinical \nsigns or symptoms",
                    "instanceType": "Note"
                  },
                  {
                    "id": "86496d71-5ce4-46f6-b3e5-1a9c8abe176c",
                    "text": "To ensure flexibility, the Outpatient \nPeriod during Treatment Period",
                    "instanceType": "Note"
                  },
                  {
                    "id": "ef140487-79a4-47db-9c28-c5a2f3dabea3",
                    "text": "The multiple collection periods will support assessment of duration of treatment and dose on \ncopper elimination and overall copper balance",
                    "instanceType": "Note"
                  },
                  {
                    "id": "d90400b6-c29a-4b05-9fa0-12da03ff84ff",
                    "text": "Participant Discontinuation/Withdrawal From the Study \n• All efforts should be made to ensure participants are willing to comply with study \nparticipation prior to conducting the screening procedures",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "6dd82ade-fe18-45fc-8e98-df4c651ae864",
                "name": "Physical examination",
                "instanceType": "Activity",
                "description": "Physical examination",
                "definedProcedures": [
                  {
                    "id": "814f6787-5362-413a-be52-799631790d50",
                    "name": "Physical Examination",
                    "procedureType": "Assessment",
                    "code": {
                      "id": "88c1fdc1-e171-4851-b085-3faf094d7366",
                      "code": "C25218",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Physical Examination",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Physical Exam",
                    "description": "A full physical examination including assessments of the cardiovascular, respiratory, gastrointestinal, and neurological systems."
                  }
                ],
                "notes": [
                  {
                    "id": "0cca0a36-f46c-4f93-a298-cf7a23b01fdd",
                    "text": "k A full physical examination will be performed at Screening, at check-in for the study, and at the End of the study/Early Termination Visit",
                    "instanceType": "Note"
                  },
                  {
                    "id": "1c679dba-26e5-43ed-9c95-962782da6cf5",
                    "text": "Otherwise, a symptom-driven physical \nexamination may be performed at other times, at the Principal Investigator’s discretion",
                    "instanceType": "Note"
                  },
                  {
                    "id": "9b922d51-6cd8-4b71-8f31-aaf89db21c2c",
                    "text": "Physical Examinations \n• A complete physical examination will include, at a minimum, assessments of the \ncardiovascular, respiratory, gastrointestinal, and neurological systems",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "e977a927-cd09-46f7-8134-1294c97dea27",
                "name": "Height, weight, and BMI",
                "instanceType": "Activity",
                "description": "Height, weight, and BMI"
              },
              {
                "id": "095516a4-2655-4f1e-8cd5-81dbe6a45969",
                "name": "Enrollment/inclusion",
                "instanceType": "Activity",
                "description": "Enrollment/inclusion"
              },
              {
                "id": "9e6d729d-392b-4f08-95a7-ad2dd90032de",
                "name": "Discontinue chelation therapy",
                "instanceType": "Activity",
                "description": "Discontinue chelation therapy",
                "notes": [
                  {
                    "id": "7579ac6b-ee30-4a3a-b229-b57eab581bd9",
                    "text": "Herbal remedies must be discontinued at least",
                    "instanceType": "Note"
                  },
                  {
                    "id": "4a2eb9de-db91-43c3-bd1b-69e67cca4c85",
                    "text": "If the study intervention is definitively discontinued, the \nparticipant should remain in the study to be evaluated for safety follow-up",
                    "instanceType": "Note"
                  },
                  {
                    "id": "456092d5-8083-4ca2-9a41-d84f55667359",
                    "text": "• Immediate safety concerns should be discussed with Alexion immediately upon \noccurrence or awareness to determine if the participant should continue or \ndiscontinue study intervention",
                    "instanceType": "Note"
                  },
                  {
                    "id": "cfe17497-bd31-4d9e-91f3-ff98a946c7e4",
                    "text": "Discontinuation of Study Intervention \nIn rare instances, it may be necessary for a participant to permanently discontinue",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "05e22e79-ce61-4789-ab0b-ddfb0587ef40",
                "name": "Discontinue zinc therapy",
                "instanceType": "Activity",
                "description": "Discontinue zinc therapy",
                "notes": [
                  {
                    "id": "51056f08-3761-4bfa-b5dc-89f94cfb4ec0",
                    "text": "To align the number of days \nwith the mention of zinc \ndiscontinuation elsewhere in the \nprotocol",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "1dd9e020-e442-4831-a718-c1e4bda4ee47",
                "name": "ALXN1840 15 mg/day",
                "instanceType": "Activity",
                "description": "ALXN1840 15 mg/day"
              },
              {
                "id": "c6b3a06f-da18-4715-b845-f41f3e254c13",
                "name": "ALXN1840 30 mg/day",
                "instanceType": "Activity",
                "description": "ALXN1840 30 mg/day"
              },
              {
                "id": "2b06c94f-fc28-4e2e-bc25-f13aae8a4ce0",
                "name": "Study intervention compliance",
                "instanceType": "Activity",
                "description": "Study intervention compliance",
                "notes": [
                  {
                    "id": "36b45ab6-00b1-4123-8e21-5cffb5b643ed",
                    "text": "• A participant may withdraw from the study at any time at his/her own request, or may \nbe withdrawn at any time at the discretion of the Investigator for safety, behavioral, \ncompliance, or administrative reasons",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "0603453c-99da-4ddf-b8f3-f2e9496d2145",
                "name": "Blood sampling for PK: Plasma total Mo and PUF-Mo",
                "instanceType": "Activity",
                "description": "Blood sampling for PK: Plasma total Mo and PUF-Mo",
                "notes": [
                  {
                    "id": "460d175e-27ed-4014-b4e6-9c467135641a",
                    "text": "When multiple procedures are scheduled to occur at the \nsame time, the following order of events should be strictly adhered to whenever possible: ECG, vital signs, blood \nsampling",
                    "instanceType": "Note"
                  },
                  {
                    "id": "5766b752-a455-41c1-be31-62a04aef35bf",
                    "text": "The copper and molybdenum concentration of each sample will be determined by inductively \ncoupled plasma mass spectrometry",
                    "instanceType": "Note"
                  },
                  {
                    "id": "b00b7683-6169-4631-9911-35119cc2ea1f",
                    "text": "• Blood pressure and heart rate measurements will be assessed with a completely \nautomated device",
                    "instanceType": "Note"
                  },
                  {
                    "id": "3ae7e575-f782-4448-8c82-0d02b0200836",
                    "text": "Vital signs will consist \nof a single pulse and blood pressure measurement",
                    "instanceType": "Note"
                  },
                  {
                    "id": "26210b8d-d07e-4d62-92eb-3e398aa972d3",
                    "text": "The average of the blood pressure readings will be \nrecorded in the CRF",
                    "instanceType": "Note"
                  },
                  {
                    "id": "e2f55850-4888-42d2-93c3-dc3a7025e185",
                    "text": "• Total molybdenum and PUF-molybdenum are surrogate measures of ALXN",
                    "instanceType": "Note"
                  },
                  {
                    "id": "da3eb170-459b-4f8d-bbab-b73c61ca7887",
                    "text": "Blood samples will be collected as described in the SoA",
                    "instanceType": "Note"
                  },
                  {
                    "id": "f21b9527-88d1-4f02-ba61-fec4a4ae9242",
                    "text": "Plasma samples will be used for ICP-MS measurement of total copper and \nPUF-copper, ceruloplasmin, ceruloplasmin-bound copper, and non-ceruloplasmin-bound copper \nmeasured via PUF-copper, and/or LBC, or assessed via NCC/NCCcorrected methods at the time \npoints indicated in the SoA",
                    "instanceType": "Note"
                  },
                  {
                    "id": "609ed23f-03ff-4cc4-b75e-f8ad864e8440",
                    "text": "Abbreviations: Cu = copper; LBC = labile bound copper; Mo = molybdenum; PD = pharmacodynamic; \nPK = pharmacokinetic; PUF = plasma ultrafiltrate",
                    "instanceType": "Note"
                  },
                  {
                    "id": "ec8d95dd-f45d-44f0-b706-cec6527490a0",
                    "text": "Vital Signs \n• Body temperature, heart rate, respiratory rate, and systolic and diastolic blood pressure",
                    "instanceType": "Note"
                  },
                  {
                    "id": "ed8e62c5-a4fa-4309-ab72-1015bed4d132",
                    "text": "Samples collected for \nanalyses of plasma concentrations may also be used to evaluate safety aspects related \nto concerns arising during or after the study",
                    "instanceType": "Note"
                  },
                  {
                    "id": "6017fcda-9b9f-4c8b-b784-3cd3a85b9718",
                    "text": "Pharmacodynamics \nPlasma total and PUF-copper, ceruloplasmin, ceruloplasmin-bound copper, and LBC will be \nassessed during the study",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "a543cd5c-7133-4d2f-8a90-ed3ad6cc872d",
                "name": "PD: Plasma total and PUF-Cu, LBC, ceruloplasmin, ceruloplasmin-bound Cu",
                "instanceType": "Activity",
                "description": "PD: Plasma total and PUF-Cu, LBC, ceruloplasmin, ceruloplasmin-bound Cu",
                "notes": [
                  {
                    "id": "c7dd565c-b896-4da9-92f7-6ceb7784b7a7",
                    "text": "Plasma samples will be used for ICP-MS measurement of total copper and \nPUF-copper, ceruloplasmin, ceruloplasmin-bound copper, and non-ceruloplasmin-bound copper \nmeasured via PUF-copper, and/or LBC, or assessed via NCC/NCCcorrected methods at the time \npoints indicated in the SoA",
                    "instanceType": "Note"
                  },
                  {
                    "id": "84f3325b-b430-41a3-a502-e56c65e26e44",
                    "text": "Pharmacodynamics \nPlasma total and PUF-copper, ceruloplasmin, ceruloplasmin-bound copper, and LBC will be \nassessed during the study",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "13dacf21-6052-4139-8397-16846d827a06",
                "name": "Chemistry, hematology, Coagulation",
                "instanceType": "Activity",
                "description": "Chemistry, hematology, Coagulation",
                "notes": [
                  {
                    "id": "46dcacc0-89eb-4a63-8053-94a1445b5e65",
                    "text": "In case of rechecks, and postdose serum \nchemistry, participants may not have fasted for",
                    "instanceType": "Note"
                  },
                  {
                    "id": "4c46aaf6-ef11-42fb-9ac2-6792bcec96fe",
                    "text": "r Laboratory assessment including chemistry, hematology, and coagulation parameters should be performed on Days -",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "09d48280-a545-4f5f-a213-6bfa0d3a36b2",
                "name": "Urinalysis",
                "instanceType": "Activity",
                "description": "Urinalysis"
              },
              {
                "id": "15901dd8-31c5-4006-80ce-b1e27c23a388",
                "name": "Urine/serum pregnancy test",
                "instanceType": "Activity",
                "description": "Urine/serum pregnancy test",
                "definedProcedures": [
                  {
                    "id": "a6289e82-d009-41f4-bdd1-595e2dd586ec",
                    "name": "Urine Collection",
                    "procedureType": "Biospecimen Collection",
                    "code": {
                      "id": "b4165844-b4ca-4223-9532-485f5a5670eb",
                      "code": "C25218",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Urine Collection",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Urine Sample Collection",
                    "description": "Collection of urine for urinalysis, drug screening, pregnancy testing, and 24-hour measurement of copper and molybdenum content."
                  },
                  {
                    "id": "522eb5d1-bc01-49a3-bd21-6a0b52cd5e08",
                    "name": "Pregnancy Test",
                    "procedureType": "Diagnostic Procedure",
                    "code": {
                      "id": "b8444d8d-5c16-44e9-b97f-acd4adec1abd",
                      "code": "C25218",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Pregnancy Test",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Pregnancy Test",
                    "description": "Urine or serum pregnancy testing for females of childbearing potential."
                  }
                ],
                "notes": [
                  {
                    "id": "d530a867-c1e2-4d2a-adfe-f60fe12e1a0b",
                    "text": "s Menstruation check is for women only; women of childbearing potential should only be enrolled after a negative serum pregnancy test result at Screening",
                    "instanceType": "Note"
                  },
                  {
                    "id": "3455ebb1-e605-4c16-9f3a-d2c352d83747",
                    "text": "Participants must be considered for discontinuation from study intervention if any of the \nfollowing occur during the study: \n• Serious hypersensitivity reaction; \n• Severe uncontrolled infection; \n• Use of disallowed medication; \n• Pregnancy or planned pregnancy",
                    "instanceType": "Note"
                  },
                  {
                    "id": "e9d51452-ce86-4fc8-826e-8a4ee20fd9aa",
                    "text": "Contraceptive Guidance and Collection of Pregnancy Information",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "b5d5d409-b4e9-4971-8d35-460700a09e7f",
                "name": "Retained serum sample (safety)",
                "instanceType": "Activity",
                "description": "Retained serum sample (safety)",
                "notes": [
                  {
                    "id": "ef3f584f-2e04-4df8-9a7d-a10f59d2a6d1",
                    "text": "Number of Participants: \nThe sample size will be approximately",
                    "instanceType": "Note"
                  },
                  {
                    "id": "77f78bcd-2e4a-43da-b467-a153ea55071c",
                    "text": "In case of rechecks, and postdose serum \nchemistry, participants may not have fasted for",
                    "instanceType": "Note"
                  },
                  {
                    "id": "36757bcb-0aa7-4d20-984f-d15760a07060",
                    "text": "s Menstruation check is for women only; women of childbearing potential should only be enrolled after a negative serum pregnancy test result at Screening",
                    "instanceType": "Note"
                  },
                  {
                    "id": "698b2270-efea-45e3-857b-fccdd5ace222",
                    "text": "x For fecal samples, each individual sample will be independently collected with record of date, time, and weight of the sample",
                    "instanceType": "Note"
                  },
                  {
                    "id": "734280f3-e042-43f0-b865-425a968c1854",
                    "text": "The copper and molybdenum concentration of each sample will be determined by inductively \ncoupled plasma mass spectrometry",
                    "instanceType": "Note"
                  },
                  {
                    "id": "e2fc2bc2-9484-40db-883b-433615c99949",
                    "text": "Samples will be collected, stored and shipped as detailed in the Laboratory Manual",
                    "instanceType": "Note"
                  },
                  {
                    "id": "8647d9f6-f397-4159-9435-f30634734de6",
                    "text": "All sample handling procedures will be documented in detail as \ndescribed in the Laboratory Manual",
                    "instanceType": "Note"
                  },
                  {
                    "id": "e6c2659a-83ab-48e9-9cdb-c27928111c3e",
                    "text": "Fecal samples will be individually collected, weighed, and stored",
                    "instanceType": "Note"
                  },
                  {
                    "id": "803f4eff-403a-4f7b-9b16-5121fcedadc8",
                    "text": "• Excess/additional samples may be stored for up to",
                    "instanceType": "Note"
                  },
                  {
                    "id": "451365bb-f76f-48fe-9b6e-c3eb1798dab2",
                    "text": "Blood samples will be collected as described in the SoA",
                    "instanceType": "Note"
                  },
                  {
                    "id": "6d873c8f-384c-4437-9257-9d6d2e771116",
                    "text": "Plasma samples will be used for ICP-MS measurement of total copper and \nPUF-copper, ceruloplasmin, ceruloplasmin-bound copper, and non-ceruloplasmin-bound copper \nmeasured via PUF-copper, and/or LBC, or assessed via NCC/NCCcorrected methods at the time \npoints indicated in the SoA",
                    "instanceType": "Note"
                  },
                  {
                    "id": "b6414031-d42c-46c7-8e8f-48587356e5a2",
                    "text": "Food and Fluid Collection for Copper and Molybdenum Concentrations \nSamples of all meal and fluid batches will be collected and analyzed for measurement of copper \nand molybdenum content",
                    "instanceType": "Note"
                  },
                  {
                    "id": "86717523-4c1a-4c56-a38f-59745f370e21",
                    "text": "Urine Collection for Measurement of Copper and Molybdenum content \nUrine samples to measure copper and molybdenum content will be collected periodically as \ndescribed in the SoA",
                    "instanceType": "Note"
                  },
                  {
                    "id": "568534e8-dd03-4d64-959a-8afd89ab6152",
                    "text": "Samples collected for \nanalyses of plasma concentrations may also be used to evaluate safety aspects related \nto concerns arising during or after the study",
                    "instanceType": "Note"
                  },
                  {
                    "id": "b19317d5-dda5-42b4-b41f-fbd20691ae92",
                    "text": "These samples will not be \nused for genetic analyses",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "b0e71e41-6828-4061-b8f6-0cbc384c9388",
                "name": "Vitals sign measurements",
                "instanceType": "Activity",
                "description": "Vitals sign measurements",
                "notes": [
                  {
                    "id": "66bd9ebf-9623-45d2-87de-56a834d8c0dc",
                    "text": "Overall Design \nThis is a single-arm, open-label, repeat-dose study to evaluate the effects of ALXN",
                    "instanceType": "Note"
                  },
                  {
                    "id": "091dfa12-a99f-4289-ae0a-2d245e7a6de1",
                    "text": "u Vital signs measurements and ECGs should be performed predose, unless otherwise specified",
                    "instanceType": "Note"
                  },
                  {
                    "id": "5a6b4bcd-b794-4ffb-bdcf-bf0d2168ff3d",
                    "text": "When multiple procedures are scheduled to occur at the \nsame time, the following order of events should be strictly adhered to whenever possible: ECG, vital signs, blood \nsampling",
                    "instanceType": "Note"
                  },
                  {
                    "id": "2628679b-d642-498c-8b93-e415ee2fd707",
                    "text": "Rescreened participants are not \nrequired to reconsent as long as they have signed the latest version of the ICF",
                    "instanceType": "Note"
                  },
                  {
                    "id": "defac92a-bd4e-4aaf-b081-496fc733c6a0",
                    "text": "If a clinically significant finding is identified",
                    "instanceType": "Note"
                  },
                  {
                    "id": "addfc6c9-92e1-47f2-8d43-7a785bb116ea",
                    "text": "• Blood pressure and heart rate measurements will be assessed with a completely \nautomated device",
                    "instanceType": "Note"
                  },
                  {
                    "id": "9a917636-c8fb-4c33-a700-1b3aeef2ee4f",
                    "text": "• Vital signs will be measured in a supine position after",
                    "instanceType": "Note"
                  },
                  {
                    "id": "5cb7370f-5cee-4cfb-a88d-38cd6ebbff9c",
                    "text": "Vital signs will consist \nof a single pulse and blood pressure measurement",
                    "instanceType": "Note"
                  },
                  {
                    "id": "22805671-a930-474b-ae9f-2e6b67708449",
                    "text": "As with vital \nsigns, if ECG interval measurements are abnormal, an additional triplicate will be \nperformed and recorded in the CRF",
                    "instanceType": "Note"
                  },
                  {
                    "id": "d077e081-630f-4c18-8740-3e2231cc5f5f",
                    "text": "Clinically significant \nlaboratory values are those deemed by the Investigator to be clinically significant \nresulting in further evaluation or treatment or those associated with an AE or clinical \nsigns or symptoms",
                    "instanceType": "Note"
                  },
                  {
                    "id": "53da7bc0-c202-434a-a3cd-ac123f594b0f",
                    "text": "Scientific Rationale for Study Design",
                    "instanceType": "Note"
                  },
                  {
                    "id": "51d58c09-01ab-4d55-bd4b-e435944b4ed5",
                    "text": "Note: “Enrolled” means all participants who sign the informed consent form",
                    "instanceType": "Note"
                  },
                  {
                    "id": "3e9e348f-a6ba-448a-bf3e-49cdc5c7b501",
                    "text": "Screen Failures  \nScreen failures are defined as participants who consent to participate in the clinical study but are \nnot subsequently assigned to study intervention",
                    "instanceType": "Note"
                  },
                  {
                    "id": "4303d4a4-d187-42a3-8a25-4cd857cf2155",
                    "text": "Copper and Molybdenum Balance Measurements \nCopper and molybdenum balance measurements will be made on all intake",
                    "instanceType": "Note"
                  },
                  {
                    "id": "d2cfc3bd-c4d4-47a9-8c92-0195437c4cd0",
                    "text": "Vital Signs \n• Body temperature, heart rate, respiratory rate, and systolic and diastolic blood pressure",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "587124ff-d858-4f2a-8b5c-78c06fe8db7a",
                "name": "12-lead ECG (triplicate)",
                "instanceType": "Activity",
                "description": "12-lead ECG (triplicate)"
              },
              {
                "id": "c25a9d0e-98d7-411b-916d-c07298b040d5",
                "name": "Adverse events",
                "instanceType": "Activity",
                "description": "Adverse events",
                "notes": [
                  {
                    "id": "c1faa8ab-b1d9-4c6c-94f1-2af833c220c5",
                    "text": "When multiple procedures are scheduled to occur at the \nsame time, the following order of events should be strictly adhered to whenever possible: ECG, vital signs, blood \nsampling",
                    "instanceType": "Note"
                  },
                  {
                    "id": "80719a6c-9eef-4514-a328-0e44b147257c",
                    "text": "Adverse Events: Definitions and Procedures for Recording, Evaluating, \nFollow-up, and Reporting",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "9a58c970-fa45-487b-afe9-094a3819d719",
                "name": "Cu/Mo-controlled meals",
                "instanceType": "Activity",
                "description": "Cu/Mo-controlled meals"
              },
              {
                "id": "778d69f6-5d53-4ac8-a835-c35a3c6569a5",
                "name": "Light exercise regimen",
                "instanceType": "Activity",
                "description": "Light exercise regimen"
              },
              {
                "id": "cd0e371f-3d5f-4c31-a9f2-672a5d878a99",
                "name": "Urination and bowel movement monitoring, menstruation checks",
                "instanceType": "Activity",
                "description": "Urination and bowel movement monitoring, menstruation checks",
                "notes": [
                  {
                    "id": "b9567b27-2659-4bc1-a892-dda1bb058d3a",
                    "text": "In case of rechecks, and postdose serum \nchemistry, participants may not have fasted for",
                    "instanceType": "Note"
                  },
                  {
                    "id": "4e6cea53-4819-415c-816c-4aa2ce394b69",
                    "text": "s Menstruation check is for women only; women of childbearing potential should only be enrolled after a negative serum pregnancy test result at Screening",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "6a029e30-f6a0-4ce7-944e-12df47c05d85",
                "name": "24-hour urine for Cu and Mo",
                "instanceType": "Activity",
                "description": "24-hour urine for Cu and Mo",
                "definedProcedures": [
                  {
                    "id": "a6289e82-d009-41f4-bdd1-595e2dd586ec",
                    "name": "Urine Collection",
                    "procedureType": "Biospecimen Collection",
                    "code": {
                      "id": "b4165844-b4ca-4223-9532-485f5a5670eb",
                      "code": "C25218",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Urine Collection",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Urine Sample Collection",
                    "description": "Collection of urine for urinalysis, drug screening, pregnancy testing, and 24-hour measurement of copper and molybdenum content."
                  }
                ]
              },
              {
                "id": "921876c4-2fe5-48c0-baa5-b5994a3df1ce",
                "name": "Feces for Cu and Mo",
                "instanceType": "Activity",
                "description": "Feces for Cu and Mo"
              },
              {
                "id": "2a63ffaf-acd4-48c7-852f-e5f8512b8e6f",
                "name": "Concomitant medication and non-pharmacologic therapy/procedure",
                "instanceType": "Activity",
                "description": "Concomitant medication and non-pharmacologic therapy/procedure",
                "notes": [
                  {
                    "id": "5dadee6c-4c7d-460a-a9a8-e441ef79b510",
                    "text": "Over-the-counter medications may be given if they \nare not expected to impact the outcome of the study",
                    "instanceType": "Note"
                  },
                  {
                    "id": "b22ef6bd-d3cd-4cf4-9146-1a4c9366051f",
                    "text": "Participants must be considered for discontinuation from study intervention if any of the \nfollowing occur during the study: \n• Serious hypersensitivity reaction; \n• Severe uncontrolled infection; \n• Use of disallowed medication; \n• Pregnancy or planned pregnancy",
                    "instanceType": "Note"
                  }
                ]
              }
            ],
            "epochs": [
              {
                "id": "f323d182-da8e-426d-9f9b-e1cba7973dbb",
                "name": "Screening",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "a5702083-5319-42b3-9fcf-9eded367cdd8",
                  "code": "C98779",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "60aa5dc9-3d59-4e23-a442-e7e996d38969",
                "name": "C-I",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "2949808d-d0cf-42dd-8a9f-1c20d3d5ff88",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "ce2375ef-dba2-42e6-a4ff-1da679de1615",
                "name": "Inpatient Period 1",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "80979aab-81e1-4261-9f77-0492376e8743",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "9910e2f6-6088-4468-998c-9dadba3878e1",
                "name": "OP",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "95a7e3e7-2c76-4cfc-af06-f3db78a02219",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "e13cdf18-257f-406f-ab12-93802e148b6b",
                "name": "Inpatient Period 2",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "7d98dfd4-9377-4767-9995-7a3c9644f71e",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "9a99dd8f-b4d4-4d8c-b419-9db33003f93f",
                "name": "UNS / EOS or ET",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "d719db83-759b-47b4-b563-51a7347900ff",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "717f2b8d-e458-4dfa-a712-3bfc2c34013c",
                "name": "Early Termination",
                "instanceType": "StudyEpoch",
                "description": "Early Termination - terminal epoch for subject path completion",
                "type": {
                  "id": "581a256b-9a94-4992-874e-d2bf0ee4ce6c",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                }
              }
            ],
            "notes": [
              {
                "id": "a07ec44e-63f8-4f47-96f5-b3efedc7105f",
                "text": "a. Within 32 days of ALXN1840 administration. Details of procedures that may be performed by sites designated as “screening sites” (only in the US) are detailed in Section 8.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "84d5ffb1-b529-46a2-9e01-726895bd9215",
                "text": "b. Participants will be admitted to the clinical research unit (CRU) at least 10 hours prior to enrollment and initiation of copper- and molybdenum-controlled diet.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "3b27f159-4c42-44ac-8ee9-8cec69ecb7a3",
                "text": "c. At the CRU’s discretion, participants may remain in the CRU or be readmitted on Day 22 with all procedures starting on Day 23.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "cdee39e0-702b-4c59-868c-5d4fda5b4057",
                "text": "d. Unscheduled study visits may occur at any time during the study and may include any study procedure as deemed necessary by the Investigator.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "2ca9e7f3-ed02-49b8-8802-d33cf9db023e",
                "text": "e. Participants are required to return to the CRU Day 54+/-2; participants will be discontinued from ALXN1840 medication by their physician at the latest by the Day 54 follow-up.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "524950fb-2493-42de-ad99-1dd0508239b3",
                "text": "f. Discharge from the unit may occur after completion of all procedures on Day 9 and on Day 40 and after the Investigator has reviewed all safety assessment (including safety laboratory tests) and confirmed that the participant is appropriate for discharge.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "fca13d05-ecba-478f-9865-8cc88882068d",
                "text": "g. A single outpatient visit or phone call and safety laboratory assessment should occur between Day 14 and Day 18. A phone call may take place on a different day than the blood draw within the Day 14 through Day 18 period.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "d55c37c9-e2a0-49c8-b28d-733064deaeb5",
                "text": "h. If needed to confirm menopause.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "28f6df66-92d1-4773-9617-8e4de727c950",
                "text": "a. Parameters include age and sex. Race and ethnicity will be collected where permitted by local regulations.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "09167cb6-0a93-428f-b7c6-d93ee980fd6e",
                "text": "b. Wilson disease history will include diagnosis date, method of diagnosis, history of cirrhosis, details of any previous liver biopsies performed, and treatment received.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "ceb581ce-a20d-48ed-b81c-b68369e67d5e",
                "text": "c. A full physical examination will be performed at Screening, at check-in for the study, and at the End of the study/Early Termination Visit. A physical examination should also be performed on any participants with ongoing adverse events prior to discharge from the unit. Otherwise, a symptom-driven physical examination may be performed at other times, at the Principal Investigator’s discretion.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "7358af4d-950b-416a-8301-824b3c34faa9",
                "text": "d. Height at screening only.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "460d2dc5-1025-45b5-be64-c5e0bf9a6af3",
                "text": "e. While in the CRU, study intervention will be administered after an overnight fast (ie, at least 10 hours) at the same time every morning; drug is to be administered with 240 mL of water and meals should be delayed a minimum of 2 hours after dosing. As an outpatient, participants are expected to take ALXN1840 at approximately the same time daily (+/- 1 hour). Participants should take the medication with a glass of water on an empty stomach; meals should be delayed a minimum of 2 hours after dosing.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "0c65af6d-0727-4bb2-a5c9-c7f3dc04aa5a",
                "text": "f. During the outpatient period, participants will use SMS text messaging to confirm study intervention administration.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "372dfcf1-e4d8-4271-a4de-63e37d675e42",
                "text": "g. Blood sampling for PK/PD will occur before ALXN1840 administration and represents a predose trough. See Table 2 for PK/PD sampling on Days 1, 25, 29, and 39.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "b7ffd445-8e9e-4150-9353-33641b45cc55",
                "text": "h. PK/PD collection will include timepoints described in the schedule of PK/PD assessment for Days 1, 25, 29, and 39 (Table 2).",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "a000b989-ee90-4bad-a3c6-639ecbcd2eb8",
                "text": "i. Samples for serum chemistry will be obtained following a fast of at least 8 hours at the Screening Visit and at check-in. In case of rechecks, and postdose serum chemistry, participants may not have fasted for 6 or 8 hours before the serum chemistry sample is taken.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "658a474c-722e-4e46-9df9-0093994efb34",
                "text": "j. Laboratory assessment including chemistry, hematology, and coagulation parameters should be performed on Days -8, -1, 8, 23, and 28 only.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "dc1c1ec9-e307-4455-860a-1052b64b82c3",
                "text": "k. Menstruation check is for women only; women of childbearing potential should only be enrolled after a negative serum pregnancy test result at Screening. Additional urine pregnancy testing will be set for the protocol unless serum testing is required by site policies, local regulation, or Institutional Review Boards (IRBs)/Independent Ethics Committees (IECs) (Section 10.2). In addition to pregnancy tests detailed at the visits in the SoA, females of childbearing potential will be required to perform urine pregnancy tests at least every 4 weeks at their home or the study site throughout their time in the study.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "14ed2ab2-1397-4308-8e7e-563680129b1e",
                "text": "l. A single 15 mL serum sample will be retained for evaluation in the event of an unexpected safety finding; retained samples may be destroyed after completion of the clinical study report.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "8e40fef0-98d7-4eac-8aab-4e3336a3d341",
                "text": "m. Vital signs assessments and ECGs should be performed predose, unless otherwise specified. Vitals signs include body temperature, heart rate, respiratory rate, and systolic and diastolic blood pressure.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "c6e636db-1812-45ac-b1b4-c0e84aee17c2",
                "text": "n. Copper- and molybdenum-controlled diet will be initiated after registration/inclusion. Participants will remain on a copper/molybdenum controlled diet throughout both the inpatient Period 1 (Day -8 to Day 9) and inpatient Period 2 (Day 23 to Day 40); during this time participants will be strongly encouraged to complete all meals. While not in the CRU, participants will be encouraged to adhere to their usual copper-controlled diet.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "8ef6aa8b-5e35-44fe-ad25-e7dfd07f8579",
                "text": "o. For each input/output balance period, 24-hour urine samples are to be collected for measurement of copper and molybdenum.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "1990a450-00ef-4a7a-ac31-8abc60449368",
                "text": "p. For fecal samples, each individual sample will be independently collected with record of date, time, and weight of the sample.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "bf1c9556-52c3-4eac-bbee-7abb5f802a0e",
                "text": ", and any \napplicable local regulations",
                "instanceType": "Note"
              },
              {
                "id": "cf58b030-7cca-425d-90a7-07c44701726d",
                "text": "and/or Alexion, may place participants at undue risk, in which \ncase, participants may remain on the",
                "instanceType": "Note"
              },
              {
                "id": "6587c31a-43b0-45aa-a55b-09f6e4c28847",
                "text": "Disclosure Statement: This is an open-label,",
                "instanceType": "Note"
              },
              {
                "id": "7bf0bfb6-79aa-4e61-9347-5e7949f0373d",
                "text": "Race and ethnicity will be collected where permitted by local regulations",
                "instanceType": "Note"
              },
              {
                "id": "e1e3b949-b005-4482-bfe2-8285be5d107b",
                "text": "v Copper- and molybdenum-controlled diet will be initiated after registration/inclusion",
                "instanceType": "Note"
              },
              {
                "id": "2ac34f34-adea-49a9-ab6e-c2a0eef4a73a",
                "text": "While not in the CRU, participants will be encouraged to adhere to their usual copper-controlled diet",
                "instanceType": "Note"
              },
              {
                "id": "90357844-18a9-46a5-ad59-00c1218ff95f",
                "text": "Given the robust improvement in copper \ncontrol, it is hypothesized that doses within the",
                "instanceType": "Note"
              },
              {
                "id": "5d2c114e-f9ff-42aa-8f4d-328c6de1c949",
                "text": "Copper balance will be assessed for the",
                "instanceType": "Note"
              },
              {
                "id": "c366e2e9-e6a3-45a4-8af4-f52806a7a39c",
                "text": "Further dose \nadjustments will be made as appropriate",
                "instanceType": "Note"
              },
              {
                "id": "85a17310-f902-4efd-9d85-6def2d5b95bd",
                "text": "St John’s wort \nAny herbal remedy or dietary supplement containing \nSt John’s wort",
                "instanceType": "Note"
              },
              {
                "id": "674f3ab8-3369-44cf-9a07-f134b0317145",
                "text": "This review of the ECG printed at the time of collection must \nbe documented",
                "instanceType": "Note"
              },
              {
                "id": "84556247-ca6d-4ee9-a31a-5bbdcc34c84b",
                "text": "• The following only applies to sites in the US",
                "instanceType": "Note"
              },
              {
                "id": "76cdc455-d897-4fb4-9fb9-78f1038f71eb",
                "text": "Site-to-site transfer of the participant will be documented \naccordingly",
                "instanceType": "Note"
              },
              {
                "id": "af7e30bc-8cf5-4c6c-82c1-c7928e22d139",
                "text": "Pharmacokinetic collection should occur as close as possible to the scheduled time",
                "instanceType": "Note"
              },
              {
                "id": "5397a8b2-99c3-4bab-a898-eaa668b864fb",
                "text": "− If such values do not return to normal/baseline within a period of time judged \nreasonable by the Investigator, the etiology should be identified, and Alexion \nnotified",
                "instanceType": "Note"
              },
              {
                "id": "abe5ca9a-1fe2-4f02-87bc-f10e4857507c",
                "text": "Benefit-Risk Assessment",
                "instanceType": "Note"
              },
              {
                "id": "e0d9f93b-a2f1-4931-9830-130e613f80a3",
                "text": "Benefit Assessment",
                "instanceType": "Note"
              },
              {
                "id": "dace6b8b-20bf-45c7-afb0-d0c984f8f771",
                "text": "Justification for Dose",
                "instanceType": "Note"
              },
              {
                "id": "dca3c549-8c8a-4733-936b-516008f9bfa3",
                "text": "Lifestyle Considerations",
                "instanceType": "Note"
              },
              {
                "id": "0ca09d55-81db-4805-9db3-349cd92a3cca",
                "text": "Recording and Follow-Up of AE and/or SAE",
                "instanceType": "Note"
              },
              {
                "id": "2283470c-e5ef-4884-8c38-50a114f3268c",
                "text": "Before titration to",
                "instanceType": "Note"
              },
              {
                "id": "c6b55c05-79da-48d9-8582-c0ef396344ab",
                "text": "The \ncollection periods will support an assessment of both copper and molybdenum balance",
                "instanceType": "Note"
              },
              {
                "id": "ae731824-3b4c-4f03-8bd8-44ced4be6ef5",
                "text": "Start times for \ncontraceptives vary \naccording to method used",
                "instanceType": "Note"
              },
              {
                "id": "00e04caf-7450-4693-99f0-fa742c2698f1",
                "text": "Electrocardiograms \n• Triplicate",
                "instanceType": "Note"
              }
            ],
            "model": {
              "id": "e800ed5b-3112-433d-a841-99979a81b01e",
              "code": "C82638",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Single Group Study",
              "instanceType": "Code"
            },
            "indications": [
              {
                "id": "aec59119-ed82-44cc-9996-5d9fcd19f49c",
                "name": "Wilson Disease",
                "isRareDisease": false,
                "instanceType": "Indication",
                "description": "Participants with Wilson Disease Treated with ALXN1840"
              }
            ],
            "procedures": [
              {
                "id": "4b3e582e-6b49-4b02-b632-87b17c85bfa4",
                "name": "Blood Draw",
                "procedureType": "Biospecimen Collection",
                "code": {
                  "id": "bc340fc0-11bd-4f8c-bf2e-829011b09e09",
                  "code": "36415",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collection of venous blood by venipuncture",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Venipuncture",
                "description": "Collection of blood samples for pharmacokinetic (PK), pharmacodynamic (PD), and clinical safety laboratory assessments (serum chemistry, hematology, coagulation, pregnancy)."
              },
              {
                "id": "3f0eef28-ad1a-46b7-88dd-b38c6e2cd4d7",
                "name": "Fecal Collection",
                "procedureType": "Biospecimen Collection",
                "code": {
                  "id": "bededf51-3719-4500-8136-0c2f394f7d9d",
                  "code": "C25218",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Fecal Collection",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Fecal Sample Collection",
                "description": "Collection of fecal samples for measurement of copper and molybdenum content."
              },
              {
                "id": "e25c94e5-af77-4f52-9ecc-900f444c3498",
                "name": "Vital Signs Measurement",
                "procedureType": "Monitoring",
                "code": {
                  "id": "bf3a0d2d-0ce4-4beb-bd78-fe2bc98aa269",
                  "code": "C25218",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Vital Signs Measurement",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Vital Signs",
                "description": "Assessment of body temperature, heart rate, respiratory rate, and systolic and diastolic blood pressure."
              },
              {
                "id": "c86a88ee-136f-4cb8-ac7c-2875392eb155",
                "name": "Electrocardiogram",
                "procedureType": "Diagnostic Procedure",
                "code": {
                  "id": "f9d69267-0906-4281-b3d3-ee71a17d124e",
                  "code": "93000",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "ECG",
                "description": "Triplicate 12-lead ECG to assess heart rate and intervals (PR, QRS, QT and QTc)."
              },
              {
                "id": "11e548fe-694c-41e8-8992-8caf3a76faaa",
                "name": "Oral Drug Administration",
                "procedureType": "Therapeutic Procedure",
                "code": {
                  "id": "abcf6168-f6a2-4130-b5e5-d9b22eee98c7",
                  "code": "C25218",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Oral Drug Administration",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "ALXN1840 Administration",
                "description": "Oral administration of ALXN1840 tablets."
              },
              {
                "id": "7abc7e13-096c-4950-bd95-7aaf5fb5c30e",
                "name": "Cannula Placement",
                "procedureType": "Therapeutic Procedure",
                "code": {
                  "id": "a14d1664-418e-4c35-ab9e-fad829ca0f55",
                  "code": "C25218",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Cannula Placement",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Venous Cannulation",
                "description": "Placement of a cannula to minimize needle sticks for repeated blood draws."
              },
              {
                "id": "a044e620-4380-49df-9897-c0fe283cf5fc",
                "name": "Neurological Assessment",
                "procedureType": "Assessment",
                "code": {
                  "id": "7690fae7-e409-47d3-98e5-96e08ba3e824",
                  "code": "C25218",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Neurological Assessment",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Neurological Assessment",
                "description": "Assessment of neurological symptoms, mentioned in the context of the Unified Wilson Disease Rating Scale (UWDRS)."
              },
              {
                "id": "9d58341e-2440-4303-b21f-c029c9c398d9",
                "name": "Adverse Event Monitoring",
                "procedureType": "Monitoring",
                "code": {
                  "id": "b1a28c8e-6434-4809-b44e-387f8d5fa9c8",
                  "code": "C25218",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Adverse Event Monitoring",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "AE Monitoring",
                "description": "Monitoring, detection, and follow-up of adverse events (AEs) and serious adverse events (SAEs)."
              },
              {
                "id": "752e4132-0666-410c-b9ca-7e6a42350115",
                "name": "Dietary Administration and Monitoring",
                "procedureType": "Therapeutic Procedure",
                "code": {
                  "id": "b4e4c1e1-be1a-4ecf-81c8-cf40119a17e6",
                  "code": "C25218",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Dietary Administration and Monitoring",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Controlled Diet",
                "description": "Administration of copper- and molybdenum-controlled meals and monitoring of food and fluid intake."
              },
              {
                "id": "253630e9-2537-4173-952f-af6a3e44ad32",
                "name": "Food and Fluid Sample Collection",
                "procedureType": "Biospecimen Collection",
                "code": {
                  "id": "184cbcc1-28f5-43bd-9b70-6204f0f3eebd",
                  "code": "C25218",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Food and Fluid Sample Collection",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Dietary Sample Collection",
                "description": "Collection of samples from all meal and fluid batches for analysis of copper and molybdenum content."
              }
            ],
            "extensionAttributes": [
              {
                "id": "95df8f35-6cf2-41b5-a81d-2633f9e92f68",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-entityMaps",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"epochAliases\": {\"SCREENING\": \"epoch_1\", \"C-I\": \"epoch_2\", \"INPATIENT PERIOD 1\": \"epoch_3\", \"INPATIENT_PERIOD_1\": \"epoch_3\", \"PERIOD_1\": \"epoch_3\", \"OP\": \"epoch_4\", \"INPATIENT PERIOD 2\": \"epoch_5\", \"INPATIENT_PERIOD_2\": \"epoch_5\", \"PERIOD_2\": \"epoch_5\", \"UNS / EOS OR ET\": \"epoch_6\", \"UNS_/_EOS_OR_ET\": \"epoch_6\"}, \"visitAliases\": {\"SCREENING (-42 TO -9)\": \"enc_1\", \"SCREENING_(-42_TO_-9)\": \"enc_1\", \"SCREENING (-21)\": \"enc_2\", \"SCREENING_(-21)\": \"enc_2\", \"SCREENING (-8)\": \"enc_3\", \"SCREENING_(-8)\": \"enc_3\", \"SCREENING (-7)\": \"enc_4\", \"SCREENING_(-7)\": \"enc_4\", \"C-I (-6 THROUGH -4)\": \"enc_5\", \"C-I_(-6_THROUGH_-4)\": \"enc_5\", \"C-I (-1)\": \"enc_6\", \"C-I_(-1)\": \"enc_6\", \"INPATIENT PERIOD 1 (DAY 1)\": \"enc_7\", \"INPATIENT_PERIOD_1_(DAY_1)\": \"enc_7\", \"INPATIENT PERIOD 1 (DAY 2-3)\": \"enc_8\", \"INPATIENT_PERIOD_1_(DAY_2-3)\": \"enc_8\", \"INPATIENT PERIOD 1 (DAY 4-7)\": \"enc_9\", \"INPATIENT_PERIOD_1_(DAY_4-7)\": \"enc_9\", \"INPATIENT PERIOD 1 (DAY 8)\": \"enc_10\", \"INPATIENT_PERIOD_1_(DAY_8)\": \"enc_10\", \"INPATIENT PERIOD 1 (DAY 9)\": \"enc_11\", \"INPATIENT_PERIOD_1_(DAY_9)\": \"enc_11\", \"OP (DAY 10-22)\": \"enc_12\", \"OP_(DAY_10-22)\": \"enc_12\", \"INPATIENT PERIOD 2 (DAY 23)\": \"enc_13\", \"INPATIENT_PERIOD_2_(DAY_23)\": \"enc_13\", \"INPATIENT PERIOD 2 (DAY 24)\": \"enc_14\", \"INPATIENT_PERIOD_2_(DAY_24)\": \"enc_14\", \"INPATIENT PERIOD 2 (DAY 25)\": \"enc_15\", \"INPATIENT_PERIOD_2_(DAY_25)\": \"enc_15\", \"INPATIENT PERIOD 2 (DAY 26-28)\": \"enc_16\", \"INPATIENT_PERIOD_2_(DAY_26-28)\": \"enc_16\", \"INPATIENT PERIOD 2 (DAY 29)\": \"enc_17\", \"INPATIENT_PERIOD_2_(DAY_29)\": \"enc_17\", \"INPATIENT PERIOD 2 (DAY 30-35)\": \"enc_18\", \"INPATIENT_PERIOD_2_(DAY_30-35)\": \"enc_18\", \"INPATIENT PERIOD 2 (DAY 36)\": \"enc_19\", \"INPATIENT_PERIOD_2_(DAY_36)\": \"enc_19\", \"INPATIENT PERIOD 2 (DAY 37-38)\": \"enc_20\", \"INPATIENT_PERIOD_2_(DAY_37-38)\": \"enc_20\", \"INPATIENT PERIOD 2 (DAY 39)\": \"enc_21\", \"INPATIENT_PERIOD_2_(DAY_39)\": \"enc_21\", \"INPATIENT PERIOD 2 (DAY 40)\": \"enc_22\", \"INPATIENT_PERIOD_2_(DAY_40)\": \"enc_22\", \"EOS DAY 54+/-2\": \"enc_23\", \"EOS_DAY_54+/-2\": \"enc_23\"}}"
              },
              {
                "id": "bed6f8b1-4b63-47a8-85f6-e0de2603d0d0",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-classifiedIssues",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"severity\": \"blocking\", \"category\": \"visit_window_conflict\", \"message\": \"Multiple visits mapped to Day 1: ['Early Termination', 'Day 1', 'EOS']\", \"affectedPath\": \"$.visitWindows[]\", \"affectedIds\": [\"visit_1\", \"visit_3\", \"visit_14\"], \"suggestion\": \"Re-derive targetDay from visit context or SoA position\"}, {\"severity\": \"warning\", \"category\": \"visit_window_conflict\", \"message\": \"Multiple visits mapped to Day 54: ['Day 54', 'End of Study']\", \"affectedPath\": \"$.visitWindows[]\", \"affectedIds\": [\"visit_12\", \"visit_13\"], \"suggestion\": \"Verify visit scheduling logic\"}]"
              },
              {
                "id": "362fbece-8b87-4183-8417-478cf41b6e5c",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-timeAnchors",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"anchor_llm_1\", \"definition\": \"Initiation of ALXN1840\", \"anchorType\": \"FirstDose\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"The accumulation period refers to time from initiation of ALXN1840 (Day 1) to expected steady state at Day 10, based on 5 times the half-life of 2 days.\"}, {\"id\": \"anchor_1\", \"definition\": \"Baseline visit/assessment\", \"anchorType\": \"Baseline\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"Baseline Day\"}, {\"id\": \"anchor_2\", \"definition\": \"Informed consent obtained\", \"anchorType\": \"InformedConsent\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"informed consent\"}, {\"id\": \"anchor_3\", \"definition\": \"procedure\", \"anchorType\": \"Custom\", \"timelineId\": null, \"dayValue\": 9, \"sourceText\": \"procedure\"}, {\"id\": \"anchor_collection_1\", \"definition\": \"24-hour collection period\", \"anchorType\": \"CollectionDay\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"24-hour urine\"}, {\"id\": \"anchor_collection_2\", \"definition\": \"24-hour collection period\", \"anchorType\": \"CollectionDay\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"24-hour collection\"}]"
              },
              {
                "id": "573f5002-74b2-4537-a434-3b10d5a3c179",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-repetitions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"rep_daily_1\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"daily urine\"}, {\"id\": \"rep_daily_2\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"once daily\"}, {\"id\": \"rep_daily_4\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"od\"}, {\"id\": \"rep_daily_67\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"OD\"}, {\"id\": \"rep_interval_1\", \"type\": \"Interval\", \"interval\": \"PT8H\", \"sourceText\": \"every \\n8 hours\"}, {\"id\": \"rep_window_1\", \"type\": \"Continuous\", \"startOffset\": \"P4D\", \"endOffset\": \"P1D\", \"sourceText\": \"Days -4 through -1\"}, {\"id\": \"rep_window_2\", \"type\": \"Continuous\", \"startOffset\": \"P7D\", \"endOffset\": \"P5D\", \"sourceText\": \"Day -7 through Day -5\"}, {\"id\": \"rep_window_3\", \"type\": \"Continuous\", \"startOffset\": \"P4D\", \"endOffset\": \"P1D\", \"sourceText\": \"Day -4 through Day -1\"}, {\"id\": \"rep_window_5\", \"type\": \"Continuous\", \"startOffset\": \"-P1D\", \"endOffset\": \"-P8D\", \"sourceText\": \"Day 1 through Day 8\"}, {\"id\": \"rep_window_6\", \"type\": \"Continuous\", \"startOffset\": \"P25D\", \"endOffset\": \"P39D\", \"sourceText\": \"Day 25 through Day 39\"}, {\"id\": \"rep_window_7\", \"type\": \"Continuous\", \"startOffset\": \"P1D\", \"endOffset\": \"P28D\", \"sourceText\": \"Day 1 through Day 28\"}, {\"id\": \"rep_window_8\", \"type\": \"Continuous\", \"startOffset\": \"P29D\", \"endOffset\": \"P39D\", \"sourceText\": \"Day 29 through Day 39\"}, {\"id\": \"rep_window_12\", \"type\": \"Continuous\", \"startOffset\": \"P25D\", \"endOffset\": \"P28D\", \"sourceText\": \"Days 25 through 28\"}, {\"id\": \"rep_window_13\", \"type\": \"Continuous\", \"startOffset\": \"P29D\", \"endOffset\": \"P39D\", \"sourceText\": \"Days 29 through 39\"}, {\"id\": \"rep_window_14\", \"type\": \"Continuous\", \"startOffset\": \"P4D\", \"endOffset\": \"P7D\", \"sourceText\": \"Days 4 - 7\"}, {\"id\": \"rep_window_15\", \"type\": \"Continuous\", \"startOffset\": \"-P26D\", \"endOffset\": \"-P28D\", \"sourceText\": \"Days 26 - 28\"}, {\"id\": \"rep_window_16\", \"type\": \"Continuous\", \"startOffset\": \"-P30D\", \"endOffset\": \"-P38D\", \"sourceText\": \"Days 30 - 38\"}, {\"id\": \"rep_window_17\", \"type\": \"Continuous\", \"startOffset\": \"P8D\", \"endOffset\": \"P9D\", \"sourceText\": \"Day -8 to Day 9\"}, {\"id\": \"rep_window_18\", \"type\": \"Continuous\", \"startOffset\": \"P23D\", \"endOffset\": \"P40D\", \"sourceText\": \"Day 23 to Day 40\"}, {\"id\": \"rep_window_19\", \"type\": \"Continuous\", \"startOffset\": \"P25D\", \"endOffset\": \"P28D\", \"sourceText\": \"Day 25 through Day 28\"}, {\"id\": \"rep_window_20\", \"type\": \"Continuous\", \"startOffset\": \"P36D\", \"endOffset\": \"P39D\", \"sourceText\": \"Day 36 through Day 39\"}, {\"id\": \"rep_window_22\", \"type\": \"Continuous\", \"startOffset\": \"P7D\", \"endOffset\": \"P5D\", \"sourceText\": \"Day -7 through \\nDay -5\"}, {\"id\": \"rep_window_29\", \"type\": \"Continuous\", \"startOffset\": \"P1D\", \"endOffset\": \"P9D\", \"sourceText\": \"Days 1 through 9\"}, {\"id\": \"rep_window_30\", \"type\": \"Continuous\", \"startOffset\": \"P31D\", \"endOffset\": \"P35D\", \"sourceText\": \"Days 31 through 35\"}, {\"id\": \"rep_window_32\", \"type\": \"Continuous\", \"startOffset\": \"P36D\", \"endOffset\": \"P39D\", \"sourceText\": \"Days 36 through 39\"}, {\"id\": \"rep_window_33\", \"type\": \"Continuous\", \"startOffset\": \"P9D\", \"endOffset\": \"P23D\", \"sourceText\": \"Day 9 to Day 23\"}, {\"id\": \"rep_window_34\", \"type\": \"Continuous\", \"sourceText\": \"Run-in Period\"}, {\"id\": \"rep_window_39\", \"type\": \"Continuous\", \"sourceText\": \"treatment period\"}, {\"id\": \"rep_window_40\", \"type\": \"Continuous\", \"sourceText\": \"Treatment Period\"}, {\"id\": \"rep_window_46\", \"type\": \"Continuous\", \"sourceText\": \"treatment \\nperiod\"}, {\"id\": \"rep_window_51\", \"type\": \"Continuous\", \"sourceText\": \"dosing period\"}, {\"id\": \"rep_window_52\", \"type\": \"Continuous\", \"sourceText\": \"pretreatment period\"}, {\"id\": \"rep_window_53\", \"type\": \"Continuous\", \"sourceText\": \"post-treatment period\"}, {\"id\": \"rep_window_54\", \"type\": \"Continuous\", \"sourceText\": \"2 hours after\"}, {\"id\": \"rep_window_56\", \"type\": \"Continuous\", \"sourceText\": \"8 hours before\"}, {\"id\": \"rep_window_57\", \"type\": \"Continuous\", \"sourceText\": \"4 hours post\"}, {\"id\": \"rep_window_58\", \"type\": \"Continuous\", \"sourceText\": \"21 days after\"}, {\"id\": \"rep_window_59\", \"type\": \"Continuous\", \"sourceText\": \"Inpatient Period\"}, {\"id\": \"rep_window_60\", \"type\": \"Continuous\", \"sourceText\": \"inpatient Period\"}, {\"id\": \"rep_window_62\", \"type\": \"Continuous\", \"sourceText\": \"Inpatient \\nPeriod\"}, {\"id\": \"rep_window_64\", \"type\": \"Continuous\", \"sourceText\": \"inpatient period\"}, {\"id\": \"rep_window_67\", \"type\": \"Continuous\", \"sourceText\": \"inpatient \\nperiod\"}, {\"id\": \"rep_window_70\", \"type\": \"Continuous\", \"sourceText\": \"balance period\"}, {\"id\": \"rep_window_71\", \"type\": \"Continuous\", \"sourceText\": \"24-hour urine\"}, {\"id\": \"rep_window_72\", \"type\": \"Continuous\", \"sourceText\": \"24-hour collection\"}, {\"id\": \"rep_daily_bound_1\", \"type\": \"Daily\", \"startOffset\": \"-P8D\", \"endOffset\": \"P9D\", \"interval\": \"P1D\", \"count\": 18, \"sourceText\": \"controlled diet (Day -8 to Day 9)\"}, {\"id\": \"rep_daily_bound_3\", \"type\": \"Daily\", \"startOffset\": \"P23D\", \"endOffset\": \"P40D\", \"interval\": \"P1D\", \"count\": 18, \"sourceText\": \"controlled diet (Day 23 to Day 40)\"}, {\"id\": \"rep_daily_bound_5\", \"type\": \"Daily\", \"startOffset\": \"-P7D\", \"endOffset\": \"-P5D\", \"interval\": \"P1D\", \"count\": 3, \"sourceText\": \"controlled diet (Day -7 through \\nDay -5)\"}, {\"id\": \"rep_daily_bound_6\", \"type\": \"Daily\", \"startOffset\": \"-P4D\", \"endOffset\": \"-P1D\", \"interval\": \"P1D\", \"count\": 4, \"sourceText\": \"controlled diet (Day -4 through Day -1)\"}, {\"id\": \"rep_daily_bound_11\", \"type\": \"Daily\", \"startOffset\": \"P3D\", \"endOffset\": \"P15D\", \"interval\": \"P1D\", \"count\": 13, \"sourceText\": \"controlled diet (3 to 15)\"}, {\"id\": \"rep_daily_bound_12\", \"type\": \"Daily\", \"startOffset\": \"P101D\", \"endOffset\": \"P201D\", \"interval\": \"P1D\", \"count\": 101, \"sourceText\": \"copper balance (101-201)\"}, {\"id\": \"rep_daily_bound_13\", \"type\": \"Daily\", \"startOffset\": \"-P4D\", \"endOffset\": \"-P1D\", \"interval\": \"P1D\", \"count\": 4, \"sourceText\": \"copper balance (Days -4 through -1)\"}, {\"id\": \"rep_daily_bound_14\", \"type\": \"Daily\", \"startOffset\": \"-P7D\", \"endOffset\": \"-P5D\", \"interval\": \"P1D\", \"count\": 3, \"sourceText\": \"molybdenum balance (Day -7 through Day -5)\"}, {\"id\": \"rep_daily_bound_15\", \"type\": \"Daily\", \"startOffset\": \"-P4D\", \"endOffset\": \"-P1D\", \"interval\": \"P1D\", \"count\": 4, \"sourceText\": \"molybdenum balance (Day -4 through Day -1)\"}, {\"id\": \"rep_daily_bound_17\", \"type\": \"Daily\", \"startOffset\": \"P1D\", \"endOffset\": \"P8D\", \"interval\": \"P1D\", \"count\": 8, \"sourceText\": \"molybdenum balance (Day 1 through Day 8)\"}, {\"id\": \"rep_daily_bound_18\", \"type\": \"Daily\", \"startOffset\": \"P25D\", \"endOffset\": \"P39D\", \"interval\": \"P1D\", \"count\": 15, \"sourceText\": \"molybdenum balance (Day 25 through Day 39)\"}, {\"id\": \"rep_daily_bound_22\", \"type\": \"Daily\", \"startOffset\": \"-P7D\", \"endOffset\": \"-P5D\", \"interval\": \"P1D\", \"count\": 3, \"sourceText\": \"molybdenum balance (Day -7 through \\nDay -5)\"}, {\"id\": \"rep_daily_bound_24\", \"type\": \"Daily\", \"startOffset\": \"-P8D\", \"endOffset\": \"P9D\", \"interval\": \"P1D\", \"count\": 18, \"sourceText\": \"molybdenum balance (Day -8 to Day 9)\"}, {\"id\": \"rep_daily_bound_25\", \"type\": \"Daily\", \"startOffset\": \"P23D\", \"endOffset\": \"P40D\", \"interval\": \"P1D\", \"count\": 18, \"sourceText\": \"molybdenum balance (Day 23 to Day 40)\"}, {\"id\": \"rep_daily_bound_29\", \"type\": \"Daily\", \"startOffset\": \"P3D\", \"endOffset\": \"P15D\", \"interval\": \"P1D\", \"count\": 13, \"sourceText\": \"copper balance (3 to 15)\"}, {\"id\": \"rep_daily_bound_30\", \"type\": \"Daily\", \"startOffset\": \"P3D\", \"endOffset\": \"P15D\", \"interval\": \"P1D\", \"count\": 13, \"sourceText\": \"molybdenum balance (3 to 15)\"}, {\"id\": \"rep_daily_bound_31\", \"type\": \"Daily\", \"startOffset\": \"P101D\", \"endOffset\": \"P301D\", \"interval\": \"P1D\", \"count\": 201, \"sourceText\": \"molybdenum balance (101-301)\"}, {\"id\": \"rep_daily_bound_32\", \"type\": \"Daily\", \"startOffset\": \"P3D\", \"endOffset\": \"P5D\", \"interval\": \"P1D\", \"count\": 3, \"sourceText\": \"copper \\nbalance (3 - 5)\"}]"
              },
              {
                "id": "cb78f29c-c161-461c-a336-fa25d5ae590c",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-traversalConstraints",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"traversal_1\", \"requiredSequence\": [\"epoch_1\", \"epoch_2\", \"epoch_3\", \"epoch_4\", \"epoch_5\", \"epoch_6\"], \"allowEarlyExit\": true, \"exitEpochIds\": [\"epoch_early_termination\"], \"mandatoryVisits\": [\"enc_1\", \"enc_1\", \"enc_23\", \"enc_23\", \"enc_7\"], \"sourceText\": \"[{'condition': 'Subject discontinues study intervention or withdraws from the study.', 'path': ['EARLY_TERMINATION']}, {'condition': 'For subjects in the US, screening may be performed at a dedicated screening-only site.', 'path': ['SCREENING_AT_DEDICATED_SITE', 'CONTINUATION_AT_MAIN_STUDY_SITE']}]\"}]"
              },
              {
                "id": "25171da7-07e8-4158-9072-32357bfa9d4e",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-footnoteConditions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"fn_cond_1\", \"conditionType\": \"general\", \"text\": \", and any \\napplicable local regulations\", \"footnoteId\": \"(b)\", \"sourceText\": \", and any \\napplicable local regulations\"}, {\"id\": \"fn_cond_2\", \"conditionType\": \"general\", \"text\": \"and/or Alexion, may place participants at undue risk, in which \\ncase, participants may remain on the\", \"footnoteId\": \"(s)\", \"sourceText\": \"and/or Alexion, may place participants at undue risk, in which \\ncase, participants may remain on the\"}, {\"id\": \"fn_cond_3\", \"conditionType\": \"general\", \"text\": \"Overall Rationale for the Amendment \\nThe main reason for preparation of this amendment was to clarify study procedures occurring \\nacross different sites in the US, so as to facilitate participant recruitment across different regions \\nof the US, and to lessen inconvenience for participants without compromising the quality of the \\nstudy\", \"footnoteId\": \"s.\", \"sourceText\": \"Overall Rationale for the Amendment \\nThe main reason for preparation of this amendment was to clarif\", \"appliesToActivityIds\": [\"grp_2\"]}, {\"id\": \"fn_cond_4\", \"conditionType\": \"general\", \"text\": \"To align the number of days \\nwith the mention of zinc \\ndiscontinuation elsewhere in the \\nprotocol\", \"footnoteId\": \"c.\", \"sourceText\": \"To align the number of days \\nwith the mention of zinc \\ndiscontinuation elsewhere in the \\nprotocol\", \"appliesToActivityIds\": [\"act_18\"]}, {\"id\": \"fn_cond_5\", \"conditionType\": \"general\", \"text\": \"Overall Design \\nThis is a single-arm, open-label, repeat-dose study to evaluate the effects of ALXN\", \"footnoteId\": \"s.\", \"sourceText\": \"Overall Design \\nThis is a single-arm, open-label, repeat-dose study to evaluate the effects of ALXN\", \"appliesToActivityIds\": [\"grp_2\", \"act_28\"]}, {\"id\": \"fn_cond_6\", \"conditionType\": \"general\", \"text\": \"Disclosure Statement: This is an open-label,\", \"footnoteId\": \"e.\", \"sourceText\": \"Disclosure Statement: This is an open-label,\"}, {\"id\": \"fn_cond_7\", \"conditionType\": \"general\", \"text\": \"Number of Participants: \\nThe sample size will be approximately\", \"footnoteId\": \"m.\", \"sourceText\": \"Number of Participants: \\nThe sample size will be approximately\", \"appliesToActivityIds\": [\"act_27\"]}, {\"id\": \"fn_cond_8\", \"conditionType\": \"general\", \"text\": \"Intervention Groups and Duration: \\nTreatment-experienced\", \"footnoteId\": \"r.\", \"sourceText\": \"Intervention Groups and Duration: \\nTreatment-experienced\", \"appliesToActivityIds\": [\"grp_4\", \"act_13\"]}, {\"id\": \"fn_cond_9\", \"conditionType\": \"timing_after\", \"text\": \"Following screening and enrollment, \\nparticipants will have a Run-in Period to support diet equilibration\", \"footnoteId\": \"y.\", \"structuredCondition\": \"sequence.after(['Screening', 'Enrollment'], 'Run-in Period')\", \"appliesToActivityIds\": [\"act_9\", \"grp_3\"], \"sourceText\": \"Following screening and enrollment, \\nparticipants will have a Run-in Period to support diet equilibr\"}, {\"id\": \"fn_cond_10\", \"conditionType\": \"general\", \"text\": \"Participants will have intake and output collection periods from Day -\", \"footnoteId\": \"t.\", \"sourceText\": \"Participants will have intake and output collection periods from Day -\", \"appliesToActivityIds\": [\"act_3\", \"grp_8\"]}, {\"id\": \"fn_cond_11\", \"conditionType\": \"general\", \"text\": \"Participants may be discharged from the clinical research unit\", \"footnoteId\": \"e.\", \"sourceText\": \"Participants may be discharged from the clinical research unit\", \"appliesToActivityIds\": [\"act_3\", \"act_2\"]}, {\"id\": \"fn_cond_12\", \"conditionType\": \"frequency_daily\", \"text\": \"In this situation, participants will be given additional investigational product to support \\ndaily dosing throughout the Outpatient Period\", \"footnoteId\": \"l.\", \"sourceText\": \"In this situation, participants will be given additional investigational product to support \\ndaily d\", \"appliesToActivityIds\": [\"act_4\"]}, {\"id\": \"fn_cond_13\", \"conditionType\": \"general\", \"text\": \"Race and ethnicity will be collected where permitted by local regulations\", \"footnoteId\": \"x.\", \"sourceText\": \"Race and ethnicity will be collected where permitted by local regulations\"}, {\"id\": \"fn_cond_14\", \"conditionType\": \"general\", \"text\": \"k A full physical examination will be performed at Screening, at check-in for the study, and at the End of the study/Early Termination Visit\", \"footnoteId\": \"d.\", \"sourceText\": \"k A full physical examination will be performed at Screening, at check-in for the study, and at the \", \"appliesToActivityIds\": [\"grp_2\", \"act_4\", \"act_14\", \"act_9\"]}, {\"id\": \"fn_cond_15\", \"conditionType\": \"general\", \"text\": \"Otherwise, a symptom-driven physical \\nexamination may be performed at other times, at the Principal Investigator’s discretion\", \"footnoteId\": \"t.\", \"sourceText\": \"Otherwise, a symptom-driven physical \\nexamination may be performed at other times, at the Principal \", \"appliesToActivityIds\": [\"grp_9\", \"act_14\"]}, {\"id\": \"fn_cond_16\", \"conditionType\": \"timing_after\", \"text\": \"m While in the CRU, study intervention will be administered after an overnight fast\", \"footnoteId\": \"y.\", \"sourceText\": \"m While in the CRU, study intervention will be administered after an overnight fast\", \"appliesToActivityIds\": [\"grp_2\", \"grp_4\"]}, {\"id\": \"fn_cond_17\", \"conditionType\": \"general\", \"text\": \"As an outpatient, participants are expected to take \\nALXN\", \"footnoteId\": \"g.\", \"sourceText\": \"As an outpatient, participants are expected to take \\nALXN\", \"appliesToActivityIds\": [\"act_4\"]}, {\"id\": \"fn_cond_18\", \"conditionType\": \"general\", \"text\": \"n During the outpatient period, participants will use SMS text messaging to confirm study intervention administration\", \"footnoteId\": \"g.\", \"sourceText\": \"n During the outpatient period, participants will use SMS text messaging to confirm study interventi\", \"appliesToActivityIds\": [\"grp_2\", \"act_4\", \"grp_4\"]}, {\"id\": \"fn_cond_19\", \"conditionType\": \"general\", \"text\": \"In case of rechecks, and postdose serum \\nchemistry, participants may not have fasted for\", \"footnoteId\": \"n.\", \"sourceText\": \"In case of rechecks, and postdose serum \\nchemistry, participants may not have fasted for\", \"appliesToActivityIds\": [\"act_33\", \"act_27\", \"act_24\"]}, {\"id\": \"fn_cond_20\", \"conditionType\": \"general\", \"text\": \"r Laboratory assessment including chemistry, hematology, and coagulation parameters should be performed on Days -\", \"footnoteId\": \"n.\", \"sourceText\": \"r Laboratory assessment including chemistry, hematology, and coagulation parameters should be perfor\", \"appliesToActivityIds\": [\"grp_6\", \"act_24\"]}, {\"id\": \"fn_cond_21\", \"conditionType\": \"timing_after\", \"text\": \"s Menstruation check is for women only; women of childbearing potential should only be enrolled after a negative serum pregnancy test result at Screening\", \"footnoteId\": \"y.\", \"sourceText\": \"s Menstruation check is for women only; women of childbearing potential should only be enrolled afte\", \"appliesToActivityIds\": [\"act_27\", \"act_26\", \"act_9\", \"act_8\", \"act_33\"]}, {\"id\": \"fn_cond_22\", \"conditionType\": \"general\", \"text\": \"u Vital signs measurements and ECGs should be performed predose, unless otherwise specified\", \"footnoteId\": \"t.\", \"sourceText\": \"u Vital signs measurements and ECGs should be performed predose, unless otherwise specified\", \"appliesToActivityIds\": [\"grp_9\", \"act_28\"]}, {\"id\": \"fn_cond_23\", \"conditionType\": \"timing_after\", \"text\": \"v Copper- and molybdenum-controlled diet will be initiated after registration/inclusion\", \"footnoteId\": \"e.\", \"sourceText\": \"v Copper- and molybdenum-controlled diet will be initiated after registration/inclusion\"}, {\"id\": \"fn_cond_24\", \"conditionType\": \"general\", \"text\": \"While not in the CRU, participants will be encouraged to adhere to their usual copper-controlled diet\", \"footnoteId\": \"s.\", \"sourceText\": \"While not in the CRU, participants will be encouraged to adhere to their usual copper-controlled die\"}, {\"id\": \"fn_cond_25\", \"conditionType\": \"general\", \"text\": \"x For fecal samples, each individual sample will be independently collected with record of date, time, and weight of the sample\", \"footnoteId\": \"m.\", \"sourceText\": \"x For fecal samples, each individual sample will be independently collected with record of date, tim\", \"appliesToActivityIds\": [\"act_27\"]}, {\"id\": \"fn_cond_26\", \"conditionType\": \"timing_after\", \"text\": \"When multiple procedures are scheduled to occur at the \\nsame time, the following order of events should be strictly adhered to whenever possible: ECG, vital signs, blood \\nsampling\", \"footnoteId\": \"e.\", \"sourceText\": \"When multiple procedures are scheduled to occur at the \\nsame time, the following order of events sho\", \"appliesToActivityIds\": [\"act_22\", \"act_30\", \"act_28\"]}, {\"id\": \"fn_cond_27\", \"conditionType\": \"general\", \"text\": \"Given the robust improvement in copper \\ncontrol, it is hypothesized that doses within the\", \"footnoteId\": \"l.\", \"sourceText\": \"Given the robust improvement in copper \\ncontrol, it is hypothesized that doses within the\"}, {\"id\": \"fn_cond_28\", \"conditionType\": \"general\", \"text\": \"The current study will explore copper balance in response to \\ntreatment with ALXN\", \"footnoteId\": \"e.\", \"sourceText\": \"The current study will explore copper balance in response to \\ntreatment with ALXN\", \"appliesToActivityIds\": [\"grp_2\", \"act_13\"]}, {\"id\": \"fn_cond_29\", \"conditionType\": \"general\", \"text\": \"Copper balance will be assessed for the\", \"footnoteId\": \"e.\", \"sourceText\": \"Copper balance will be assessed for the\"}, {\"id\": \"fn_cond_30\", \"conditionType\": \"general\", \"text\": \"Further dose \\nadjustments will be made as appropriate\", \"footnoteId\": \"y.\", \"sourceText\": \"Further dose \\nadjustments will be made as appropriate\"}, {\"id\": \"fn_cond_31\", \"conditionType\": \"general\", \"text\": \"Deviation from the dose modification guidelines must be agreed with the Alexion Medical \\nMonitor\", \"footnoteId\": \"t.\", \"sourceText\": \"Deviation from the dose modification guidelines must be agreed with the Alexion Medical \\nMonitor\", \"appliesToActivityIds\": [\"act_3\", \"act_11\"]}, {\"id\": \"fn_cond_32\", \"conditionType\": \"general\", \"text\": \"Over-the-counter medications may be given if they \\nare not expected to impact the outcome of the study\", \"footnoteId\": \"r.\", \"sourceText\": \"Over-the-counter medications may be given if they \\nare not expected to impact the outcome of the stu\", \"appliesToActivityIds\": [\"grp_2\", \"act_36\"]}, {\"id\": \"fn_cond_33\", \"conditionType\": \"general\", \"text\": \"Herbal remedies must be discontinued at least\", \"footnoteId\": \"y.\", \"sourceText\": \"Herbal remedies must be discontinued at least\", \"appliesToActivityIds\": [\"act_17\"]}, {\"id\": \"fn_cond_34\", \"conditionType\": \"general\", \"text\": \"St John’s wort \\nAny herbal remedy or dietary supplement containing \\nSt John’s wort\", \"footnoteId\": \"t.\", \"sourceText\": \"St John’s wort \\nAny herbal remedy or dietary supplement containing \\nSt John’s wort\"}, {\"id\": \"fn_cond_35\", \"conditionType\": \"timing_after\", \"text\": \"After EOS Visit\", \"footnoteId\": \"d.\", \"sourceText\": \"After EOS Visit\", \"appliesToActivityIds\": [\"act_4\"]}, {\"id\": \"fn_cond_36\", \"conditionType\": \"general\", \"text\": \"Contraception \\nParticipants must consistently and correctly use one or \\nmore of the appropriate contraceptive methods \\ndescribed in Section\", \"footnoteId\": \"t.\", \"sourceText\": \"Contraception \\nParticipants must consistently and correctly use one or \\nmore of the appropriate cont\", \"appliesToActivityIds\": [\"act_6\"]}, {\"id\": \"fn_cond_37\", \"conditionType\": \"general\", \"text\": \"A minimal set of screen failure information is \\nrequired to ensure transparent reporting of screen failure participants to meet the Consolidated \\nStandards of Reporting Trials\", \"footnoteId\": \"n.\", \"sourceText\": \"A minimal set of screen failure information is \\nrequired to ensure transparent reporting of screen f\", \"appliesToActivityIds\": [\"act_9\"]}, {\"id\": \"fn_cond_38\", \"conditionType\": \"general\", \"text\": \"Minimal information includes demography, screen failure details\", \"footnoteId\": \"s.\", \"sourceText\": \"Minimal information includes demography, screen failure details\", \"appliesToActivityIds\": [\"act_9\"]}, {\"id\": \"fn_cond_39\", \"conditionType\": \"general\", \"text\": \"Individuals who do not meet the criteria for participation in this study\", \"footnoteId\": \"d.\", \"sourceText\": \"Individuals who do not meet the criteria for participation in this study\", \"appliesToActivityIds\": [\"grp_2\"]}, {\"id\": \"fn_cond_40\", \"conditionType\": \"general\", \"text\": \"Rescreened participants are not \\nrequired to reconsent as long as they have signed the latest version of the ICF\", \"footnoteId\": \"r.\", \"sourceText\": \"Rescreened participants are not \\nrequired to reconsent as long as they have signed the latest versio\", \"appliesToActivityIds\": [\"act_28\", \"act_8\", \"act_1\", \"act_9\"]}, {\"id\": \"fn_cond_41\", \"conditionType\": \"general\", \"text\": \"If the study intervention is definitively discontinued, the \\nparticipant should remain in the study to be evaluated for safety follow-up\", \"footnoteId\": \"n.\", \"sourceText\": \"If the study intervention is definitively discontinued, the \\nparticipant should remain in the study \", \"appliesToActivityIds\": [\"grp_2\", \"act_17\", \"grp_6\", \"grp_4\"]}, {\"id\": \"fn_cond_42\", \"conditionType\": \"general\", \"text\": \"Discontinuation of study intervention for abnormal liver function should be considered by the \\nInvestigator when a participant meets one of the conditions outlined in the Dose Modification \\ncriteria\", \"footnoteId\": \"d.\", \"sourceText\": \"Discontinuation of study intervention for abnormal liver function should be considered by the \\nInves\", \"appliesToActivityIds\": [\"grp_2\", \"grp_4\"]}, {\"id\": \"fn_cond_43\", \"conditionType\": \"general\", \"text\": \"If a clinically significant finding is identified\", \"footnoteId\": \"t.\", \"sourceText\": \"If a clinically significant finding is identified\", \"appliesToActivityIds\": [\"act_4\", \"act_28\"]}, {\"id\": \"fn_cond_44\", \"conditionType\": \"general\", \"text\": \"This review of the ECG printed at the time of collection must \\nbe documented\", \"footnoteId\": \"d.\", \"sourceText\": \"This review of the ECG printed at the time of collection must \\nbe documented\"}, {\"id\": \"fn_cond_45\", \"conditionType\": \"timing_after\", \"text\": \"Participants must be considered for discontinuation from study intervention if any of the \\nfollowing occur during the study: \\n• Serious hypersensitivity reaction; \\n• Severe uncontrolled infection; \\n• Use of disallowed medication; \\n• Pregnancy or planned pregnancy\", \"footnoteId\": \"E.\", \"sourceText\": \"Participants must be considered for discontinuation from study intervention if any of the \\nfollowing\", \"appliesToActivityIds\": [\"act_3\", \"act_36\", \"grp_2\", \"grp_4\", \"act_26\"]}, {\"id\": \"fn_cond_46\", \"conditionType\": \"general\", \"text\": \"The study staff should \\nnotify Alexion and their site monitor of all study withdrawals as soon as possible\", \"footnoteId\": \"s.\", \"sourceText\": \"The study staff should \\nnotify Alexion and their site monitor of all study withdrawals as soon as po\", \"appliesToActivityIds\": [\"grp_2\"]}, {\"id\": \"fn_cond_47\", \"conditionType\": \"general\", \"text\": \"• A participant may withdraw from the study at any time at his/her own request, or may \\nbe withdrawn at any time at the discretion of the Investigator for safety, behavioral, \\ncompliance, or administrative reasons\", \"footnoteId\": \"F.\", \"sourceText\": \"• A participant may withdraw from the study at any time at his/her own request, or may \\nbe withdrawn\", \"appliesToActivityIds\": [\"act_3\", \"grp_2\", \"grp_6\", \"act_21\"]}, {\"id\": \"fn_cond_48\", \"conditionType\": \"general\", \"text\": \"• Immediate safety concerns should be discussed with Alexion immediately upon \\noccurrence or awareness to determine if the participant should continue or \\ndiscontinue study intervention\", \"footnoteId\": \"d.\", \"sourceText\": \"• Immediate safety concerns should be discussed with Alexion immediately upon \\noccurrence or awarene\", \"appliesToActivityIds\": [\"grp_2\", \"act_17\", \"grp_6\", \"grp_4\"]}, {\"id\": \"fn_cond_49\", \"conditionType\": \"general\", \"text\": \"• All screening evaluations must be completed and reviewed to confirm that potential \\nparticipants meet all eligibility criteria\", \"footnoteId\": \"t.\", \"sourceText\": \"• All screening evaluations must be completed and reviewed to confirm that potential \\nparticipants m\", \"appliesToActivityIds\": [\"act_9\", \"grp_1\"]}, {\"id\": \"fn_cond_50\", \"conditionType\": \"timing_after\", \"text\": \"• The following only applies to sites in the US\", \"footnoteId\": \"e.\", \"sourceText\": \"• The following only applies to sites in the US\"}, {\"id\": \"fn_cond_51\", \"conditionType\": \"general\", \"text\": \"Some sites may perform screening procedures only and \\nnot any of the remaining study procedures\", \"footnoteId\": \"e.\", \"sourceText\": \"Some sites may perform screening procedures only and \\nnot any of the remaining study procedures\", \"appliesToActivityIds\": [\"grp_2\", \"act_9\"]}, {\"id\": \"fn_cond_52\", \"conditionType\": \"general\", \"text\": \"Site-to-site transfer of the participant will be documented \\naccordingly\", \"footnoteId\": \"r.\", \"sourceText\": \"Site-to-site transfer of the participant will be documented \\naccordingly\"}, {\"id\": \"fn_cond_53\", \"conditionType\": \"general\", \"text\": \"The copper and molybdenum concentration of each sample will be determined by inductively \\ncoupled plasma mass spectrometry\", \"footnoteId\": \"A.\", \"sourceText\": \"The copper and molybdenum concentration of each sample will be determined by inductively \\ncoupled pl\", \"appliesToActivityIds\": [\"act_22\", \"act_27\"]}, {\"id\": \"fn_cond_54\", \"conditionType\": \"general\", \"text\": \"All participants will drink water from the same large water bottle \\ndispenser\", \"footnoteId\": \"s.\", \"sourceText\": \"All participants will drink water from the same large water bottle \\ndispenser\", \"appliesToActivityIds\": [\"act_3\"]}, {\"id\": \"fn_cond_55\", \"conditionType\": \"general\", \"text\": \"Samples will be collected, stored and shipped as detailed in the Laboratory Manual\", \"footnoteId\": \"t.\", \"sourceText\": \"Samples will be collected, stored and shipped as detailed in the Laboratory Manual\", \"appliesToActivityIds\": [\"act_27\", \"grp_6\"]}, {\"id\": \"fn_cond_56\", \"conditionType\": \"general\", \"text\": \"All sample handling procedures will be documented in detail as \\ndescribed in the Laboratory Manual\", \"footnoteId\": \"d.\", \"sourceText\": \"All sample handling procedures will be documented in detail as \\ndescribed in the Laboratory Manual\", \"appliesToActivityIds\": [\"act_27\", \"grp_6\"]}, {\"id\": \"fn_cond_57\", \"conditionType\": \"general\", \"text\": \"Fecal samples will be individually collected, weighed, and stored\", \"footnoteId\": \"l.\", \"sourceText\": \"Fecal samples will be individually collected, weighed, and stored\", \"appliesToActivityIds\": [\"act_27\"]}, {\"id\": \"fn_cond_58\", \"conditionType\": \"general\", \"text\": \"Pharmacokinetic collection should occur as close as possible to the scheduled time\", \"footnoteId\": \"l.\", \"sourceText\": \"Pharmacokinetic collection should occur as close as possible to the scheduled time\"}, {\"id\": \"fn_cond_59\", \"conditionType\": \"general\", \"text\": \"• Blood pressure and heart rate measurements will be assessed with a completely \\nautomated device\", \"footnoteId\": \"y.\", \"sourceText\": \"• Blood pressure and heart rate measurements will be assessed with a completely \\nautomated device\", \"appliesToActivityIds\": [\"act_22\", \"act_28\"]}, {\"id\": \"fn_cond_60\", \"conditionType\": \"general\", \"text\": \"• Vital signs will be measured in a supine position after\", \"footnoteId\": \"s.\", \"sourceText\": \"• Vital signs will be measured in a supine position after\", \"appliesToActivityIds\": [\"act_28\"]}, {\"id\": \"fn_cond_61\", \"conditionType\": \"general\", \"text\": \"Vital signs will consist \\nof a single pulse and blood pressure measurement\", \"footnoteId\": \"e.\", \"sourceText\": \"Vital signs will consist \\nof a single pulse and blood pressure measurement\", \"appliesToActivityIds\": [\"act_22\", \"act_28\"]}, {\"id\": \"fn_cond_62\", \"conditionType\": \"general\", \"text\": \"The average of the blood pressure readings will be \\nrecorded in the CRF\", \"footnoteId\": \"y.\", \"sourceText\": \"The average of the blood pressure readings will be \\nrecorded in the CRF\", \"appliesToActivityIds\": [\"act_22\"]}, {\"id\": \"fn_cond_63\", \"conditionType\": \"general\", \"text\": \"As with vital \\nsigns, if ECG interval measurements are abnormal, an additional triplicate will be \\nperformed and recorded in the CRF\", \"footnoteId\": \"y.\", \"sourceText\": \"As with vital \\nsigns, if ECG interval measurements are abnormal, an additional triplicate will be \\np\", \"appliesToActivityIds\": [\"act_28\"]}, {\"id\": \"fn_cond_64\", \"conditionType\": \"general\", \"text\": \"• The Investigator must review the laboratory report, document this review, and record any \\nclinically relevant changes occurring during the study in the AE section of the CRF\", \"footnoteId\": \"y.\", \"sourceText\": \"• The Investigator must review the laboratory report, document this review, and record any \\nclinical\", \"appliesToActivityIds\": [\"grp_2\", \"act_4\", \"grp_6\"]}, {\"id\": \"fn_cond_65\", \"conditionType\": \"general\", \"text\": \"Clinically significant \\nlaboratory values are those deemed by the Investigator to be clinically significant \\nresulting in further evaluation or treatment or those associated with an AE or clinical \\nsigns or symptoms\", \"footnoteId\": \"s.\", \"sourceText\": \"Clinically significant \\nlaboratory values are those deemed by the Investigator to be clinically sign\", \"appliesToActivityIds\": [\"act_28\", \"act_4\", \"grp_6\", \"act_13\"]}, {\"id\": \"fn_cond_66\", \"conditionType\": \"general\", \"text\": \"− If such values do not return to normal/baseline within a period of time judged \\nreasonable by the Investigator, the etiology should be identified, and Alexion \\nnotified\", \"footnoteId\": \"r.\", \"sourceText\": \"− If such values do not return to normal/baseline within a period of time judged \\nreasonable by the \"}, {\"id\": \"fn_cond_67\", \"conditionType\": \"general\", \"text\": \"− All laboratory values from non-protocol-specified laboratory assessments must \\nalso be recorded in the CRF\", \"footnoteId\": \"A.\", \"sourceText\": \"− All laboratory values from non-protocol-specified laboratory assessments must \\nalso be recorded in\", \"appliesToActivityIds\": [\"act_3\", \"grp_6\"]}, {\"id\": \"fn_cond_68\", \"conditionType\": \"general\", \"text\": \"• Total molybdenum and PUF-molybdenum are surrogate measures of ALXN\", \"footnoteId\": \"d.\", \"sourceText\": \"• Total molybdenum and PUF-molybdenum are surrogate measures of ALXN\", \"appliesToActivityIds\": [\"act_22\"]}, {\"id\": \"fn_cond_69\", \"conditionType\": \"general\", \"text\": \"• Excess/additional samples may be stored for up to\", \"footnoteId\": \"y.\", \"sourceText\": \"• Excess/additional samples may be stored for up to\", \"appliesToActivityIds\": [\"act_27\"]}, {\"id\": \"fn_cond_70\", \"conditionType\": \"general\", \"text\": \"Blood samples will be collected as described in the SoA\", \"footnoteId\": \"y.\", \"sourceText\": \"Blood samples will be collected as described in the SoA\", \"appliesToActivityIds\": [\"act_22\", \"act_27\"]}, {\"id\": \"fn_cond_71\", \"conditionType\": \"procedure_conditional\", \"text\": \"Plasma samples will be used for ICP-MS measurement of total copper and \\nPUF-copper, ceruloplasmin, ceruloplasmin-bound copper, and non-ceruloplasmin-bound copper \\nmeasured via PUF-copper, and/or LBC, or assessed via NCC/NCCcorrected methods at the time \\npoints indicated in the SoA\", \"footnoteId\": \"l.\", \"sourceText\": \"Plasma samples will be used for ICP-MS measurement of total copper and \\nPUF-copper, ceruloplasmin, c\", \"appliesToActivityIds\": [\"act_22\", \"act_27\", \"act_23\"]}, {\"id\": \"fn_cond_72\", \"conditionType\": \"general\", \"text\": \"Benefit-Risk Assessment\", \"footnoteId\": \"3.\", \"sourceText\": \"Benefit-Risk Assessment\"}, {\"id\": \"fn_cond_73\", \"conditionType\": \"general\", \"text\": \"Benefit Assessment\", \"footnoteId\": \"2.\", \"sourceText\": \"Benefit Assessment\"}, {\"id\": \"fn_cond_74\", \"conditionType\": \"general\", \"text\": \"Scientific Rationale for Study Design\", \"footnoteId\": \"2.\", \"sourceText\": \"Scientific Rationale for Study Design\", \"appliesToActivityIds\": [\"grp_2\", \"act_28\"]}, {\"id\": \"fn_cond_75\", \"conditionType\": \"general\", \"text\": \"Justification for Dose\", \"footnoteId\": \"3.\", \"sourceText\": \"Justification for Dose\"}, {\"id\": \"fn_cond_76\", \"conditionType\": \"general\", \"text\": \"Lifestyle Considerations\", \"footnoteId\": \"3.\", \"sourceText\": \"Lifestyle Considerations\"}, {\"id\": \"fn_cond_77\", \"conditionType\": \"general\", \"text\": \"Adverse Events: Definitions and Procedures for Recording, Evaluating, \\nFollow-up, and Reporting\", \"footnoteId\": \"3.\", \"sourceText\": \"Adverse Events: Definitions and Procedures for Recording, Evaluating, \\nFollow-up, and Reporting\", \"appliesToActivityIds\": [\"act_30\"]}, {\"id\": \"fn_cond_78\", \"conditionType\": \"general\", \"text\": \"Recording and Follow-Up of AE and/or SAE\", \"footnoteId\": \"3.\", \"sourceText\": \"Recording and Follow-Up of AE and/or SAE\"}, {\"id\": \"fn_cond_79\", \"conditionType\": \"general\", \"text\": \"Contraceptive Guidance and Collection of Pregnancy Information\", \"footnoteId\": \"4.\", \"sourceText\": \"Contraceptive Guidance and Collection of Pregnancy Information\", \"appliesToActivityIds\": [\"act_26\"]}, {\"id\": \"fn_cond_80\", \"conditionType\": \"general\", \"text\": \"Note: “Enrolled” means all participants who sign the informed consent form\", \"footnoteId\": \"1840.\", \"sourceText\": \"Note: “Enrolled” means all participants who sign the informed consent form\", \"appliesToActivityIds\": [\"act_1\", \"act_28\"]}, {\"id\": \"fn_cond_81\", \"conditionType\": \"timing_before\", \"text\": \"Before titration to\", \"footnoteId\": \"29.\", \"sourceText\": \"Before titration to\"}, {\"id\": \"fn_cond_82\", \"conditionType\": \"general\", \"text\": \"The \\ncollection periods will support an assessment of both copper and molybdenum balance\", \"footnoteId\": \"39.\", \"sourceText\": \"The \\ncollection periods will support an assessment of both copper and molybdenum balance\"}, {\"id\": \"fn_cond_83\", \"conditionType\": \"frequency_continuous\", \"text\": \"To ensure flexibility, the Outpatient \\nPeriod during Treatment Period\", \"footnoteId\": \"23.\", \"sourceText\": \"To ensure flexibility, the Outpatient \\nPeriod during Treatment Period\", \"appliesToActivityIds\": [\"act_4\", \"act_13\"]}, {\"id\": \"fn_cond_84\", \"conditionType\": \"general\", \"text\": \"p PK/PD collection will include timepoints described in the schedule of PK/PD assessment for Days\", \"footnoteId\": \"39.\", \"sourceText\": \"p PK/PD collection will include timepoints described in the schedule of PK/PD assessment for Days\", \"appliesToActivityIds\": [\"grp_5\"]}, {\"id\": \"fn_cond_85\", \"conditionType\": \"general\", \"text\": \"Abbreviations: Cu = copper; LBC = labile bound copper; Mo = molybdenum; PD = pharmacodynamic; \\nPK = pharmacokinetic; PUF = plasma ultrafiltrate\", \"footnoteId\": \"1840.\", \"sourceText\": \"Abbreviations: Cu = copper; LBC = labile bound copper; Mo = molybdenum; PD = pharmacodynamic; \\nPK = \", \"appliesToActivityIds\": [\"act_22\"]}, {\"id\": \"fn_cond_86\", \"conditionType\": \"general\", \"text\": \"The multiple collection periods will support assessment of duration of treatment and dose on \\ncopper elimination and overall copper balance\", \"footnoteId\": \"39.\", \"sourceText\": \"The multiple collection periods will support assessment of duration of treatment and dose on \\ncopper\", \"appliesToActivityIds\": [\"act_13\"]}, {\"id\": \"fn_cond_87\", \"conditionType\": \"general\", \"text\": \"End of Study Definition \\nA participant is considered to have completed the study if he/she has completed all phases of the \\nstudy including the last scheduled procedure shown in the Schedule of Activities\", \"footnoteId\": \"4.\", \"sourceText\": \"End of Study Definition \\nA participant is considered to have completed the study if he/she has compl\", \"appliesToActivityIds\": [\"grp_2\"]}, {\"id\": \"fn_cond_88\", \"conditionType\": \"general\", \"text\": \"Start times for \\ncontraceptives vary \\naccording to method used\", \"footnoteId\": \"4.\", \"sourceText\": \"Start times for \\ncontraceptives vary \\naccording to method used\"}, {\"id\": \"fn_cond_89\", \"conditionType\": \"general\", \"text\": \"Abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule of \\nActivities\", \"footnoteId\": \"4.\", \"sourceText\": \"Abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Sched\", \"appliesToActivityIds\": [\"act_2\", \"grp_2\"]}, {\"id\": \"fn_cond_90\", \"conditionType\": \"general\", \"text\": \"Screen Failures  \\nScreen failures are defined as participants who consent to participate in the clinical study but are \\nnot subsequently assigned to study intervention\", \"footnoteId\": \"4.\", \"sourceText\": \"Screen Failures  \\nScreen failures are defined as participants who consent to participate in the clin\", \"appliesToActivityIds\": [\"act_1\", \"grp_2\", \"grp_4\", \"act_9\", \"act_28\"]}, {\"id\": \"fn_cond_91\", \"conditionType\": \"general\", \"text\": \"Discontinuation of Study Intervention \\nIn rare instances, it may be necessary for a participant to permanently discontinue\", \"footnoteId\": \"1.\", \"sourceText\": \"Discontinuation of Study Intervention \\nIn rare instances, it may be necessary for a participant to p\", \"appliesToActivityIds\": [\"grp_2\", \"act_17\", \"grp_4\"]}, {\"id\": \"fn_cond_92\", \"conditionType\": \"timing_before\", \"text\": \"Participant Discontinuation/Withdrawal From the Study \\n• All efforts should be made to ensure participants are willing to comply with study \\nparticipation prior to conducting the screening procedures\", \"footnoteId\": \"2.\", \"sourceText\": \"Participant Discontinuation/Withdrawal From the Study \\n• All efforts should be made to ensure partic\", \"appliesToActivityIds\": [\"act_3\", \"grp_2\", \"act_9\", \"act_13\"]}, {\"id\": \"fn_cond_93\", \"conditionType\": \"general\", \"text\": \"STUDY ASSESSMENTS AND PROCEDURES \\n• Study procedures and their timing are summarized in the SoA\", \"footnoteId\": \"8.\", \"sourceText\": \"STUDY ASSESSMENTS AND PROCEDURES \\n• Study procedures and their timing are summarized in the SoA\", \"appliesToActivityIds\": [\"grp_2\", \"grp_6\"]}, {\"id\": \"fn_cond_94\", \"conditionType\": \"general\", \"text\": \"Efficacy Assessments\", \"footnoteId\": \"1.\", \"sourceText\": \"Efficacy Assessments\", \"appliesToActivityIds\": [\"grp_6\"]}, {\"id\": \"fn_cond_95\", \"conditionType\": \"general\", \"text\": \"Copper and Molybdenum Balance Measurements \\nCopper and molybdenum balance measurements will be made on all intake\", \"footnoteId\": \"1.\", \"sourceText\": \"Copper and Molybdenum Balance Measurements \\nCopper and molybdenum balance measurements will be made \", \"appliesToActivityIds\": [\"act_28\", \"grp_8\"]}, {\"id\": \"fn_cond_96\", \"conditionType\": \"general\", \"text\": \"Food and Fluid Collection for Copper and Molybdenum Concentrations \\nSamples of all meal and fluid batches will be collected and analyzed for measurement of copper \\nand molybdenum content\", \"footnoteId\": \"1.\", \"sourceText\": \"Food and Fluid Collection for Copper and Molybdenum Concentrations \\nSamples of all meal and fluid ba\", \"appliesToActivityIds\": [\"act_27\"]}, {\"id\": \"fn_cond_97\", \"conditionType\": \"general\", \"text\": \"Urine Collection for Measurement of Copper and Molybdenum content \\nUrine samples to measure copper and molybdenum content will be collected periodically as \\ndescribed in the SoA\", \"footnoteId\": \"2.\", \"sourceText\": \"Urine Collection for Measurement of Copper and Molybdenum content \\nUrine samples to measure copper a\", \"appliesToActivityIds\": [\"act_4\", \"act_27\", \"act_9\"]}, {\"id\": \"fn_cond_98\", \"conditionType\": \"general\", \"text\": \"Safety Assessments \\nPlanned time points for all safety assessments are provided in the SoA\", \"footnoteId\": \"2.\", \"sourceText\": \"Safety Assessments \\nPlanned time points for all safety assessments are provided in the SoA\", \"appliesToActivityIds\": [\"grp_6\", \"grp_7\"]}, {\"id\": \"fn_cond_99\", \"conditionType\": \"general\", \"text\": \"Physical Examinations \\n• A complete physical examination will include, at a minimum, assessments of the \\ncardiovascular, respiratory, gastrointestinal, and neurological systems\", \"footnoteId\": \"1.\", \"sourceText\": \"Physical Examinations \\n• A complete physical examination will include, at a minimum, assessments of \", \"appliesToActivityIds\": [\"act_8\", \"act_14\", \"grp_6\"]}, {\"id\": \"fn_cond_100\", \"conditionType\": \"general\", \"text\": \"Vital Signs \\n• Body temperature, heart rate, respiratory rate, and systolic and diastolic blood pressure\", \"footnoteId\": \"2.\", \"sourceText\": \"Vital Signs \\n• Body temperature, heart rate, respiratory rate, and systolic and diastolic blood pres\", \"appliesToActivityIds\": [\"act_22\", \"act_28\"]}, {\"id\": \"fn_cond_101\", \"conditionType\": \"general\", \"text\": \"Electrocardiograms \\n• Triplicate\", \"footnoteId\": \"3.\", \"sourceText\": \"Electrocardiograms \\n• Triplicate\"}, {\"id\": \"fn_cond_102\", \"conditionType\": \"general\", \"text\": \"Clinical Safety Laboratory Assessments \\n• See Section\", \"footnoteId\": \"4.\", \"sourceText\": \"Clinical Safety Laboratory Assessments \\n• See Section\", \"appliesToActivityIds\": [\"grp_6\"]}, {\"id\": \"fn_cond_103\", \"conditionType\": \"timing_after\", \"text\": \"Samples collected for \\nanalyses of plasma concentrations may also be used to evaluate safety aspects related \\nto concerns arising during or after the study\", \"footnoteId\": \"1840.\", \"sourceText\": \"Samples collected for \\nanalyses of plasma concentrations may also be used to evaluate safety aspects\", \"appliesToActivityIds\": [\"act_27\", \"grp_6\", \"grp_5\", \"grp_2\", \"act_22\"]}, {\"id\": \"fn_cond_104\", \"conditionType\": \"general\", \"text\": \"These samples will not be \\nused for genetic analyses\", \"footnoteId\": \"1840.\", \"sourceText\": \"These samples will not be \\nused for genetic analyses\", \"appliesToActivityIds\": [\"grp_5\", \"act_27\"]}, {\"id\": \"fn_cond_105\", \"conditionType\": \"general\", \"text\": \"Pharmacodynamics \\nPlasma total and PUF-copper, ceruloplasmin, ceruloplasmin-bound copper, and LBC will be \\nassessed during the study\", \"footnoteId\": \"6.\", \"sourceText\": \"Pharmacodynamics \\nPlasma total and PUF-copper, ceruloplasmin, ceruloplasmin-bound copper, and LBC wi\", \"appliesToActivityIds\": [\"grp_2\", \"act_23\", \"act_22\"]}, {\"id\": \"fn_cond_106\", \"conditionType\": \"general\", \"text\": \"Genetics \\nGenetics will not be evaluated in this study\", \"footnoteId\": \"7.\", \"sourceText\": \"Genetics \\nGenetics will not be evaluated in this study\", \"appliesToActivityIds\": [\"grp_2\"]}, {\"id\": \"fn_cond_107\", \"conditionType\": \"general\", \"text\": \"Immunogenicity Assessments \\nNot applicable\", \"footnoteId\": \"9.\", \"sourceText\": \"Immunogenicity Assessments \\nNot applicable\", \"appliesToActivityIds\": [\"grp_6\"]}, {\"id\": \"fn_cond_108\", \"conditionType\": \"general\", \"text\": \"Health Economics Data and/or Medical Resource Utilization \\nHealth economic and medical resource utilization parameters are not evaluated in this study\", \"footnoteId\": \"10.\", \"sourceText\": \"Health Economics Data and/or Medical Resource Utilization \\nHealth economic and medical resource util\", \"appliesToActivityIds\": [\"grp_2\", \"act_11\"]}]"
              },
              {
                "id": "a3c3cab1-8ebd-4fc3-ae77-d12799788a8b",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-endpointAlgorithms",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"ep_1\", \"name\": \"Exploratory Endpoint 1\", \"endpointType\": \"Exploratory\", \"inputs\": [\"CR\", \"OS\", \"PR\"], \"unit\": \"%\", \"sourceText\": \"--- Page 51 ---\\nProtocol Amendment 3.1 (US) \\n \\nALXN1840-WD-204 \\n18 Mar 2022 \\nPage 51 of 74 \\nAlexion Confidential \\n9. \\nSTATISTICAL CONSIDERATIONS \\n9.1. \\nStatistical Hypotheses \\n9.1.1. \\nPrimary Hypothes\"}, {\"id\": \"ep_2\", \"name\": \"analysis will be excluded from the Per \\nProtocol (PP) Set\", \"endpointType\": \"Primary\", \"inputs\": [\"CR\", \"PR\"], \"timeWindow\": {\"reference\": \"the per\", \"duration\": null}, \"algorithm\": \"informed consent form; pd = pharmacodynamic; pk = pharmacokinetic\", \"sourceText\": \"primary endpoint analysis will be excluded from the Per \\nProtocol (PP) Set. Major protocol deviations, and the PP Set, will be \\ndefined, documented, and agreed within Alexion prior to database lock. \\n\"}, {\"id\": \"ep_3\", \"name\": \"of this study is to demonstrate a net negative copper balance with daily \\nrepeat-dose ALXN1840 treat\", \"endpointType\": \"Primary\", \"inputs\": [\"OS\", \"PR\"], \"unit\": \"mg\", \"sourceText\": \"primary objective of this study is to demonstrate a net negative copper balance with daily \\nrepeat-dose ALXN1840 treatment (15 mg and 30 mg) in participants with WD. \\n\"}]"
              },
              {
                "id": "22f023c0-13e6-4e75-876b-4452a12765d7",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-derivedVariables",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"dv_1\", \"name\": \"will be\", \"variableType\": \"Custom\", \"sourceVariables\": [\"ALT\"], \"derivationRule\": \"the \\ndifference between measured copper input in food and drink and measured copper output in \\nurine and feces\", \"unit\": \"15\", \"sourceText\": \"--- Page 9 ---\\nProtocol Amendment 3.1 (US) \\n \\nALXN1840-WD-204 \\n18 Mar 2022 \\nPage 9 of 74 \\nAlexion Confidential \\n1. \\nPROTOCOL SUMMARY \\n1.1. \\nSynopsis \\nProtocol Title: A Phase 2, Open-label Study to Ass\"}, {\"id\": \"dv_6\", \"name\": \"Derived Variable 6\", \"variableType\": \"Custom\", \"sourceVariables\": [\"heart rate\", \"blood pressure\", \"5 times\", \"on copper\", \"pk parameters\"], \"baselineVisit\": \"day \\n39\", \"analysisWindow\": \"day \\n39\", \"unit\": \"15\", \"sourceText\": \"\\n• Vital sign assessments (blood pressure and heart rate) \\nExploratory \\nDetermine dose response of ALXN1840 15 mg/day \\nand 30 mg/day for copper balance in participants \\nwith WD \\nAssess dose response o\"}, {\"id\": \"dv_7\", \"name\": \"Derived Variable 7\", \"variableType\": \"Custom\", \"baselineVisit\": \"day -4\", \"sourceText\": \"\\n• \\nBaseline Day -4 through Day -1 \"}, {\"id\": \"dv_12\", \"name\": \"copper balance\", \"variableType\": \"ChangeFromBaseline\", \"sourceVariables\": [\"total molybdenum\", \"weight\", \"safety\", \"a \\ntotal\", \"ALT\"], \"derivationRule\": \"the difference between measured copper input in food and drink and measured \\ncopper output in urine and feces\", \"baselineVisit\": \"day 54\", \"analysisWindow\": \"day 54\", \"unit\": \"toxic\", \"sourceText\": \"\\n• \\nEnd of Study Visit Day 54 +/- 2 days  \\nAbbreviations: AP = accumulation period; CRU = clinical research unit; EOS = End of Study; I/O = input/output; \\nPD = pharmacodynamic; PK = pharmacokinetic; S\"}, {\"id\": \"dv_17\", \"name\": \"Derived Variable 17\", \"variableType\": \"Custom\", \"sourceVariables\": [\"heart rate\", \"blood pressure\", \"5 times\", \"on copper\", \"pk parameters\"], \"baselineVisit\": \"day 39\", \"analysisWindow\": \"day 39\", \"unit\": \"15\", \"sourceText\": \"\\n• Vital sign assessments (blood pressure and heart rate) \\nExploratory \\nDetermine dose response of ALXN1840 15 mg/day \\nand 30 mg/day for copper balance in participants \\nwith WD \\nAssess dose response o\"}, {\"id\": \"dv_19\", \"name\": \"will be\", \"variableType\": \"Baseline\", \"sourceVariables\": [\"safety analysis\", \"criteria established\", \"heart rate\", \"fractional intake\", \"world health\", \"full analysis\", \"same methods\", \"pk\", \"noncompartmental methods\", \"actual sampling\", \"sas\", \"ALT\", \"AST\", \"descriptive statistics\"], \"derivationRule\": \"the mean daily copper balance over each of the 4 \\ncollection periods\", \"baselineVisit\": \"day -8\", \"analysisWindow\": \"day 9\", \"unit\": \"15\", \"sourceText\": \"\\n• Cohort 2 (treatment naïve): Patients who have received WD therapy for ≤ 28 days \\nFollowing screening and enrollment, participants will check-in to the CRU on Day -8 for the \\nRun-in Period. The purp\"}, {\"id\": \"dv_26\", \"name\": \"Derived Variable 26\", \"variableType\": \"Custom\", \"sourceVariables\": [\"AST\"], \"baselineVisit\": \"day25\", \"analysisWindow\": \"day 28\", \"unit\": \"15\", \"sourceText\": \"\\n• Accumulation ratio (AR) calculated as: \\nFor 15 mg/day:  \\n− Cmax,Day25/Cmax,Day1 \\n− Ctrough,Day26/Ctrough,Day2 \\n− AUCtau,Day25/AUC tau,Day1  \\nFor 30 mg/day:  \\n− Cmax,Day39/Cmax,Day29,adjusted \\n− Ctr\"}, {\"id\": \"dv_30\", \"name\": \"may be\", \"variableType\": \"PercentChange\", \"sourceVariables\": [\"heart rate\", \"fridericia\", \"following descriptive\", \"any emerging\", \"BMI\", \"ALT\", \"following \\ndescriptive\"], \"derivationRule\": \"sae \\nserious adverse event  \\nsap \\nstatistical analysis plan  \\nsoa \\nschedule of activities \\nsrc \\nsafety review committee \\nsusar \\nsuspected unexpected serious adverse reaction \\nteae \\ntreatment-emergent adverse event  \\nt½ \\nterminal elimination half-life  \\ntlag \\ntime delay between the time of dosing and time of appearance of molybdenum \\nconcentration \\ntmax \\ntime to maximum concentration  \\ntpc \\ntripartite complex \\nttm \\ntetrathiomolybdate \\nuln \\nupper limit of normal \\nuwdrs \\nunified wilson disease rating scale \\nvd/f \\napparent volume of distribution  \\nwd \\nwilson disease  \\nwho \\nworld health organization\", \"unit\": \"15\", \"sourceText\": \"\\n• Apparent volume of distribution (Vd/F). \\nAdditional plasma PK parameters may be calculated if deemed appropriate. \\nPlasma concentrations of total molybdenum and PUF molybdenum vs. time data will be\"}]"
              },
              {
                "id": "18996c85-43a0-40bf-acf0-35fe46b6984e",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-stateMachine",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"sm_1\", \"initialState\": \"Screening\", \"terminalStates\": [\"Completed\", \"Discontinued\", \"Withdrawn\", \"Death\", \"LostToFollowUp\"], \"states\": [\"OnTreatment\", \"Discontinued\", \"Withdrawn\", \"Death\"], \"transitions\": [{\"fromState\": \"OnTreatment\", \"toState\": \"Discontinued\", \"trigger\": \"Discontinuation from treatment\"}]}"
              },
              {
                "id": "14aa3d79-1c4d-4ac5-be0d-005604079743",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-dosingRegimens",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"dosing_1\", \"treatmentName\": \"ALXN1840\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 30.0, \"unit\": \"mg\"}, {\"amount\": 15.0, \"unit\": \"mg\"}], \"sourceText\": \" \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\nAdministration of Study \\nInterventionm \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\nALXN1840 15 mg/day \\n \\n \\n \\n \\n \\n \\nX X \\nX X X \\nX \\nX \\nX X \\nX \\n \\n \\n \\n \\n \\n \\n \\n \\n\"}]"
              },
              {
                "id": "6af5678a-fc17-4d06-8084-9cf78a5c91a8",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-visitWindows",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"visit_4\", \"visitName\": \"screening\", \"targetDay\": -14, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 1, \"sourceText\": \"treatment-naïve participants are eligible for this study. Following screening and enrollment, \\nparticipants will have a Run-in Period to support diet equilibration (Day -7 through Day -5) and \\nmeasure\"}, {\"id\": \"visit_2\", \"visitName\": \"baseline\", \"targetDay\": 0, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 2, \"sourceText\": \"periods versus the pretreatment baseline in \\nparticipants with WD \\nChange in mean daily copper balance as measured by the \"}, {\"id\": \"visit_1\", \"visitName\": \"Early Termination\", \"targetDay\": 1, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 3, \"sourceText\": \"Assess net copper balance with daily repeat-dose \\nALXN1840 treatment (15 mg and 30 mg) in \\nparticipants with Wilson disease (WD) \"}, {\"id\": \"visit_3\", \"visitName\": \"Day 1\", \"targetDay\": 1, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 4, \"sourceText\": \"Note: The accumulation period refers to time from initiation of ALXN1840 (Day 1) to expected steady state at Day \\n10, based on 5 times the half-life of 2 days.   \\nOverall Design \"}, {\"id\": \"visit_13\", \"visitName\": \"End of Study\", \"targetDay\": 54, \"windowBefore\": 2, \"windowAfter\": 2, \"isRequired\": true, \"visitNumber\": 17, \"sourceText\": \"End of Study Visit Day 54 +/- 2 days  \\nAbbreviations: AP = accumulation period; CRU = clinical research unit; EOS = End of Study; I/O = input/output; \\nPD = pharmacodynamic; PK = pharmacokinetic; SS = \"}, {\"id\": \"visit_18\", \"visitName\": \"Day 7\", \"targetDay\": 7, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 6, \"sourceText\": \"Day 7, indicating the possibility of tissue accumulation, particularly in the setting of high liver \\ncopper concentration (Plitz, 2019).  \\nIf the half-life of ALXN1840 in liver were longer than that o\"}, {\"id\": \"visit_7\", \"visitName\": \"Day 9\", \"targetDay\": 9, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 7, \"sourceText\": \"Participants may be discharged from the clinical research unit (CRU) on Day 9 to return on Day \\n22 or Day 23 (predose); all procedures will start on Day 23. To ensure flexibility, the Outpatient \\nPeri\"}, {\"id\": \"visit_16\", \"visitName\": \"Day 14\", \"targetDay\": 14, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 8, \"sourceText\": \"g A single outpatient visit or phone call and safety laboratory assessment should occur between Day 14 and Day 18. A phone call may take place on a different \\nday than the blood draw within the Day 14\"}, {\"id\": \"visit_9\", \"visitName\": \"Day 22\", \"targetDay\": 22, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 9, \"sourceText\": \"who are discharged will be re-admitted on Day 22 or Day 23 for Treatment Period 2 and will remain in house \\nuntil Day 40. To ensure flexibility, the Outpatient Period may be extended up to an addition\"}, {\"id\": \"visit_6\", \"visitName\": \"Day 23\", \"targetDay\": 23, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 10, \"sourceText\": \"data through Day 23 for each participant. \\nParticipants will have intake and output collection periods from Day -4 through Day -1, from \\nDay 1 through Day 8 (initial 15 mg/day collection period), and \"}, {\"id\": \"visit_11\", \"visitName\": \"Day 25\", \"targetDay\": 25, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 11, \"sourceText\": \"Day 25 through Day 39 (Days 25 through 28, I/O for 15 mg; Days 29 through 39, I/O for 30 mg) \\n5. During these periods all intake (including food and drink) and output (including urine and feces) will \"}, {\"id\": \"visit_5\", \"visitName\": \"Day 29\", \"targetDay\": 29, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 12, \"sourceText\": \"treatment period of approximately 28 days followed by titration up to 30 mg/day on Day 29. \\nBefore titration to 30 mg/day, the Safety Review Committee (SRC) will review available safety \\ndata through \"}, {\"id\": \"visit_17\", \"visitName\": \"Day 36\", \"targetDay\": 36, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 13, \"sourceText\": \"Day 36 through Day 39 for the 30 mg/day dose: if steady state is achieved, molybdenum(out) \\nwill equal molybdenum(in). \\n2.2. \"}, {\"id\": \"visit_8\", \"visitName\": \"Day 39\", \"targetDay\": 39, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 14, \"sourceText\": \"through Day 39. \\n2. Participants will be admitted to the CRU for Treatment Period 1 on Day -8 and may be discharged on Day 9 \\nor remain in the CRU for their own safety or to maintain the integrity of \"}, {\"id\": \"visit_10\", \"visitName\": \"Day 40\", \"targetDay\": 40, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 15, \"sourceText\": \"until Day 40. To ensure flexibility, the Outpatient Period may be extended up to an additional 14 days with \\nInvestigator approval. In this situation, participants will be given additional investigati\"}, {\"id\": \"visit_12\", \"visitName\": \"Day 54\", \"targetDay\": 54, \"windowBefore\": 2, \"windowAfter\": 2, \"isRequired\": true, \"visitNumber\": 16, \"sourceText\": \"End of Study Visit Day 54 +/- 2 days  \\nAbbreviations: AP = accumulation period; CRU = clinical research unit; EOS = End of Study; I/O = input/output; \\nPD = pharmacodynamic; PK = pharmacokinetic; SS = \"}, {\"id\": \"visit_19\", \"visitName\": \"Week 24\", \"targetDay\": 162, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 18, \"targetWeek\": 24, \"sourceText\": \"for 9 participants at Week 24 when the primary endpoint assessment was conducted, or at the last \\ndose received for participants with early discontinuation. The 15 to 60 mg/day dose range has \\nbeen de\"}, {\"id\": \"visit_15\", \"visitName\": \"Follow-up\", \"targetDay\": 365, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 19, \"sourceText\": \"Day 54 follow-up. \\nf Discharge from the unit may occur after completion of all procedures on Day 9 and on Day 40 and after the Investigator has reviewed all safety assessment \\n(including safety labora\"}]"
              },
              {
                "id": "0791b059-6a2d-46c5-9672-40fcb6c1091e",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-activityBindings",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"binding_1\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_1\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily controlled_meal from Day -8 to Day 9\"}, {\"id\": \"binding_2\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_2\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily controlled_meal from Day -8 to Day 9\"}, {\"id\": \"binding_3\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_3\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily controlled_meal from Day 23 to Day 40\"}, {\"id\": \"binding_4\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_4\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily controlled_meal from Day 23 to Day 40\"}, {\"id\": \"binding_5\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_5\", \"expectedOccurrences\": 3, \"sourceText\": \"Daily controlled_meal from Day -7 to Day -5\"}, {\"id\": \"binding_6\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_6\", \"expectedOccurrences\": 4, \"sourceText\": \"Daily controlled_meal from Day -4 to Day -1\"}, {\"id\": \"binding_7\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_7\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily controlled_meal from Day -8 to Day 9\"}, {\"id\": \"binding_8\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_8\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily controlled_meal from Day 23 to Day 40\"}, {\"id\": \"binding_9\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_9\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily controlled_meal from Day -8 to Day 9\"}, {\"id\": \"binding_10\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_10\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily controlled_meal from Day 23 to Day 40\"}, {\"id\": \"binding_11\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_11\", \"expectedOccurrences\": 13, \"sourceText\": \"Daily controlled_meal from Day 3 to Day 15\"}, {\"id\": \"binding_12\", \"activityId\": \"balance_collection\", \"activityName\": \"copper balance\", \"repetitionId\": \"rep_daily_bound_12\", \"expectedOccurrences\": 101, \"sourceText\": \"Daily balance_collection from Day 101 to Day 201\"}, {\"id\": \"binding_13\", \"activityId\": \"balance_collection\", \"activityName\": \"copper balance\", \"repetitionId\": \"rep_daily_bound_13\", \"expectedOccurrences\": 4, \"sourceText\": \"Daily balance_collection from Day -4 to Day -1\"}, {\"id\": \"binding_14\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_14\", \"expectedOccurrences\": 3, \"sourceText\": \"Daily balance_collection from Day -7 to Day -5\"}, {\"id\": \"binding_15\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_15\", \"expectedOccurrences\": 4, \"sourceText\": \"Daily balance_collection from Day -4 to Day -1\"}, {\"id\": \"binding_16\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_16\", \"expectedOccurrences\": 4, \"sourceText\": \"Daily balance_collection from Day -4 to Day -1\"}, {\"id\": \"binding_17\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_17\", \"expectedOccurrences\": 8, \"sourceText\": \"Daily balance_collection from Day 1 to Day 8\"}, {\"id\": \"binding_18\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_18\", \"expectedOccurrences\": 15, \"sourceText\": \"Daily balance_collection from Day 25 to Day 39\"}, {\"id\": \"binding_19\", \"activityId\": \"balance_collection\", \"activityName\": \"copper balance\", \"repetitionId\": \"rep_daily_bound_19\", \"expectedOccurrences\": 101, \"sourceText\": \"Daily balance_collection from Day 101 to Day 201\"}, {\"id\": \"binding_20\", \"activityId\": \"balance_collection\", \"activityName\": \"copper balance\", \"repetitionId\": \"rep_daily_bound_20\", \"expectedOccurrences\": 101, \"sourceText\": \"Daily balance_collection from Day 101 to Day 201\"}, {\"id\": \"binding_21\", \"activityId\": \"balance_collection\", \"activityName\": \"copper balance\", \"repetitionId\": \"rep_daily_bound_21\", \"expectedOccurrences\": 4, \"sourceText\": \"Daily balance_collection from Day -4 to Day -1\"}, {\"id\": \"binding_22\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_22\", \"expectedOccurrences\": 3, \"sourceText\": \"Daily balance_collection from Day -7 to Day -5\"}, {\"id\": \"binding_23\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_23\", \"expectedOccurrences\": 4, \"sourceText\": \"Daily balance_collection from Day -4 to Day -1\"}, {\"id\": \"binding_24\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_24\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily balance_collection from Day -8 to Day 9\"}, {\"id\": \"binding_25\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_25\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily balance_collection from Day 23 to Day 40\"}, {\"id\": \"binding_26\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_26\", \"expectedOccurrences\": 4, \"sourceText\": \"Daily balance_collection from Day -4 to Day -1\"}, {\"id\": \"binding_27\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_27\", \"expectedOccurrences\": 8, \"sourceText\": \"Daily balance_collection from Day 1 to Day 8\"}, {\"id\": \"binding_28\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_28\", \"expectedOccurrences\": 15, \"sourceText\": \"Daily balance_collection from Day 25 to Day 39\"}, {\"id\": \"binding_29\", \"activityId\": \"balance_collection\", \"activityName\": \"copper balance\", \"repetitionId\": \"rep_daily_bound_29\", \"expectedOccurrences\": 13, \"sourceText\": \"Daily balance_collection from Day 3 to Day 15\"}, {\"id\": \"binding_30\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_30\", \"expectedOccurrences\": 13, \"sourceText\": \"Daily balance_collection from Day 3 to Day 15\"}, {\"id\": \"binding_31\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_31\", \"expectedOccurrences\": 201, \"sourceText\": \"Daily balance_collection from Day 101 to Day 301\"}, {\"id\": \"binding_32\", \"activityId\": \"balance_collection\", \"activityName\": \"copper \\nbalance\", \"repetitionId\": \"rep_daily_bound_32\", \"expectedOccurrences\": 3, \"sourceText\": \"Daily balance_collection from Day 3 to Day 5\"}, {\"id\": \"binding_33\", \"activityId\": \"balance_collection\", \"activityName\": \"copper balance\", \"repetitionId\": \"rep_daily_bound_33\", \"expectedOccurrences\": 101, \"sourceText\": \"Daily balance_collection from Day 101 to Day 201\"}]"
              },
              {
                "id": "a6adad59-1c62-4d40-a5d8-a38882e3a25a",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-titrationSchedules",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"titration_1\", \"titrationType\": \"escalation\", \"doseLevels\": [{\"doseValue\": \"15 mg\", \"startDay\": 1, \"endDay\": 28, \"sourceText\": \"15 mg/day for approximately 28 days, followed by titration up to 30 mg\"}, {\"doseValue\": \"30 mg\", \"startDay\": 29, \"requiresPriorDose\": \"15 mg\", \"transitionRule\": \"After 28 days on 15 mg\", \"sourceText\": \"15 mg/day for approximately 28 days, followed by titration up to 30 mg\"}], \"interventionName\": \"ALXN1840 Treatment\", \"sourceText\": \"15 mg/day for approximately 28 days, followed by titration up to 30 mg\"}]"
              },
              {
                "id": "534bb78e-cbf7-4eaf-a164-331c1bba162e",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-analysisWindows",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"window_baseline_1\", \"windowType\": \"baseline\", \"name\": \"Baseline Period\", \"startDay\": 4, \"endDay\": -1, \"description\": \"Pre-treatment baseline from Day 4 to Day -1\", \"sourceText\": \"Baseline Day -4 through Day -1\"}]"
              },
              {
                "id": "d312d6be-ae5f-4846-9e1d-a6e7b112ff8a",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-integrityIssues",
                "instanceType": "ExtensionAttribute",
                "valueString": "[\"INTEGRITY: Repetition 'rep_window_2' has positive offset but source mentions negative day\", \"INTEGRITY: Repetition 'rep_window_3' has positive offset but source mentions negative day\", \"INTEGRITY: Repetition 'rep_window_17' has positive offset but source mentions negative day\", \"INTEGRITY: Repetition 'rep_window_22' has positive offset but source mentions negative day\"]"
              }
            ],
            "administrations": [
              {
                "id": "72689159-a820-4230-825c-9d4f8bc78e86",
                "name": "ALXN1840 Administration",
                "instanceType": "Administration",
                "dose": "30.0 mg / 15.0 mg",
                "doseFrequency": "QD",
                "route": {
                  "id": "ec5dac04-76df-435a-ab05-7378f9c4358b",
                  "code": "Oral",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Oral",
                  "instanceType": "Code"
                },
                "description": " \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nAdministration of Study \nInterventionm \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nALXN1840 15 mg/day \n \n \n \n \n \n \nX X \nX X X \nX \nX \nX X \nX \n \n \n \n \n \n \n \n \n"
              }
            ]
          }
        ],
        "titles": [
          {
            "id": "3efa4368-bacd-489e-a0d0-94a4a69737e8",
            "text": "A Phase 2, Open-label Study to Assess Copper and Molybdenum Balance in Participants with Wilson Disease Treated with ALXN1840",
            "type": {
              "id": "84c9c29f-deaf-457e-8fb4-6292122de02f",
              "code": "Official Study Title",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Official Study Title",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          },
          {
            "id": "ebaffdb2-f400-415e-8030-007ae0036a3c",
            "text": "Copper and Molybdenum Balance in Participants with Wilson Disease Treated with ALXN1840",
            "type": {
              "id": "e2dd890e-8809-4371-bd15-20a8450faf37",
              "code": "Brief Study Title",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Brief Study Title",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          }
        ],
        "studyIdentifiers": [
          {
            "id": "4c82a2ff-283a-487e-a241-11f0244ad33a",
            "text": "ALXN1840-WD-204",
            "instanceType": "StudyIdentifier",
            "scopeId": "e1ab2250-9f15-4f78-ab0f-c23cf6ccd8cc",
            "type": {
              "code": "C132351",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Sponsor Protocol Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "1c6be151-dd56-427c-abbc-053dbc283caf",
            "text": "2020-001104-41",
            "instanceType": "StudyIdentifier",
            "scopeId": "6148809d-ec5b-419b-b681-40b41676bf88",
            "type": {
              "code": "C98714",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Clinical Trial Registry Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "78f52c29-1e85-44ff-b498-faea0b70d82b",
            "text": "119006",
            "instanceType": "StudyIdentifier",
            "scopeId": "34af7836-ef13-4758-baf6-bdb221215878",
            "type": {
              "code": "C218685",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "US FDA Investigational New Drug Application Number",
              "instanceType": "Code"
            }
          },
          {
            "id": "290856fe-f2b1-4769-8e77-71917ba26777",
            "text": "NCT04573309",
            "instanceType": "StudyIdentifier",
            "scopeId": "cb607d3b-42b6-4666-bcba-793e7a7081d5",
            "type": {
              "code": "C172240",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Clinicaltrials.gov Identifier",
              "instanceType": "Code"
            }
          }
        ],
        "organizations": [
          {
            "id": "e1ab2250-9f15-4f78-ab0f-c23cf6ccd8cc",
            "name": "Alexion Pharmaceuticals, Inc.",
            "type": {
              "id": "909f1ac7-7a30-43d8-9df0-4403ebf1d3db",
              "code": "C54086",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Pharmaceutical Company",
              "instanceType": "Code"
            },
            "identifier": "Alexion Pharmaceuticals, Inc.",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "34af7836-ef13-4758-baf6-bdb221215878",
            "name": "US Food and Drug Administration (FDA)",
            "type": {
              "id": "4abc5c15-af41-4b3f-ad35-12258a8ebe6d",
              "code": "C25461",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Regulatory Agency",
              "instanceType": "Code"
            },
            "identifier": "US Food and Drug Administration (FDA)",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "cb607d3b-42b6-4666-bcba-793e7a7081d5",
            "name": "ClinicalTrials.gov",
            "type": {
              "id": "3acff75a-3534-469c-a8d5-3e936ea116f4",
              "code": "C19326",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Healthcare Facility",
              "instanceType": "Code"
            },
            "identifier": "ClinicalTrials.gov",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "6148809d-ec5b-419b-b681-40b41676bf88",
            "name": "EudraCT",
            "type": {
              "id": "f429a0d1-d9df-42a2-afdf-4ba2e932623b",
              "code": "C19326",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Healthcare Facility",
              "instanceType": "Code"
            },
            "identifier": "EudraCT",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          }
        ],
        "studyPhase": {
          "id": "f38d4d95-7dbb-48a7-bd37-1da69ba7bc23",
          "code": "Phase2",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Phase2",
          "instanceType": "Code"
        },
        "eligibilityCriterionItems": [
          {
            "id": "b2f51e24-c5c4-437a-966b-076c6607f1a5",
            "name": "Criterion 1",
            "text": "Participants aged ≥18 at the time of signing the ICF.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "f6370240-fc7e-4598-b558-480f6203a869",
            "name": "Criterion 2",
            "text": "Diagnosis of WD by Leipzig Criteria ≥ 4 documented by testing as outlined in the 2012 European Association for the Study of Liver WD Clinical Practice Guidelines (Ferenci, 2003; EASL, 2012) or by historical test results for WD including some or all of the following: \n• Presence of Kayser Fleischer rings, \n• Neurological symptoms, \n• Serum ceruloplasmin below reference range, \n• Coombs-negative hemolytic anemia, \n• Elevated liver or urinary copper, \n• Presence of mutations in the ATP7B gene, or \n• Other, as considered appropriate, may be used instead to confirm the diagnosis of WD.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "cbf829bd-51c0-47c0-9131-0831df348f77",
            "name": "Criterion 3",
            "text": "Participants who in the opinion of the referring Investigator may benefit from decoppering therapy.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "69e5535c-0bab-4ccd-8e4f-8524d9f14a9c",
            "name": "Criterion 4",
            "text": "Participants must be able to comply with all study-related procedures.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "ded41175-22f6-45e3-ba91-d57febdbc2cb",
            "name": "Criterion 5",
            "text": "Participants must be able to reside in the CRU for intensive metabolic monitoring of copper and molybdenum.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "440c7567-855a-421b-bdcb-1f3a6bf9538d",
            "name": "Criterion 6",
            "text": "Participants willing to discontinue chelator therapy for approximately 4 days prior to initiation of ALXN1840 to allow a baseline assessment of copper balance.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "9dbde838-c224-4c8a-814b-126ed2452a42",
            "name": "Criterion 7",
            "text": "Participants with adequate venous access to allow collection of required blood samples.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "ab378618-3130-499b-a756-55802f968bcb",
            "name": "Criterion 8",
            "text": "Participants must be able to swallow intact ALXN1840 tablets.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "0b8b19b8-f144-4c91-b3f8-8f7a68587499",
            "name": "Criterion 9",
            "text": "Participants willing to avoid use of minerals containing copper, zinc, or molybdenum throughout the study duration.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "774a063a-9612-4123-b3e7-eb9932ecea4a",
            "name": "Criterion 10",
            "text": "Participants willing to adhere to copper/molybdenum-controlled diet during inpatient periods and willing to comply with a low copper dietary requirement during the Outpatient Period.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "9a8e28af-0bf1-4a50-ab6d-1e4fc9314b89",
            "name": "Criterion 11",
            "text": "Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. \na. Male participants: \n• Male participants, if heterosexually active and with a female spouse or partner of childbearing potential or a pregnant or breastfeeding spouse or partner, must agree to use barrier contraception (male condom) for the duration of the study and for at least 3 months after the end of systemic exposure of the study intervention. Male participants must not donate sperm for at least 3 months after the end of systemic exposure of the study intervention. \n• Female spouses or partners of male participants who are of childbearing potential must use highly effective contraception as defined below and in Section 10.4, starting at least 1 menstrual cycle before (the male participant’s) first study intervention administration and continuing until at least 3 months after the end of their male partner’s systemic exposure to the study intervention. \n• Barrier contraception (male condom) is required even with documented medical assessment of surgical success of a vasectomy. For male participants who have had a vasectomy (with documented evidence of azoospermia if possible) and agree to use a male condom for the stated time period, no additional contraceptive method is required by their female partner. \nb. Female participants: \n• Female participants or female partners of male participants of childbearing potential (including breastfeeding females), if heterosexually active, must be willing to follow protocol-specified contraception guidance starting at least 1 menstrual cycle before first study intervention administration and continuing for at least 3 months after the end of systemic exposure of the study intervention. Female participants must not donate ova for at least 3 months after the end of systemic exposure of the study intervention. \n• Female participants who are documented as being of non-childbearing potential as defined in Section 10.4 are exempt from contraception requirements. \n• Highly effective contraceptive methods for female participants and female partners of male participants are described in Section 10.4.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "4faffc6f-373d-4d6f-9774-5247e53165e5",
            "name": "Criterion 12",
            "text": "Participants capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "62083091-f811-4e6a-a742-1d61e1b98f25",
            "name": "Criterion 13",
            "text": "Decompensated cirrhosis or model for end-stage liver disease (MELD) score > 13.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "aa39a194-c243-4c61-b50d-d93c08ddddc7",
            "name": "Criterion 14",
            "text": "Modified Nazer score > 7 (Dhawan, 2005).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "23e42a7e-f809-4eda-9147-69b9f1e4e1fc",
            "name": "Criterion 15",
            "text": "Clinically significant gastrointestinal bleed within past 3 months.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "945421b7-1a77-4505-9816-53492101b03e",
            "name": "Criterion 16",
            "text": "Alanine aminotransferase (ALT) > 2 × upper limit of normal (ULN).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "6fb6b934-18b2-4769-a692-dea40a2afc40",
            "name": "Criterion 17",
            "text": "Marked neurological disease requiring assistance with self-care or activities of daily life.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "41cd35ec-4225-4c61-9915-ff50f51b797d",
            "name": "Criterion 18",
            "text": "Hemoglobin less than lower limit of the reference range for age and sex.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "c91e82c7-d3d7-42bc-b7c1-cd7f053c9277",
            "name": "Criterion 19",
            "text": "Active infection with hepatitis B virus (positive hepatitis B surface antigen) or C virus (participants with positive hepatitis C antibody result would require confirmation of active disease with a positive hepatitis C polymerase chain reaction test), or seropositivity for human immunodeficiency virus (HIV).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "9cf8567c-4122-4c05-a60d-13d88dcbef45",
            "name": "Criterion 20",
            "text": "History or presence of/significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders, or psychiatric disorder that in the opinion of the Investigator may constitute a risk when taking the study intervention; or may interfere with the interpretation of data.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "1cb5fc17-def3-4ef2-ab9e-582aec2955b9",
            "name": "Criterion 21",
            "text": "Previous treatment with ALXN1840 or other form of tetrathiomolybdate within 1 year prior to dosing.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "256dd8bd-4423-4329-b1c9-3dd38bc1feae",
            "name": "Criterion 22",
            "text": "Previous treatment with zinc within 21 days prior to Day 1.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "b0ca9344-0fd5-480d-95e5-8d2aa3d2479d",
            "name": "Criterion 23",
            "text": "The use of an experimental or unapproved/unlicensed therapy at the same time or within 90 days or 5 half-lives, whichever is longer, prior to the Screening Visit.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "618db30e-99f4-4484-855c-39d5ce049952",
            "name": "Criterion 24",
            "text": "Participants in renal failure, defined as in end-stage renal disease on dialysis (chronic kidney disease [CKD] stage 5) or creatinine clearance < 30 mL/min (Levey, 2006).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "17ba90f4-0565-48f0-8921-90b5ed7acc33",
            "name": "Criterion 25",
            "text": "Pregnant (or females who are planning to become pregnant) or breastfeeding females (women of childbearing potential must have a negative serum pregnancy test result at screening).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "1507e990-0e9f-4ae9-b57e-cffa6bb67c77",
            "name": "Criterion 26",
            "text": "Known sensitivity to ALXN1840, ALXN1840 excipients (anhydrous dicalcium phosphate, anhydrous sodium carbonate), or any of the ingredients contained in ALXN1840 or related compounds.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "ac4cff5a-203d-441a-ba87-11d54423c1bf",
            "name": "Criterion 27",
            "text": "In the opinion of the Investigator, the participant and/or their legal guardian is likely to be non-compliant or uncooperative during the study.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "6b3df426-b921-4f89-bb50-4dd561b22b2a",
            "name": "Criterion 28",
            "text": "History of illicit drug abuse, history of significant alcohol abuse within 1 year prior to the Screening Visit, or clinical evidence of substance and/or alcohol abuse within the 2 years before screening. Alcohol abuse is defined as regular weekly intake of more than 14 units (for both males and females), using the following National Health Service (NHS) alcohol tracker http://www.nhs.uk/Tools/Pages/drinks-tracker.aspx.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "924fffb5-b930-4247-93f5-7b034ab673d6",
            "name": "Criterion 29",
            "text": "Positive urine drug toxicology screen at Screening or on Day -8 (cannabinoids will not be tested).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "5c286157-4859-4896-a5d7-4c14ca25604b",
            "name": "Criterion 30",
            "text": "Alcohol consumption within 48 hours prior to study intervention administration or positive alcohol breath test at screening or on Day -8.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "67fa510a-f42c-4307-bf82-df8377cc6484",
            "name": "Criterion 31",
            "text": "Participants unwilling to consistently complete every meal and tolerate a controlled, limited menu for the duration of the study.",
            "instanceType": "EligibilityCriterionItem"
          }
        ],
        "studyInterventions": [
          {
            "id": "316f2e1e-7429-4973-86aa-2f0ea9c9c5a4",
            "name": "ALXN1840",
            "type": {
              "id": "a55e99ad-3c09-4565-911a-5797ca0081bb",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "role": {
              "id": "222919f6-e705-4072-9207-20283bc7249b",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "ALXN1840 (bis-choline tetrathiomolybdate; formerly known as WTX101) is a novel copper binding agent in development for the treatment of Wilson disease (WD).",
            "productIds": [
              "913fcc9c-ff68-4db4-ade6-3d0710f2f463"
            ],
            "administrationIds": [
              "623acfcc-b288-4918-a0ac-17fc01900c3d"
            ]
          },
          {
            "id": "c4ec2bf6-4840-4394-8cc2-5e37edd9ec22",
            "name": "Paracetamol/acetaminophen",
            "type": {
              "id": "5be197dd-bb1f-4bfd-9581-9d420b3dce7f",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "48bd795c-3b99-4ce9-a054-840a10ff0494",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Permitted for use as an exception with the approval of the Investigator at doses of a maximum 1000 mg per day.",
            "administrationIds": [
              "fa338b69-bfa9-407c-96d1-2e6ce5bc16c1"
            ]
          },
          {
            "id": "5477f5b7-61ce-4879-93e2-ad2cac942d3b",
            "name": "Ibuprofen",
            "type": {
              "id": "a24219f3-80d0-48b9-abe1-57f814019ff1",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "ac50ef05-48af-4312-86a3-35215c446973",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Permitted for use with caution and approval of the Investigator. The dose must not exceed 1200 mg in any 24-hour period.",
            "administrationIds": [
              "d1c4ddf2-ee44-4297-b16b-5a6360a6f3b3"
            ]
          }
        ],
        "administrableProducts": [
          {
            "id": "913fcc9c-ff68-4db4-ade6-3d0710f2f463",
            "name": "ALXN1840",
            "administrableDoseForm": {
              "id": "e37581b8-ac9f-4dcf-9df9-11d3557ab57e",
              "code": "C42998",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Tablet",
              "instanceType": "Code"
            },
            "productDesignation": {
              "id": "b410fde7-c81a-4f4c-961f-9a2f77942f59",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "15 mg",
            "substanceIds": [
              "c14e6332-5682-4e3a-a1cb-acdeef610a88"
            ],
            "manufacturer": "Alexion"
          }
        ],
        "narrativeContentItems": [
          {
            "id": "67130e0e-0714-4e18-b005-24121158359d",
            "name": "PROTOCOL SUMMARY",
            "text": "PROTOCOL SUMMARY",
            "order": 0,
            "instanceType": "NarrativeContent",
            "sectionNumber": "1",
            "sectionTitle": "PROTOCOL SUMMARY",
            "sectionType": {
              "id": "990fad3b-4e67-4709-8078-1063701bd864",
              "code": "Synopsis",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Synopsis",
              "instanceType": "Code"
            },
            "childIds": [
              "67680731-2a44-4d61-ace9-41f3a6696248",
              "41b17165-dce2-4e02-a234-8ce90f90e78e",
              "33414d3a-4e31-4b4e-86ed-3d67d268313a"
            ]
          },
          {
            "id": "2f70b733-0516-40a0-b5ed-e2669d51653b",
            "name": "INTRODUCTION",
            "text": "INTRODUCTION",
            "order": 1,
            "instanceType": "NarrativeContent",
            "sectionNumber": "2",
            "sectionTitle": "INTRODUCTION",
            "sectionType": {
              "id": "4a264075-6338-4e26-b7ab-6e96a409b869",
              "code": "Introduction",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Introduction",
              "instanceType": "Code"
            },
            "childIds": [
              "0ebb6da2-d7e5-477c-8110-aa072ce26f2f",
              "04e423df-5113-44d3-a2eb-fd0b8938ef46",
              "9c5f61b0-fbaf-4de0-accc-ed6950347bbe"
            ]
          },
          {
            "id": "438e3b07-3a17-4255-bc2a-5b11c09e1f20",
            "name": "OBJECTIVES AND ENDPOINTS",
            "text": "OBJECTIVES AND ENDPOINTS",
            "order": 2,
            "instanceType": "NarrativeContent",
            "sectionNumber": "3",
            "sectionTitle": "OBJECTIVES AND ENDPOINTS",
            "sectionType": {
              "id": "8021fd2a-1716-486f-923e-cf095d9dbb44",
              "code": "Objectives",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Objectives",
              "instanceType": "Code"
            }
          },
          {
            "id": "eb36b8c1-c0fa-4d2a-9795-78095906bfa1",
            "name": "STUDY DESIGN",
            "text": "STUDY DESIGN",
            "order": 3,
            "instanceType": "NarrativeContent",
            "sectionNumber": "4",
            "sectionTitle": "STUDY DESIGN",
            "sectionType": {
              "id": "9a15f3b9-bee6-404f-a2a1-c9327576b6f4",
              "code": "Study Design",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Design",
              "instanceType": "Code"
            },
            "childIds": [
              "284f4b69-19e1-4213-823a-ea8126410212",
              "78d81b39-b2c5-4c17-854b-58ba4110b12a",
              "5f47fac4-5e14-48ae-b37b-f1aa0919946f",
              "b3812905-74af-4972-847a-490245aafb66"
            ]
          },
          {
            "id": "c5f32d44-51f3-4e6c-8b8b-e85317c70ab4",
            "name": "STUDY POPULATION",
            "text": "STUDY POPULATION",
            "order": 4,
            "instanceType": "NarrativeContent",
            "sectionNumber": "5",
            "sectionTitle": "STUDY POPULATION",
            "sectionType": {
              "id": "e30a6558-9746-47fb-bc4c-7835941ec1a6",
              "code": "Study Population",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Population",
              "instanceType": "Code"
            },
            "childIds": [
              "ea5b0497-f2aa-460b-b72e-533c6b24f989",
              "8ba5ed35-ff2a-496d-a96f-77b9dff3b5e1",
              "f8b4f5a1-bd13-4a42-a5aa-8003f03c84d6",
              "6be33a99-6f0a-4edd-abc5-ab8b073757e8"
            ]
          },
          {
            "id": "c1068cad-be77-440c-a235-473898f929a6",
            "name": "STUDY INTERVENTION",
            "text": "STUDY INTERVENTION",
            "order": 5,
            "instanceType": "NarrativeContent",
            "sectionNumber": "6",
            "sectionTitle": "STUDY INTERVENTION",
            "sectionType": {
              "id": "25b3f815-b439-4da0-a431-5dbeac34f43b",
              "code": "Treatment",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Treatment",
              "instanceType": "Code"
            }
          },
          {
            "id": "6d03b2d4-e692-4554-982c-77941f14f220",
            "name": "[TITLE NOT PROVIDED]",
            "text": "[TITLE NOT PROVIDED]",
            "order": 6,
            "instanceType": "NarrativeContent",
            "sectionNumber": "10",
            "sectionTitle": "[TITLE NOT PROVIDED]",
            "sectionType": {
              "id": "6bdb61b3-f065-4b27-a211-c8aa2300c8de",
              "code": "Other",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Other",
              "instanceType": "Code"
            },
            "childIds": [
              "72afdedc-8162-412e-959c-98022f3b3d69",
              "c06fc388-ba3c-40fb-a644-15998602b037",
              "4ef32ce0-3f6c-49b8-8fee-1faa9a0bba63",
              "65b01d8b-b63a-4c4f-8249-b40f425dfa3b",
              "2a3143c2-dc71-4aac-9792-b2901ad3de4b",
              "008f2f7d-61cf-4493-9a40-b78969ffb909",
              "646d33d7-36da-41d3-a79b-ce48e241653f"
            ]
          },
          {
            "id": "aeb3a0c8-ee81-4de7-abf6-dfecc896cb23",
            "name": "REFERENCES",
            "text": "REFERENCES",
            "order": 7,
            "instanceType": "NarrativeContent",
            "sectionNumber": "11",
            "sectionTitle": "REFERENCES",
            "sectionType": {
              "id": "6178acf2-c3d8-4011-9ff5-c1109dea884c",
              "code": "References",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "References",
              "instanceType": "Code"
            }
          }
        ],
        "abbreviations": [
          {
            "id": "7e4b7419-f406-4e36-bdab-f0d07b9ad673",
            "abbreviatedText": "SoA",
            "expandedText": "Schedule of Activities",
            "instanceType": "Abbreviation"
          },
          {
            "id": "ad944ede-0fd5-43cb-b68c-02b05f557254",
            "abbreviatedText": "AE",
            "expandedText": "Adverse Event",
            "instanceType": "Abbreviation"
          },
          {
            "id": "995ada0f-dea3-4bb6-ac4f-4858041a0325",
            "abbreviatedText": "SAE",
            "expandedText": "Serious Adverse Event",
            "instanceType": "Abbreviation"
          },
          {
            "id": "6501f25a-8284-4dbf-b2ea-6cdc234c268f",
            "abbreviatedText": "COVID-19",
            "expandedText": "Coronavirus Disease 2019",
            "instanceType": "Abbreviation"
          },
          {
            "id": "a7364fe8-5db9-41af-82b7-c21322373a61",
            "abbreviatedText": "WD",
            "expandedText": "Wilson disease",
            "instanceType": "Abbreviation"
          },
          {
            "id": "8c67d0d5-793c-4d3c-902e-6eb1ba134169",
            "abbreviatedText": "ADME",
            "expandedText": "absorption, distribution, metabolism, and excretion",
            "instanceType": "Abbreviation"
          },
          {
            "id": "12b13c5b-70f1-4d43-a92b-bd47380ddb55",
            "abbreviatedText": "NCC",
            "expandedText": "non-ceruloplasmin-bound copper",
            "instanceType": "Abbreviation"
          },
          {
            "id": "2327ccab-4b1b-4934-b4b9-2ebc3e304862",
            "abbreviatedText": "NCCcorrected",
            "expandedText": "non-ceruloplasmin-bound copper (NCC) corrected",
            "instanceType": "Abbreviation"
          },
          {
            "id": "2f868349-8c05-4447-baa4-ae0a9733e9f5",
            "abbreviatedText": "TPC",
            "expandedText": "tetrathiomolybdate- copper -albumin tripartite complex",
            "instanceType": "Abbreviation"
          },
          {
            "id": "aad0497c-356d-4e5a-8e82-0b582fbe95fb",
            "abbreviatedText": "PK",
            "expandedText": "pharmacokinetics",
            "instanceType": "Abbreviation"
          }
        ],
        "amendments": [
          {
            "id": "d187ce7d-bfb8-43c4-9e65-ce3671df02af",
            "number": "3.1 (US)",
            "name": "Amendment 3.1 (US)",
            "scope": {
              "id": "a5d1c9b1-971f-4538-b0e6-53196737d855",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "76cb77f1-8bf6-4182-958d-9c5421ebc5f8",
              "code": {
                "id": "8f84ada9-33c5-4f79-b767-f7e17bbd297f",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "155c96a6-e686-405c-bfe5-447df2285f44",
                "type": {
                  "id": "17f66dc9-4917-4930-b109-9baef3b59dcc",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "The main reason for preparation of this amendment was to clarify study procedures occurring across different sites in the US, so as to facilitate participant recruitment across different regions of the US, and to lessen inconvenience for participants without compromising the quality of the study.",
            "effectiveDate": "2022-03-18",
            "reasonIds": [
              "0edb1b13-24a3-4f00-b2ee-a2ca1db520ce",
              "bdeaf76f-0dc9-4651-95d1-b2ec3d35e559"
            ],
            "previousVersion": "3",
            "newVersion": "3.1 (US)"
          },
          {
            "id": "4efcef14-a2cb-4d01-894b-a7ac2c4ebc85",
            "number": "3",
            "name": "Amendment 3",
            "scope": {
              "id": "889dc734-6c17-4c6a-a47c-d98a6c5dcf44",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "504d6d7c-10c3-4a69-a07b-bc3842751266",
              "code": {
                "id": "eeae39b5-afc0-4a55-9268-09592926e5e6",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "0f3af070-e1e6-4c25-abad-f586a863967a",
                "type": {
                  "id": "b9ba3836-15cc-4871-bf2f-ca1453f1ab36",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "The main reason for preparation of this amendment was to update the washout period for zinc.",
            "effectiveDate": "2021-08-31",
            "reasonIds": [
              "97f5480d-9956-4a50-9021-99d6109188a3",
              "f2525e11-e272-42b9-91be-10c50e48b1b2"
            ],
            "previousVersion": "2",
            "newVersion": "3"
          },
          {
            "id": "c690b4e6-9a16-4fcf-95b6-8eb9f19763a1",
            "number": "2",
            "name": "Amendment 2",
            "scope": {
              "id": "b60849be-bdec-4bb8-9f35-99d1271e73c4",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "ee741eb0-aa4c-4eb1-ac50-ca7eeaf26636",
              "code": {
                "id": "0379ca1a-da10-43f4-951b-7da1c34681d6",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "006b005a-ac34-4e2a-9153-fbee1f806812",
                "type": {
                  "id": "e7864db5-2a82-4dca-933c-7d7b22cced92",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "The main reason for preparation of this amendment was to revise the exclusion criterion for a urine drug screen. Changes implemented via Administrative Letter 1 and Administrative Letter 2, as well as COVID vaccination guidance, have also been incorporated.",
            "effectiveDate": "2021-03-19",
            "reasonIds": [
              "7201812f-c9b2-44cb-8910-03b7c533512f",
              "43c08a1e-5dd9-423a-a341-27ae5f23561f",
              "d179f896-be74-459e-811f-96751e794e09",
              "ffee263b-27f2-4dcf-8aa9-a1ed7ad47c45"
            ],
            "previousVersion": "1",
            "newVersion": "2"
          },
          {
            "id": "592b5d7f-f3df-4521-99b8-a187319cde24",
            "number": "1",
            "name": "Amendment 1",
            "scope": {
              "id": "1712750d-9f43-4a8a-bc44-9ed7264753d6",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "32f62c7f-fb5c-4a00-ac15-4ee65f4dbe5c",
              "code": {
                "id": "ef744896-c1b7-4273-91bf-ee1f8edc3c06",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "a660a4dc-d31d-4b73-8c09-9750229cb1f2",
                "type": {
                  "id": "d83bb6a8-e144-4db3-b9fc-7feaa83882a1",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "The main reason for preparation of this amendment was to update procedures outlined in the Schedule of Activities, remove contradictory text on the reporting of serious adverse events, and add details of an interim analysis.",
            "effectiveDate": "2020-08-18",
            "reasonIds": [
              "b6f54a85-49de-4551-aecd-34572e7eb4c3",
              "dfe8450a-32a7-4f84-b88e-f72c5a8243b6",
              "758400b9-9b28-47ca-b3e8-324f9eb1a032",
              "08af0b29-df95-42a2-9315-056e1424674e"
            ],
            "previousVersion": "Original Protocol",
            "newVersion": "1"
          }
        ],
        "medicalDevices": [
          {
            "id": "4cdac778-107a-4b6c-8ec0-a3e54657c816",
            "name": "Venous Cannula",
            "instanceType": "MedicalDevice",
            "label": "Cannula",
            "description": "A cannula placed in a vein to allow for repeated blood sampling with minimal needle sticks.",
            "deviceType": {
              "id": "4ec3d295-43c0-4798-a03b-64e4587975a4",
              "code": "Drug Delivery Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Drug Delivery Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "d363b386-825f-412f-a644-391a7e64a7ff",
            "name": "12-lead ECG Machine",
            "instanceType": "MedicalDevice",
            "label": "ECG Machine",
            "description": "Device used to perform triplicate 12-lead electrocardiograms.",
            "deviceType": {
              "id": "f9b3029a-4429-4671-a87b-525b9eb20887",
              "code": "Diagnostic Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Diagnostic Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "495ae948-50fa-4029-9d54-dcb335efc2da",
            "name": "Automated Blood Pressure Monitor",
            "instanceType": "MedicalDevice",
            "label": "Automated BP Monitor",
            "description": "A completely automated device for assessing blood pressure and heart rate.",
            "deviceType": {
              "id": "ca602eb1-667c-4151-8028-75ab9ec00883",
              "code": "Monitoring Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Monitoring Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "d7816ce8-302b-4504-9448-dad67279dea3",
            "name": "Inductively Coupled Plasma Mass Spectrometer",
            "instanceType": "MedicalDevice",
            "label": "ICP-MS",
            "description": "Laboratory equipment used to determine the copper and molybdenum concentration of food, fluid, urine, and fecal samples.",
            "deviceType": {
              "id": "de5f366a-af34-401c-bed7-e44a52706785",
              "code": "Diagnostic Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Diagnostic Device",
              "instanceType": "Code"
            }
          }
        ],
        "conditions": [
          {
            "id": "67598c8b-96ab-45fe-9e60-c03166126109",
            "name": "Moderate ALT Elevation",
            "instanceType": "Condition",
            "description": "ALT is greater than 3 times and less than or equal to 5 times the upper limit of normal.",
            "text": "ALT > 3 × ULN and ≤ 5 × ULN"
          },
          {
            "id": "5718a5ea-027c-4f3b-99cb-0e35d5d7ba9a",
            "name": "High ALT Elevation",
            "instanceType": "Condition",
            "description": "ALT is greater than 5 times the upper limit of normal.",
            "text": "ALT > 5 × ULN"
          },
          {
            "id": "a1ec30e7-3e26-4321-a973-508081fa58aa",
            "name": "Thrombocytopenia",
            "instanceType": "Condition",
            "description": "Platelet count is less than 100,000 per cubic millimeter.",
            "text": "Platelets < 100,000/mm3"
          },
          {
            "id": "b26df061-24f9-421a-98e6-8207611dac0f",
            "name": "Anemia",
            "instanceType": "Condition",
            "description": "Hemoglobin is less than 10 grams per deciliter.",
            "text": "Hemoglobin < 10 g/dL"
          },
          {
            "id": "4514bc42-0949-4482-9043-f2b1f2e8c803",
            "name": "Neutropenia",
            "instanceType": "Condition",
            "description": "Neutrophil count decreases by more than 30% from baseline and is below the reference range.",
            "text": "> 30% ↓ from baseline Neutrophils below reference range at baseline"
          },
          {
            "id": "26b22854-47f1-4d91-bc34-8b8210eaf6b8",
            "name": "Potential Liver Injury (Hy's Law)",
            "instanceType": "Condition",
            "description": "Bilirubin is greater than 2 times ULN accompanied by ALT greater than 3 times ULN.",
            "text": "Bilirubin > 2 × ULN Accompanied by ALT > 3 × ULN, indicative of liver injury"
          },
          {
            "id": "35baffbb-79a0-4bc9-837d-2a4896d3b9eb",
            "name": "Neurologic Worsening",
            "instanceType": "Condition",
            "description": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment.",
            "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment"
          },
          {
            "id": "2cbb5b06-3dac-406e-8211-18978559abf5",
            "name": "Psychiatric Worsening",
            "instanceType": "Condition",
            "description": "Evidence of clinically significant acute psychiatric worsening.",
            "text": "Evidence of clinically significant acute psychiatric worsening which may include but not limited to suicidality, acute depression, or psychosis."
          },
          {
            "id": "09d1ac31-b17c-48ff-bf03-a0d6e99930b2",
            "name": "Serious Hypersensitivity Reaction",
            "instanceType": "Condition",
            "description": "Occurrence of a serious hypersensitivity reaction.",
            "text": "Serious hypersensitivity reaction"
          },
          {
            "id": "db47a491-f374-4857-a0e4-4720f01bd599",
            "name": "Severe Uncontrolled Infection",
            "instanceType": "Condition",
            "description": "Occurrence of a severe uncontrolled infection.",
            "text": "Severe uncontrolled infection"
          },
          {
            "id": "63d27f7f-8a9b-49c5-99e7-f7a2b9f37734",
            "name": "Use of Disallowed Medication",
            "instanceType": "Condition",
            "description": "Participant uses a disallowed medication.",
            "text": "Use of disallowed medication"
          },
          {
            "id": "8715c6d7-07cb-4948-be87-8a9d29b656ce",
            "name": "Pregnancy",
            "instanceType": "Condition",
            "description": "Participant becomes pregnant or plans to become pregnant.",
            "text": "Pregnancy or planned pregnancy"
          },
          {
            "id": "6f2bf85d-676f-47fe-a5b0-e1e5bdbb2340",
            "name": "Acceptable Safety for Titration",
            "instanceType": "Condition",
            "description": "Safety data through Day 23 is reviewed by the SRC and deemed acceptable for dose titration.",
            "text": "Before titration to 30 mg/day, the Safety Review Committee (SRC) will review available safety data through Day 23 for each participant."
          }
        ],
        "rationale": "Protocol version"
      }
    ],
    "name": "A Phase 2, Open-label Study to Assess Copper and Molybdenum Balance in Participants with Wilson Disease Treated with ALXN1840"
  },
  "administrations": [
    {
      "id": "623acfcc-b288-4918-a0ac-17fc01900c3d",
      "name": "ALXN1840 initial dose",
      "instanceType": "Administration",
      "dose": "15 mg",
      "doseFrequency": "once daily",
      "route": {
        "id": "1ef97a8d-4d60-4f7f-877c-d0bf92cfbe17",
        "code": "Oral",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Oral",
        "instanceType": "Code"
      },
      "duration": "Approximately 28 days (Day 1 through Day 28)"
    },
    {
      "id": "fa338b69-bfa9-407c-96d1-2e6ce5bc16c1",
      "name": "ALXN1840 titrated dose",
      "instanceType": "Administration",
      "dose": "30 mg",
      "doseFrequency": "once daily",
      "route": {
        "id": "3da962d1-1a9c-4387-84da-a001340facd8",
        "code": "Oral",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Oral",
        "instanceType": "Code"
      },
      "duration": "From Day 29 through Day 39"
    },
    {
      "id": "d1c4ddf2-ee44-4297-b16b-5a6360a6f3b3",
      "name": "ALXN1840 dose reduction",
      "instanceType": "Administration",
      "dose": "15 mg",
      "doseFrequency": "every other day",
      "route": {
        "id": "07100d91-c6ce-411f-a8c2-1153ee98f8f6",
        "code": "Oral",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Oral",
        "instanceType": "Code"
      },
      "duration": "Dose modification for specific adverse events until resolution of abnormality."
    }
  ],
  "substances": [
    {
      "id": "c14e6332-5682-4e3a-a1cb-acdeef610a88",
      "name": "bis-choline tetrathiomolybdate",
      "instanceType": "Substance",
      "description": "Active ingredient of ALXN1840. Also referred to as WTX101."
    },
    {
      "id": "a1c8f35b-05b3-4c0d-8522-e369212055a1",
      "name": "tetrathiomolybdic acid",
      "instanceType": "Substance",
      "description": "Each 15 mg ALXN1840 tablet contains 7.8 mg of tetrathiomolybdic acid."
    }
  ],
  "studyDefinitionDocument": {
    "id": "ad9e4e94-2ee0-4e1a-b470-63e089ae9f9e",
    "name": "A Phase 2, Open-label Study to Assess Copper and Molybdenum Balance in Participants with Wilson Disease Treated with ALXN1840",
    "documentType": "Protocol",
    "language": "en",
    "instanceType": "StudyDefinitionDocument",
    "version": "3.1",
    "versionDate": "2022-03-18",
    "contentIds": [
      "67130e0e-0714-4e18-b005-24121158359d",
      "2f70b733-0516-40a0-b5ed-e2669d51653b",
      "438e3b07-3a17-4255-bc2a-5b11c09e1f20",
      "eb36b8c1-c0fa-4d2a-9795-78095906bfa1",
      "c5f32d44-51f3-4e6c-8b8b-e85317c70ab4",
      "c1068cad-be77-440c-a235-473898f929a6",
      "6d03b2d4-e692-4554-982c-77941f14f220",
      "aeb3a0c8-ee81-4de7-abf6-dfecc896cb23"
    ]
  },
  "geographicScope": {
    "id": "b443cd77-a19e-443d-a3a7-6df97a04b9b7",
    "name": "Study Geographic Scope",
    "scopeType": "Multinational",
    "instanceType": "GeographicScope",
    "countryIds": [
      "106df28d-9412-42d5-8047-084a76cd570b"
    ],
    "regions": [
      "North America",
      "Europe"
    ]
  },
  "countries": [
    {
      "id": "106df28d-9412-42d5-8047-084a76cd570b",
      "name": "United States",
      "instanceType": "Country",
      "code": "US"
    }
  ],
  "ingredients": [
    {
      "id": "afa08cb5-dee0-459f-b37b-6eea38638914",
      "name": "bis-choline tetrathiomolybdate",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "0d9509e9-fbc0-4e05-8a57-a596a9eb9c53"
    },
    {
      "id": "4bc01e56-b1d4-4447-9945-06fa54aa9f65",
      "name": "Acetaminophen",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "6033de3b-3327-4ccc-8025-247c40e40964"
    },
    {
      "id": "c7952267-b34d-452b-b02e-1bd04a9a94f8",
      "name": "Ibuprofen",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "f6c3c8c5-362c-4851-8918-a261da2539c0"
    }
  ],
  "strengths": [
    {
      "id": "06d96cba-7c59-4d89-beb5-1e87e07a0224",
      "instanceType": "Strength",
      "value": 15,
      "unit": "mg",
      "numerator": {
        "value": 15,
        "unit": "mg"
      },
      "denominator": {
        "value": 1,
        "unit": "tablet"
      }
    },
    {
      "id": "a9e30f6b-4730-4ca6-8303-6c8f487344e7",
      "instanceType": "Strength",
      "value": 30,
      "unit": "mg",
      "numerator": {
        "value": 30,
        "unit": "mg"
      },
      "denominator": {
        "value": 1,
        "unit": "tablet"
      }
    },
    {
      "id": "bb10fcfe-a2e3-4b0e-b99f-8bbaffcaf11e",
      "instanceType": "Strength",
      "value": 1000,
      "unit": "mg",
      "numerator": {
        "value": 1000,
        "unit": "mg"
      },
      "denominator": {
        "value": 1,
        "unit": "day"
      }
    },
    {
      "id": "98fe4cd9-8b08-4093-a854-cb5bae200447",
      "instanceType": "Strength",
      "value": 1200,
      "unit": "mg",
      "numerator": {
        "value": 1200,
        "unit": "mg"
      },
      "denominator": {
        "value": 24,
        "unit": "hour"
      }
    }
  ],
  "transitionRules": [
    {
      "id": "7865b9af-6833-42a5-ba8c-6551401278bf",
      "name": "Dose Titration to 30mg",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "fromElementId": "e0e3a0b7-4556-4839-b7fd-b84d12442c0d",
      "toElementId": "f95ff557-7b94-4b02-9f0d-2a4e0eb2ca9f",
      "text": "Following the Run-in Period, participants will be administered ALXN1840 at 15 mg/day for a treatment period of approximately 28 days followed by titration up to 30 mg/day on Day 29."
    },
    {
      "id": "2471cd66-b4c8-42ca-9d16-e92a205bac9b",
      "name": "Dose Reduction or Interruption",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "The dose should be decreased or interrupted if any of the relevant Dose Modification Criteria are met."
    },
    {
      "id": "92314e17-6a85-43e5-965f-a8a9b98e5048",
      "name": "Discontinuation for Safety or Other Reasons",
      "instanceType": "TransitionRule",
      "transitionType": "Discontinuation",
      "text": "Participants must be considered for discontinuation from study intervention if any of the following occur during the study: Serious hypersensitivity reaction; Severe uncontrolled infection; Use of disallowed medication; Pregnancy or planned pregnancy; or Alexion or the Investigator deems it is necessary for the participant."
    },
    {
      "id": "0be13707-17d8-4bf5-aabc-834025523d87",
      "name": "Rechallenge After Dose Modification",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "A maximum of 3 rechallenges will be allowed."
    },
    {
      "id": "9f6b3166-013f-40d1-a6bb-76535331c223",
      "name": "Remain on 15mg Dose",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "participants may remain on the 15 mg/day dose for the duration of the study [if there are safety concerns]."
    }
  ],
  "documentContentReferences": [
    {
      "id": "9a6bd902-7e52-4da5-86c4-3f2a00e95919",
      "name": "SoA Reference in Amendment Summary",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "1.3",
      "sectionTitle": "Schedule of Activities (SoA)",
      "description": "Reference from the Amendment Summary of Changes table to Table 1 in the Schedule of Activities."
    },
    {
      "id": "8de4fc0c-5023-4463-9039-d17dab1afe85",
      "name": "Screening Procedures Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "8",
      "sectionTitle": "Study Assessments and Procedures",
      "description": "Reference from the Amendment Summary of Changes table to Section 8 for details on procedures at US screening sites."
    },
    {
      "id": "38870667-22bd-40e6-abfb-7a3b2ddbd47b",
      "name": "COVID-19 Vaccine Risk Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "10.5",
      "sectionTitle": "COVID-19 Vaccine Risk Assessment",
      "description": "Reference from Section 2.3.1.1 to Section 10.5 for potential risks and mitigation measures due to COVID-19 vaccine."
    },
    {
      "id": "67372ee0-fabf-41d9-87fe-3cb2f9de03df",
      "name": "Dose Modification for Risk Mitigation",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "6.6",
      "sectionTitle": "Dose Modification",
      "description": "Reference from Table 3 to Section 6.6 for dose modification or discontinuation as a risk mitigation strategy."
    },
    {
      "id": "cecb4ba0-e417-4acf-bc44-1641061227ca",
      "name": "Investigator's Brochure Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "N/A",
      "sectionTitle": "Investigator's Brochure",
      "description": "Reference from Table 3 to the Investigator's Brochure (IB) for data supporting risk assessment."
    },
    {
      "id": "169f37fa-20bd-4dc0-9933-3ae66c92f95b",
      "name": "Adaptive Design Features Table",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Table 4",
      "sectionTitle": "Adaptive Protocol Features",
      "description": "Reference from Section 4.1 to Table 4, which describes adaptive design features."
    },
    {
      "id": "c398e14e-8cd9-4cae-87bd-f3c77144b25f",
      "name": "Dose Modification Criteria Table",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Table 7",
      "sectionTitle": "ALXN1840 Dose Modifications for Individual Participants",
      "description": "Reference from Table 4 to Table 7 for dose modification criteria."
    },
    {
      "id": "e6f026d6-4e5f-45c8-b890-46d962a36e74",
      "name": "Exclusion Criteria for Blood Donation",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "5.2",
      "sectionTitle": "Exclusion Criteria",
      "description": "Reference from Table 5 (Lifestyle Considerations) to Section 5.2 regarding blood donation restrictions."
    },
    {
      "id": "b0768f4c-b2a9-4767-8043-ae27b037a72c",
      "name": "Contraceptive Guidance Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "10.4",
      "sectionTitle": "Contraceptive Guidance and Collection of Pregnancy Information",
      "description": "Reference from Table 5 (Lifestyle Considerations) to Section 10.4 for details on appropriate contraceptive methods."
    },
    {
      "id": "7f3146c2-4cdc-4a3a-bb77-d64e9e53aa2b",
      "name": "Inclusion Criteria for Contraception",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "5.1",
      "sectionTitle": "Inclusion Criteria",
      "description": "Reference from Table 5 (Lifestyle Considerations) to Section 5.1 for contraception start time requirements."
    },
    {
      "id": "4064a318-1205-41e5-a7e9-21b5ec7ff662",
      "name": "SoA for Intervention Discontinuation",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "1.3",
      "sectionTitle": "Schedule of Activities (SoA)",
      "description": "Reference from Section 7.1 to the SoA for data collection procedures upon discontinuation of study intervention."
    },
    {
      "id": "7f93374f-c0bd-44fd-bb56-51b785e4f91f",
      "name": "Dose Modification for Discontinuation",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "6.6",
      "sectionTitle": "Dose Modification",
      "description": "Reference from Section 7.1 to dose modification criteria for discontinuing intervention due to abnormal liver function."
    },
    {
      "id": "9b92030b-4ff3-4409-a6fe-fcfb64e68901",
      "name": "Pregnancy Discontinuation Criteria",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "8.2.6",
      "sectionTitle": "Pregnancy",
      "description": "Reference from Section 7.1 to the pregnancy section as a reason for study intervention discontinuation."
    },
    {
      "id": "e1fc2651-de04-4855-80a2-c48d4e8b2253",
      "name": "SoA for Participant Withdrawal",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "1.3",
      "sectionTitle": "Schedule of Activities (SoA)",
      "description": "Reference from Section 7.2 to the SoA for procedures upon participant withdrawal from the study."
    },
    {
      "id": "553aca30-ecae-418f-b13b-ae77356c55c2",
      "name": "QTc Withdrawal Criteria",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "7",
      "sectionTitle": "DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL",
      "description": "Reference from Section 8.2.3 to Section 7 for QTc withdrawal criteria."
    },
    {
      "id": "9184d494-6891-49de-b635-e3a97f125283",
      "name": "Clinical Laboratory Tests List",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "10.2",
      "sectionTitle": "Clinical Laboratory Tests",
      "description": "Reference from Section 8.2.4 to Section 10.2 for the list of clinical laboratory tests to be performed."
    },
    {
      "id": "dac9fa0d-ada5-47de-b83c-3f61903b3d46",
      "name": "AE/SAE Reporting Procedures",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "10.3",
      "sectionTitle": "Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting",
      "description": "Reference from Section 8.3 to Section 10.3 for procedures on recording, evaluating, and reporting AEs and SAEs."
    },
    {
      "id": "e7c1373f-baa4-413d-b85c-4461d8868d06",
      "name": "Lost to Follow-up Definition",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "7.3",
      "sectionTitle": "Lost to Follow-up",
      "description": "Reference from Section 8.3.3 to Section 7.3 for the definition of 'lost to follow-up'."
    },
    {
      "id": "80526a85-6e02-4e43-9752-27d6ea3bd72d",
      "name": "Genetics Section Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "8.7",
      "sectionTitle": "Genetics",
      "description": "Reference from Section 8.3.6 to Section 8.7 to clarify that samples will not be used for genetic testing."
    },
    {
      "id": "52c78458-d738-4dca-ae3b-39f39f43c3b0",
      "name": "SoA for PK Sampling",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Table 1",
      "sectionTitle": "Schedule of Activities",
      "description": "Reference from Section 8.5 to the SoA (Table 1) for the schedule of pharmacokinetic sample collection."
    },
    {
      "id": "b7b66f7e-cdee-4dbc-8303-874fbd4d455c",
      "name": "Molybdenum Measurement Details",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "8.1.1",
      "sectionTitle": "Copper and Molybdenum Balance Measurements",
      "description": "Reference from Section 8.5 to Section 8.1.1 for details on molybdenum measurement in food, drinks, urine, and feces."
    },
    {
      "id": "6be54198-3161-4490-8755-3ae5959a4e30",
      "name": "SoA for PD Sampling",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Table 1",
      "sectionTitle": "Schedule of Activities",
      "description": "Reference from Section 8.6 to the SoA (Table 1) for the schedule of pharmacodynamic sample collection."
    },
    {
      "id": "b7b1fd34-397c-45d9-8127-2dc709a5e211",
      "name": "Biomarker Details Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "8.6",
      "sectionTitle": "Pharmacodynamics",
      "description": "Reference from Section 8.8 to Section 8.6 for details on pharmacodynamic biomarkers."
    },
    {
      "id": "e1d5421a-3715-4ee7-a261-a8e1801610eb",
      "name": "Analysis Populations Table",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Table 8",
      "sectionTitle": "Populations for Analysis",
      "description": "Reference from Section 9.3 to Table 8, which defines the populations for analyses."
    }
  ],
  "commentAnnotations": [
    {
      "id": "89e7e499-a4d6-458c-80fa-1f36c3e5e67b",
      "text": "This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union, the US Food and Drug Administration’s (FDA) regulation at 21 CFR part 312.30(b), and any applicable local regulations.",
      "annotationType": "Note",
      "instanceType": "CommentAnnotation",
      "sourceSection": "PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE",
      "pageNumber": 3
    },
    {
      "id": "48275689-37e3-4876-9f30-4e5c940c4e0d",
      "text": "The main reason for preparation of this amendment was to clarify study procedures occurring across different sites in the US, so as to facilitate participant recruitment across different regions of the US, and to lessen inconvenience for participants without compromising the quality of the study.",
      "annotationType": "Clarification",
      "instanceType": "CommentAnnotation",
      "sourceSection": "PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE",
      "pageNumber": 3
    },
    {
      "id": "f100d291-b2d2-49d4-9d70-88cb87c45797",
      "text": "Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; IB = Investigator’s Brochure; PK = pharmacokinetics; WD = Wilson disease.",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Table 3: Potential Risks and Mitigation Strategy",
      "pageNumber": 21
    },
    {
      "id": "1d7bbf76-8968-4058-94b9-18f642c05d01",
      "text": "Abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule of Activities.",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Table 5: Participant Lifestyle Considerations",
      "pageNumber": 35
    },
    {
      "id": "426efc2d-c793-4aa2-b171-b30f225e065a",
      "text": "Abbreviations: ICF = informed consent form; PD = pharmacodynamic; PK = pharmacokinetic.",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Table 8: Populations for Analysis",
      "pageNumber": 51
    },
    {
      "id": "c1286fa3-efe6-452d-9af3-5a2f5c03ea55",
      "text": "Note: total molybdenum and PUF molybdenum concentration-time profiles on Day 28 after the last 15 mg ALXN1840 dose will be extrapolated to Day 29 (0-24 hr) and subtracted from the observed Day 29 concentration-time profiles after the first 30 mg",
      "annotationType": "Note",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Section 9.4.4",
      "pageNumber": 53
    }
  ],
  "studyDefinitionDocumentVersions": [
    {
      "id": "62193373-224f-40e0-8c4a-46eca9da4de4",
      "versionNumber": "3.1",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2022-03-18",
      "description": "Current protocol version as of document date.",
      "amendmentNumber": "Amendment 3.1 (US)"
    },
    {
      "id": "1078216a-3ac2-4bc0-a55b-8034915e22b3",
      "versionNumber": "3.0",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2021-08-31",
      "description": "Previous protocol version.",
      "amendmentNumber": "Amendment 3"
    },
    {
      "id": "b84a5c39-a4aa-450e-9613-cbd143b387d9",
      "versionNumber": "2.0",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2021-03-19",
      "description": "Previous protocol version.",
      "amendmentNumber": "Amendment 2"
    },
    {
      "id": "8c169e2d-002d-4588-bfe7-46fe41cd8bb9",
      "versionNumber": "1.0",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2020-08-18",
      "description": "Previous protocol version.",
      "amendmentNumber": "Amendment 1"
    },
    {
      "id": "01c94829-9564-4b13-8184-cfddfdf1595d",
      "versionNumber": "Original",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2020-05-12",
      "description": "Original approved protocol."
    }
  ],
  "studyAmendmentImpacts": [
    {
      "id": "98eb4a4e-392d-4a82-a526-44669e1001c8",
      "amendmentId": "addcadc5-70a6-4e1e-a00c-3fb17b7c89a3",
      "affectedSection": "Section 1.3 Schedule of Activities (SoA), Table 1",
      "impactLevel": "Administrative",
      "instanceType": "StudyAmendmentImpact",
      "description": "Addition of a footnote to reference procedures for US-only screening sites."
    },
    {
      "id": "86f25a3c-17e0-4d58-a28a-e782e6b6ff27",
      "amendmentId": "addcadc5-70a6-4e1e-a00c-3fb17b7c89a3",
      "affectedSection": "Section 4.2 Scientific Rationale for Study Design",
      "impactLevel": "Minor",
      "instanceType": "StudyAmendmentImpact",
      "description": "Modified a timeframe related to zinc discontinuation to ensure consistency throughout the protocol."
    },
    {
      "id": "a8554147-bd36-4261-b237-2a733fbc0d24",
      "amendmentId": "addcadc5-70a6-4e1e-a00c-3fb17b7c89a3",
      "affectedSection": "Section 8 Study Assessments and Procedures",
      "impactLevel": "Major",
      "instanceType": "StudyAmendmentImpact",
      "description": "Introduced a new operational procedure allowing for screening-only sites in the US to facilitate participant recruitment."
    }
  ],
  "studyAmendmentReasons": [
    {
      "id": "7bdcc4d7-2e51-45f5-b4d8-49c09661ce0d",
      "amendmentId": "addcadc5-70a6-4e1e-a00c-3fb17b7c89a3",
      "reasonText": "The main reason for preparation of this amendment was to clarify study procedures occurring across different sites in the US, so as to facilitate participant recruitment across different regions of the US, and to lessen inconvenience for participants without compromising the quality of the study.",
      "category": "Operational",
      "isPrimary": true,
      "instanceType": "StudyAmendmentReason"
    },
    {
      "id": "f368182d-eb9d-4fbc-96af-a625293d03e5",
      "amendmentId": "addcadc5-70a6-4e1e-a00c-3fb17b7c89a3",
      "reasonText": "To align the number of days with the mention of zinc discontinuation elsewhere in the protocol.",
      "category": "Administrative",
      "isPrimary": false,
      "instanceType": "StudyAmendmentReason"
    },
    {
      "id": "778717be-9504-4225-9ec6-95cd1fce7fbe",
      "amendmentId": "addcadc5-70a6-4e1e-a00c-3fb17b7c89a3",
      "reasonText": "To facilitate participant recruitment across different regions of the US and to lessen inconvenience for participants without compromising the quality of the study.",
      "category": "Operational",
      "isPrimary": false,
      "instanceType": "StudyAmendmentReason"
    }
  ],
  "studyChanges": [
    {
      "id": "5c499eab-7408-4616-8979-fd68ea2dc244",
      "amendmentId": "addcadc5-70a6-4e1e-a00c-3fb17b7c89a3",
      "changeType": "Addition",
      "instanceType": "StudyChange",
      "sectionNumber": "1.3",
      "summary": "Addition of text to the footnote to state that procedures specific to screening sites (only in the US) detailed in Section 8."
    },
    {
      "id": "add106e5-2020-4c33-b1b4-c3f13236354a",
      "amendmentId": "addcadc5-70a6-4e1e-a00c-3fb17b7c89a3",
      "changeType": "Modification",
      "instanceType": "StudyChange",
      "sectionNumber": "4.2",
      "beforeText": "However, the physiologic turnover of human gastrointestinal epithelial cells is 3 - 5 days (Darwich, 2014); therefore, the inhibitory effect of zinc on intestinal copper absorption is expected to be minimal 30 days after discontinuation of zinc.",
      "afterText": "However, the physiologic turnover of human gastrointestinal epithelial cells is 3 - 5 days (Darwich, 2014); therefore, the inhibitory effect of zinc on intestinal copper absorption is expected to be minimal 21 days after discontinuation of zinc.",
      "summary": "The number of days for minimal zinc effect after discontinuation was changed from 30 to 21 for consistency."
    },
    {
      "id": "a68c3c03-ae00-42e7-912f-86879c6d269c",
      "amendmentId": "addcadc5-70a6-4e1e-a00c-3fb17b7c89a3",
      "changeType": "Addition",
      "instanceType": "StudyChange",
      "sectionNumber": "8",
      "summary": "Addition of text applicable only to the US that details the possibility for sites in the US to only perform screening procedures and not any of the remaining study procedures."
    }
  ],
  "computationalExecution": {
    "ready": true,
    "supportedSystems": [
      "EDC",
      "ePRO",
      "CTMS",
      "RTSM"
    ],
    "validationStatus": "issues_found"
  }
}